No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d3bc5A1, 1.0000, 0.00, 1.000, 262, 262, X-RAY CRYSTAL STRUCTURE OF HUMAN PPAR GAMMA WITH 2-(5-(3-(2- (5-METHYL-2-PHENYLOXAZOL-4-YL)ETHOXY)BENZYL)-2-PHENYL-2H-1 23-TRIAZOL-4-YL)ACETIC ACID
2, d4xldA1, 0.9873, 0.44, 0.992, 262, 260, CRYSTAL STRUCTURE OF THE HUMAN PPARG-LBD/ROSIGLITAZONE COMPLEX OBTAINED BY DRY CO-CRYSTALLIZATION AND IN SITU DIFFRACTION
3, d1wm0X1, 0.9803, 0.82, 0.989, 268, 261, PPARGAMMA IN COMPLEX WITH A 2-BABA COMPOUND
4, d2zvtA_, 0.9783, 0.89, 0.992, 274, 261, CYS285SER MUTANT PPARGAMMA LIGAND-BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
5, d2zk6A_, 0.9777, 0.86, 0.989, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH C8-BODIPY
6, d3adwA_, 0.9771, 0.88, 0.996, 274, 261, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE AND 15-OXO-EICOSATETRAENOIC ACID
7, d2zk2A_, 0.9766, 0.89, 0.989, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH GLUTATHION CONJUGATED 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
8, d2zk1A_, 0.9760, 0.90, 0.992, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214- PROSTAGLANDIN J2
9, d3wmhA_, 0.9755, 0.71, 1.000, 264, 259, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT75
10, d2zk4A_, 0.9754, 0.93, 0.992, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-OXO- EICOSATETRAENOIC ACID
11, d3adxA_, 0.9751, 0.96, 0.989, 274, 261, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN AND NITRO-233
12, d2zk3A_, 0.9751, 0.93, 0.992, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 8-OXO- EICOSATETRAENOIC ACID
13, d2zk5A_, 0.9747, 0.95, 0.989, 274, 261, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH NITRO-233
14, d3prgA_, 0.9741, 0.65, 0.988, 267, 258, LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR
15, d3vspA_, 0.9730, 0.81, 1.000, 265, 259, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT28
16, d1knuA_, 0.9722, 0.90, 0.985, 265, 260, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST
17, d3ty0A1, 0.9708, 1.17, 0.992, 275, 262, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH (R)-5-(3- ((3-(6-METHOXYBENZO[D]ISOXAZOL-3-YL)-2-OXO-23-DIHYDRO-1H- BENZO[D]IMIDAZOL-1-YL)METHYL)PHENYL)-5-METHYLOXAZOLIDINE-24-DIONE
18, d1zgyA_, 0.9702, 1.17, 0.992, 275, 262, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
19, p5ji0D_, 0.9690, 0.95, 0.985, 272, 259, PPARGAMMA-RXRALPHA(S427F) HETERODIMER IN COMPLEX WITH SRC-1 ROSIGLITAZONE AND 9-CIS-RETANOIC ACID
20, d2om9C_, 0.9683, 0.92, 0.969, 269, 259, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
21, d2om9A_, 0.9682, 0.70, 0.992, 270, 257, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
22, d1fm9D_, 0.9676, 0.70, 0.992, 270, 257, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.
23, d4a4vA_, 0.9663, 1.03, 0.988, 272, 259, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
24, p5ugmB_, 0.9662, 0.91, 0.992, 264, 258, CRYSTAL STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH EDAGLITAZONE
25, d3an3A_, 0.9662, 0.86, 0.992, 271, 258, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO3S
26, d2yfeA_, 0.9662, 1.08, 0.996, 263, 258, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 1
27, d3gbkA_, 0.9661, 0.77, 1.000, 264, 257, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST
28, d2f4bA_, 0.9661, 0.91, 0.977, 271, 258, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH AN AGONIST
29, p5ugmA_, 0.9660, 0.89, 0.984, 271, 258, CRYSTAL STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH EDAGLITAZONE
30, d2athA_, 0.9660, 0.86, 0.992, 271, 258, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IM COMPLEX WITH AN AGONIST
31, d4xuhA_, 0.9659, 0.89, 0.984, 271, 258, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH SULINDAC SULFIDE
32, d3vsoA_, 0.9659, 0.89, 0.996, 264, 258, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT21
33, d3noaA_, 0.9658, 0.77, 1.000, 263, 257, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEX WITH A POTENCY IMPROVED AGONIST
34, d1fm6D_, 0.9658, 0.90, 0.984, 271, 258, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
35, p5gtoA_, 0.9657, 1.12, 0.988, 272, 259, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH S35
36, d3kduB1, 0.9656, 0.88, 0.996, 267, 258, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-((4-METHYLPHENOXY)CARBONYL)GLYCINE
37, p5dwlA_, 0.9650, 1.22, 0.619, 268, 260, HUMAN PPARGAMMA LIGAND BINDING DMAIN IN COMPLEX WITH SR1664
38, p3sp6A_, 0.9648, 1.08, 0.988, 271, 260, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
39, d2g0gB_, 0.9645, 1.34, 0.632, 270, 261, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
40, d2g0gA_, 0.9645, 0.96, 0.981, 271, 258, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
41, d3adsA_, 0.9643, 0.92, 0.981, 271, 258, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
42, p5gtnA_, 0.9640, 0.84, 1.000, 262, 257, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH R35
43, d3r5nA_, 0.9640, 1.30, 1.000, 271, 260, CRYSTAL STRUCTURE OF PPARGAMMALBD COMPLEXED WITH THE AGONIST MAGNOLOL
44, d3advA_, 0.9638, 0.45, 1.000, 256, 254, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH SEROTONIN
45, d2znoA_, 0.9638, 0.84, 1.000, 262, 257, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
46, d4r6sA_, 0.9637, 1.11, 0.996, 266, 258, CRYSTAL STRUCTURE OF PPARGAMMMA IN COMPLEX WITH SR1663
47, p3e00D2, 0.9634, 0.83, 0.992, 262, 257, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH GW9662 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
48, d3an4A_, 0.9633, 1.06, 0.988, 266, 259, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO4R
49, d3kdtB1, 0.9632, 0.74, 1.000, 262, 256, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-(METHOXYCARBONYL)GLYCINE
50, d4a4wA_, 0.9628, 1.32, 0.627, 268, 260, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
51, d3noaB_, 0.9626, 0.90, 1.000, 263, 257, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEX WITH A POTENCY IMPROVED AGONIST
52, d2zk0A_, 0.9626, 0.98, 0.984, 271, 258, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN
53, p5twoA_, 0.9623, 0.89, 0.984, 270, 257, PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGNAD BINDING DOMAIN IN COMPLEX WITH A NOVEL SELECTIVELY PPAR GAMMA-MODULATING LIGAND VSP- 51
54, d2f4bB_, 0.9621, 0.82, 0.977, 270, 256, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH AN AGONIST
55, d3po9A_, 0.9620, 1.01, 0.981, 271, 258, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPROPYLTIN
56, d4yt1A_, 0.9619, 0.77, 0.996, 261, 256, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT76
57, d2hfpA_, 0.9619, 0.77, 1.000, 261, 256, CRYSTAL STRUCTURE OF PPAR GAMMA WITH N-SULFONYL-2-INDOLE CARBOXAMIDE LIGANDS
58, d3b0qA_, 0.9618, 1.09, 0.996, 272, 259, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MCC555
59, p6an1A_, 0.9617, 1.10, 0.996, 262, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND AM-879
60, d3gbkB_, 0.9616, 0.78, 0.992, 261, 256, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST
61, d2athB_, 0.9615, 1.07, 0.977, 271, 258, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IM COMPLEX WITH AN AGONIST
62, d5u42A_, 0.9614, 1.03, 0.988, 271, 258, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 11
63, d5u3qB_, 0.9613, 0.95, 0.640, 271, 258, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 1
64, d3vjhA_, 0.9613, 0.96, 0.640, 270, 258, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL35
65, d3pbaA_, 0.9613, 0.82, 0.996, 261, 256, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MONOSULFATE TETRABROMO-BISPHENOL A (MONOTBBPA)
66, d2g0hB_, 0.9613, 0.79, 0.996, 262, 256, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
67, d1k74D_, 0.9613, 1.05, 0.977, 271, 258, THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN PPARGAMMA AND RXRALPHA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH GW409544 AND 9-CIS RETINOIC ACID AND CO-ACTIVATOR PEPTIDES.
68, d2xkwA_, 0.9612, 1.16, 0.969, 272, 259, LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE
69, d5u3sA_, 0.9611, 0.81, 0.996, 261, 256, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 3
70, d2prgA_, 0.9609, 0.96, 0.640, 271, 258, LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
71, d2g0hA_, 0.9608, 1.07, 0.981, 271, 258, STRUCTURE-BASED DRUG DESIGN OF A NOVEL FAMILY OF PPAR PARTIAL AGONISTS: VIRTUAL SCREENING X-RAY CRYSTALLOGRAPHY AND IN VITRO/IN VIVO BIOLOGICAL ACTIVITIES
72, d3vjiA_, 0.9605, 0.99, 0.965, 271, 258, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL53
73, d3r8iB_, 0.9605, 1.11, 0.988, 262, 257, CRYSTAL STRUCTURE OF PPARGAMMA WITH AN ACHIRAL UREIDOFIBRATE DERIVATIVE (RT86)
74, d3b0rA_, 0.9603, 1.03, 0.992, 270, 257, HUMAN PPAR GAMMA LIGAND BINDING DMAIN COMPLEXED WITH GW9662 IN A COVALENT BONDED FORM
75, d3kduA_, 0.9599, 0.84, 1.000, 262, 256, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-((4-METHYLPHENOXY)CARBONYL)GLYCINE
76, d3tkmA1, 0.9596, 1.11, 0.634, 264, 257, CRYSTAL STRUCTURE PPAR DELTA BINDING GW0742
77, d2i4pA_, 0.9596, 1.09, 0.636, 266, 258, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 30 DAYS.
78, d5y2oA_, 0.9594, 1.06, 0.988, 270, 257, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN-PIOGLITAZONE COMPLEX
79, d2i4zA_, 0.9592, 1.05, 0.996, 262, 256, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). THIS STRUCTURE HAS BEEN OBTAINED FROM CRYSTALS SOAKED FOR 6 HOURS.
80, d3lmpA_, 0.9590, 1.05, 1.000, 270, 257, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
81, p5gtpA_, 0.9588, 0.87, 0.996, 264, 256, THE AGONIST-FREE STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN THE PRESENCE OF THE SRC-1 COACTIVATOR PEPTIDE
82, d2i4jA_, 0.9587, 0.88, 0.977, 261, 256, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE AGONIST LT160 (UREIDOFIBRATE DERIVATIVE)
83, p5dv6A_, 0.9584, 1.07, 0.984, 270, 257, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1404 IN A COVALENT BONDED FORM
84, d4xumA_, 0.9584, 0.87, 0.988, 261, 256, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
85, d3r8iA_, 0.9584, 0.78, 0.996, 260, 255, CRYSTAL STRUCTURE OF PPARGAMMA WITH AN ACHIRAL UREIDOFIBRATE DERIVATIVE (RT86)
86, d3osiA_, 0.9581, 1.07, 1.000, 270, 257, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRACHLORO-BISPHENOL A (TCBPA)
87, d3oswA_, 0.9580, 0.77, 1.000, 260, 255, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRABROMO-BISPHENOL A (TBBPA)
88, d3kdtA_, 0.9580, 0.77, 1.000, 261, 255, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-13- OXAZOL-4-YL)METHOXY)BENZYL)-N-(METHOXYCARBONYL)GLYCINE
89, p5dv3A_, 0.9579, 1.10, 0.630, 264, 257, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1405 IN A COVALENT BONDED FORM
90, d3v9yA_, 0.9579, 1.07, 0.973, 263, 258, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
91, d3d6dA_, 0.9577, 0.90, 0.980, 261, 256, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LT175(R-ENANTIOMER)
92, p4f9mA_, 0.9576, 1.11, 0.981, 270, 257, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
93, d3cdpA_, 0.9573, 0.97, 0.988, 261, 256, CRYSTAL STRUCTURE OF PPAR-GAMMA LBD COMPLEXED WITH A PARTIAL AGONIST ANALOGUE OF CLOFIBRIC ACID
94, d3b1mA_, 0.9573, 1.11, 0.984, 270, 257, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR CERCO-A
95, d3hodA_, 0.9571, 0.81, 0.992, 260, 255, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
96, d3cdsA_, 0.9570, 1.12, 0.984, 270, 257, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPAR-GAMMA AND THE AGONIST LT248 (CLOFIBRIC ACID ANALOGUE)
97, d5ttoA_, 0.9569, 1.10, 0.984, 270, 257, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1643
98, d5u3tA_, 0.9568, 0.81, 1.000, 260, 255, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 4
99, d5u5lA_, 0.9567, 0.97, 0.642, 270, 257, X-RAY CRYSTAL STRUCTURE OF THE PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH RIVOGLITAZONE
100, d3h0aD_, 0.9567, 0.71, 0.992, 259, 254, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) AND RETINOIC ACID RECEPTOR ALPHA (RXRA) IN COMPLEX WITH 9-CIS RETINOIC ACID CO-ACTIVATOR PEPTIDE AND A PARTIAL AGONIST
101, d1fm6X_, 0.9566, 1.29, 0.988, 265, 258, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
102, p5dvcA_, 0.9564, 1.31, 0.969, 272, 258, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1453 IN A COVALENT BONDED FORM
103, d2vstA_, 0.9563, 1.18, 0.985, 268, 259, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)- HODE
104, d3b3kA_, 0.9562, 0.82, 1.000, 260, 255, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE FULL AGONIST LT175
105, p3vn2A_, 0.9554, 1.14, 0.984, 270, 257, CRYSTAL STRUCTURE OF PPARGAMMA COMPLEXED WITH TELMISARTAN
106, d2om9B_, 0.9554, 0.75, 1.000, 261, 254, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
107, d2om9D_, 0.9553, 0.89, 0.984, 260, 255, AJULEMIC ACID A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA
108, d1prgA_, 0.9552, 0.89, 0.984, 260, 255, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
109, d3gwxB_, 0.9551, 1.15, 0.981, 270, 257, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
110, d5u3wA_, 0.9546, 1.12, 0.636, 271, 258, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 7
111, d2hwrA_, 0.9545, 0.94, 0.645, 266, 256, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
112, d5u43A_, 0.9543, 1.24, 1.000, 261, 256, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 12
113, d1gwxB_, 0.9542, 0.95, 0.645, 266, 256, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
114, d5azvA_, 0.9540, 1.16, 0.636, 271, 258, CRYSTAL STRUCTURE OF HPPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 17-OXODHA
115, p5dv8A_, 0.9538, 0.92, 0.996, 259, 255, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1451 IN A COVALENT BONDED FORM
116, d3v9tA_, 0.9535, 1.28, 0.992, 269, 259, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
117, d3et3A1, 0.9533, 0.82, 0.996, 258, 254, STRUCTURE OF PPARGAMMA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
118, d3qt0A_, 0.9532, 0.84, 0.988, 259, 254, REVEALING A STEROID RECEPTOR LIGAND AS A UNIQUE PPARGAMMA AGONIST
119, d2hwqA_, 0.9532, 1.08, 0.984, 267, 257, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
120, d3adtA_, 0.9531, 1.00, 0.984, 261, 255, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-HYDROXY-INDOLE ACETATE
121, d3g9eA_, 0.9527, 0.82, 0.996, 259, 254, ALEGLITAAR. A NEW. POTENT AND BALANCED DUAL PPARA/G AGONIST FOR THE TREATMENT OF TYPE II DIABETES
122, d2vv0A_, 0.9526, 0.74, 1.000, 258, 253, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA
123, p6f2lA_, 0.9524, 0.84, 0.996, 259, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570: STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 15 DAYS.
124, d4jl4A_, 0.9524, 0.84, 0.984, 259, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570 [(2S)-3-(BIPHENYL-4-YL)-2-(BIPHENYL-4-YLOXY)PROPANOIC ACID]
125, d4r2uA_, 0.9523, 1.06, 0.988, 268, 255, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1664
126, d3ho0A_, 0.9523, 1.06, 0.992, 260, 256, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
127, d3aduA_, 0.9523, 1.20, 0.984, 270, 257, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE
128, p4y29A_, 0.9522, 0.83, 1.000, 259, 254, IDENTIFICATION OF A NOVEL PPARG LIGAND THAT REGULATES METABOLISM
129, d3sz1A_, 0.9521, 0.62, 0.992, 257, 252, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH LUTEOLIN AND MYRISTIC ACID
130, d1gwxA_, 0.9521, 0.73, 0.996, 258, 253, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
131, d5u3rA_, 0.9520, 1.10, 0.634, 270, 257, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 2
132, d4e4qA_, 0.9520, 1.18, 0.638, 270, 257, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND FS214
133, d1i7iA_, 0.9520, 1.05, 0.988, 268, 255, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242
134, d5u3vB_, 0.9519, 0.73, 0.992, 258, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 6
135, p3t03A_, 0.9515, 1.18, 0.638, 267, 257, CRYSTAL STRUCTURE OF PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A NOVEL PARTIAL AGONIST GQ-16
136, p3s9sA_, 0.9514, 1.00, 0.984, 265, 255, LIGAND BINDING DOMAIN OF PPARGAMMA COMPLEXED WITH A BENZIMIDAZOLE PARTIAL AGONIST
137, d3fejA_, 0.9513, 0.99, 0.976, 258, 254, DESIGN AND BIOLOGICAL EVALUATION OF NOVEL BALANCED DUAL PPARA/G AGONISTS
138, d5wqxA_, 0.9512, 0.78, 0.996, 258, 253, COVALENT BOND FORMATION OF SYNTHETIC LIGAND WITH HPPARG-LBD
139, d3u9qA_, 0.9512, 0.77, 0.996, 257, 253, LIGAND BINDING DOMAIN OF PPARGAMMA COMPLEXED WITH DECANOIC ACID AND PGC-1A PEPTIDE
140, d1zeoA_, 0.9509, 0.65, 0.992, 257, 252, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST
141, d3et2A_, 0.9508, 1.06, 0.984, 263, 255, STRUCTURE OF PPARDELTA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
142, d5wr0A_, 0.9507, 1.07, 0.645, 266, 256, HUISGEN CYCLOADDITION FOR PPARG-LBD LABELING BY SOAKING METHOD
143, d5wr1A_, 0.9506, 0.78, 0.996, 257, 253, COVALENT BOND FORMATION OF BIFUNCTIONAL LIGAND WITH HPPARG-LBD
144, d2vv3A_, 0.9505, 0.78, 0.996, 257, 253, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-OXODHA
145, d2npaC_, 0.9502, 0.79, 0.996, 257, 253, THE CRYSTAL STRUCTURE OF THE HUMAN PPARAPLPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A A-HYDROXYIMINO PHENYLPROPANOIC ACID
146, d4bcrB_, 0.9500, 1.35, 0.636, 267, 258, STRUCTURE OF PPARALPHA IN COMPLEX WITH WY14643
147, d5y2tA_, 0.9499, 1.31, 0.633, 265, 256, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN - LOBEGLITAZONE COMPLEX
148, d3v9vA_, 0.9498, 0.94, 1.000, 261, 254, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A CERCOSPORAMIDE DERIVATIVE MODULATOR
149, d4e4kA_, 0.9497, 0.82, 0.996, 258, 253, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND JO21
150, d3x1iA_, 0.9497, 1.09, 0.988, 268, 255, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXO- TETRACOSAHEXAENOIC ACID
151, d5u3zA_, 0.9496, 0.81, 0.992, 257, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 10
152, d3gwxA_, 0.9496, 0.97, 0.643, 268, 255, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
153, d3wj5A1, 0.9495, 1.16, 0.638, 270, 257, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN
154, d4jazA_, 0.9494, 0.89, 0.988, 256, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND TRANS- RESVERATROL
155, d3cwdB_, 0.9492, 1.11, 0.988, 268, 255, MOLECULAR RECOGNITION OF NITRO-FATTY ACIDS BY PPAR GAMMA
156, d2b50B_, 0.9491, 1.05, 0.988, 260, 254, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 2
157, d4em9A_, 0.9490, 1.39, 0.647, 263, 258, HUMAN PPAR GAMMA IN COMPLEX WITH NONANOIC ACIDS
158, d2vsrA_, 0.9490, 0.83, 0.992, 259, 253, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE
159, d3cs8A2, 0.9488, 0.71, 1.000, 257, 252, STRUCTURAL AND BIOCHEMICAL BASIS FOR THE BINDING SELECTIVITY OF PPARG TO PGC-1A
160, d2gtkA_, 0.9487, 1.26, 0.984, 265, 256, STRUCTURE-BASED DESIGN OF INDOLE PROPIONIC ACIDS AS NOVEL PPARAG CO-AGONISTS
161, d1nyxA_, 0.9484, 0.85, 0.984, 258, 253, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST
162, d3et2B_, 0.9482, 0.95, 0.992, 260, 254, STRUCTURE OF PPARDELTA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
163, d3et0A1, 0.9480, 1.13, 0.648, 267, 256, STRUCTURE OF PPARGAMMA WITH 3-(5-METHOXY-1H-INDOL-3-YL)- PROPIONIC ACID
164, d4ci5A_, 0.9478, 0.86, 0.992, 258, 253, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR GAMMA AGONIST
165, d2xyjA_, 0.9473, 1.08, 0.988, 260, 255, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
166, p5y7xB_, 0.9472, 1.03, 0.639, 263, 255, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DELTA IN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST 
167, d3et1B_, 0.9471, 1.23, 0.637, 262, 256, STRUCTURE OF PPARALPHA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
168, d2fvjA_, 0.9469, 1.40, 0.632, 270, 258, A NOVEL ANTI-ADIPOGENIC PARTIAL AGONIST OF PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR-GAMMA (PPARG) RECRUITS PPARG-COACTIVATOR-1 ALPHA (PGC1A) BUT POTENTIATES INSULIN SIGNALING IN VITRO
169, d5u46A_, 0.9466, 0.87, 1.000, 258, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH GW501516
170, d5u3tB_, 0.9464, 0.95, 0.642, 264, 254, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 4
171, d3k8sB_, 0.9462, 1.10, 0.647, 265, 255, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH T2384
172, d5u3yA_, 0.9461, 0.89, 0.996, 258, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 9
173, d4prgC_, 0.9458, 1.32, 0.637, 263, 256, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
174, p6enqA_, 0.9457, 1.29, 0.965, 270, 257, STRUCTURE OF HUMAN PPAR GAMMA LBD IN COMPLEX WITH LANIFIBRANOR (IVA337)
175, d5u45B_, 0.9456, 0.70, 1.000, 256, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 14
176, p5dshA_, 0.9456, 1.01, 0.642, 265, 254, HUMAN PPARGAMMA LIGAND BINDING DMAIN COMPLEXED WITH SB1406 IN A COVALENT BONDED FORM
177, d3ty0B1, 0.9456, 0.90, 0.996, 258, 253, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH (R)-5-(3- ((3-(6-METHOXYBENZO[D]ISOXAZOL-3-YL)-2-OXO-23-DIHYDRO-1H- BENZO[D]IMIDAZOL-1-YL)METHYL)PHENYL)-5-METHYLOXAZOLIDINE-24-DIONE
178, d2vv1A_, 0.9454, 1.46, 0.961, 275, 258, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA
179, p4fgyA_, 0.9453, 0.83, 0.992, 256, 252, IDENTIFICATION OF A UNIQUE PPAR LIGAND WITH AN UNEXPECTED BINDING MODE AND ANTIBETIC ACTIVITY
180, d2vv2A_, 0.9453, 1.14, 0.984, 265, 255, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA
181, d3x1hA_, 0.9451, 0.83, 0.992, 256, 252, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-OXO- TRICOSAHEXAENOIC ACID
182, d5u46B_, 0.9450, 0.71, 1.000, 256, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH GW501516
183, d4prgA_, 0.9450, 0.98, 0.642, 264, 254, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
184, d2pobA_, 0.9449, 1.32, 0.961, 270, 257, PPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A FARGLITAZAR ANALOGUE GW4709
185, d5u3qA_, 0.9445, 0.99, 0.996, 255, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 1
186, d4emaA_, 0.9445, 1.13, 0.643, 265, 255, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH ROSIGLITAZONE
187, d3kmgA_, 0.9445, 0.74, 0.984, 256, 251, THE X-RAY CRYSTAL STRUCTURE OF PPAR-GAMMA IN COMPLEX WITH AN INDOLE DERIVATIVE MODULATOR GSK538 AND AN SRC-1 PEPTIDE
188, d1y0sA_, 0.9443, 0.86, 0.996, 259, 252, CRYSTAL STRUCTURE OF PPAR DELTA COMPLEXED WITH GW2331
189, d2q61A_, 0.9441, 1.17, 0.639, 260, 255, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN BOUND TO PARTIAL AGONIST SR145
190, d4pvuA_, 0.9440, 0.76, 0.984, 256, 251, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE R ENANTIOMER OF MBX-102 (METAGLIDASEN)
191, d2npaA_, 0.9437, 0.85, 0.996, 257, 252, THE CRYSTAL STRUCTURE OF THE HUMAN PPARAPLPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A A-HYDROXYIMINO PHENYLPROPANOIC ACID
192, d5lsgA_, 0.9429, 1.40, 0.638, 269, 257, PPARGAMMA COMPLEX WITH THE BETULINIC ACID
193, d5u42B_, 0.9424, 0.78, 0.996, 256, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 11
194, d2xyxB_, 0.9424, 0.98, 0.640, 263, 253, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
195, d3kmgD_, 0.9418, 0.97, 0.656, 263, 253, THE X-RAY CRYSTAL STRUCTURE OF PPAR-GAMMA IN COMPLEX WITH AN INDOLE DERIVATIVE MODULATOR GSK538 AND AN SRC-1 PEPTIDE
196, d3gz9A_, 0.9416, 0.80, 0.996, 256, 251, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA (PPARD) IN COMPLEX WITH A FULL AGONIST
197, d3furA_, 0.9415, 1.27, 0.645, 262, 256, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH INT131
198, d2gwxB_, 0.9415, 0.82, 0.980, 256, 251, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
199, d2vv4A_, 0.9414, 1.12, 0.642, 267, 254, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE
200, d1i7gA_, 0.9414, 0.88, 0.992, 254, 251, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN FROM HUMAN PPAR-ALPHA IN COMPLEX WITH THE AGONIST AZ 242
201, d2znqB1, 0.9413, 1.10, 0.642, 259, 254, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP401
202, d5u3sB_, 0.9410, 1.34, 0.639, 259, 255, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 3
203, d2q5sA_, 0.9410, 1.02, 0.640, 263, 253, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST NTZDPA
204, d2yfeB_, 0.9409, 0.85, 0.988, 256, 251, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 1
205, d3wj4A1, 0.9408, 1.03, 0.968, 264, 252, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN
206, d4xuhB_, 0.9407, 0.92, 0.988, 254, 251, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH SULINDAC SULFIDE
207, d3sz1B_, 0.9406, 1.13, 0.960, 258, 253, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH LUTEOLIN AND MYRISTIC ACID
208, d4a4vB_, 0.9404, 1.06, 0.964, 258, 252, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
209, d2q5pA_, 0.9404, 1.05, 0.968, 265, 252, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST MRL24
210, d2znpB1, 0.9403, 0.84, 0.996, 256, 251, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP204
211, p3dzuD2, 0.9402, 1.53, 0.642, 261, 257, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH BVT.13 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
212, d2xywB_, 0.9402, 0.97, 0.980, 257, 252, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
213, d2p54A_, 0.9401, 1.02, 0.652, 263, 253, A CRYSTAL STRUCTURE OF PPAR ALPHA BOUND WITH SRC1 PEPTIDE AND GW735
214, d1prgB_, 0.9401, 1.41, 0.643, 267, 255, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
215, d4a4wB_, 0.9398, 1.16, 0.949, 270, 253, LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 2
216, d2znqA_, 0.9391, 1.05, 0.968, 264, 252, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP401
217, d3d6dB_, 0.9387, 1.39, 0.643, 262, 255, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LT175(R-ENANTIOMER)
218, d5u43B_, 0.9385, 1.21, 0.949, 270, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 12
219, d3cdpB_, 0.9382, 0.97, 0.643, 262, 252, CRYSTAL STRUCTURE OF PPAR-GAMMA LBD COMPLEXED WITH A PARTIAL AGONIST ANALOGUE OF CLOFIBRIC ACID
220, d3ia6A_, 0.9381, 1.21, 0.953, 270, 253, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
221, d3hodB_, 0.9381, 0.69, 0.988, 254, 249, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
222, d5u45A_, 0.9380, 1.22, 0.949, 270, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 14
223, d5u3xA_, 0.9380, 0.98, 0.643, 262, 252, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 8
224, d3cdsB_, 0.9380, 1.22, 0.638, 262, 254, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPAR-GAMMA AND THE AGONIST LT248 (CLOFIBRIC ACID ANALOGUE)
225, d3b3kB_, 0.9380, 1.21, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE FULL AGONIST LT175
226, d2xywA_, 0.9378, 1.23, 0.949, 270, 253, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
227, d1k7lE_, 0.9377, 1.06, 0.652, 263, 253, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
228, d2gwxA_, 0.9375, 1.39, 0.643, 267, 255, MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
229, d3cwdA_, 0.9371, 1.06, 0.639, 265, 252, MOLECULAR RECOGNITION OF NITRO-FATTY ACIDS BY PPAR GAMMA
230, d2xyjB_, 0.9371, 0.92, 0.992, 257, 251, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
231, d5u3vA_, 0.9370, 1.36, 0.646, 259, 254, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 6
232, d2rewA_, 0.9369, 1.03, 0.643, 262, 252, CRYSTAL STRUCTURE OF PPARALPHA LIGAND BINDING DOMAIN WITH BMS-631707
233, d3k8sA_, 0.9368, 0.93, 0.641, 255, 251, CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH T2384
234, d5u3rB_, 0.9365, 1.27, 0.953, 262, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 2
235, d2q61B_, 0.9365, 1.19, 0.640, 261, 253, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN BOUND TO PARTIAL AGONIST SR145
236, d1knuB_, 0.9365, 1.26, 0.964, 259, 253, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST
237, d2b50A_, 0.9364, 1.25, 0.968, 258, 252, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 2
238, d2i4jB_, 0.9362, 1.17, 0.644, 261, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE AGONIST LT160 (UREIDOFIBRATE DERIVATIVE)
239, d4pwlA_, 0.9359, 1.27, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE S ENANTIOMER OF MBX-102 (METAGLIDASEN)
240, d5u44B_, 0.9358, 0.86, 0.996, 255, 250, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 13
241, d2q6rB_, 0.9358, 1.36, 0.640, 260, 253, CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED WITH PARTIAL AGONIST SF147
242, d3et1A_, 0.9356, 1.30, 0.953, 258, 253, STRUCTURE OF PPARALPHA WITH 3-[5-METHOXY-1-(4-METHOXY- BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID
243, d2q5sB_, 0.9353, 1.66, 0.645, 263, 256, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST NTZDPA
244, p5y7xA_, 0.9352, 1.29, 0.960, 258, 253, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DELTA IN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST 
245, d5u3wB_, 0.9352, 1.49, 0.642, 258, 254, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 7
246, d3dy6A_, 0.9351, 0.97, 0.645, 261, 251, PPARDELTA COMPLEXED WITH AN ANTHRANILIC ACID PARTIAL AGONIST
247, d4o8fA_, 0.9350, 1.14, 0.639, 257, 252, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA MUTANT R357A AND ROSIGLITAZONE
248, d5f9bA_, 0.9349, 1.00, 0.992, 252, 250, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN THE COMPLEX WITH CAULOPHYLLOGENIN
249, d2q8sA_, 0.9347, 0.79, 0.988, 254, 249, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
250, d1k7lA_, 0.9347, 0.69, 0.996, 253, 248, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
251, d2zk0B_, 0.9346, 1.56, 0.643, 267, 255, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN
252, d1y0sB_, 0.9346, 1.23, 0.956, 259, 252, CRYSTAL STRUCTURE OF PPAR DELTA COMPLEXED WITH GW2331
253, d5u5lB_, 0.9344, 1.26, 0.636, 258, 253, X-RAY CRYSTAL STRUCTURE OF THE PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH RIVOGLITAZONE
254, d1k7lG_, 0.9344, 1.33, 0.956, 254, 252, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
255, d3ho0B_, 0.9342, 1.58, 0.643, 267, 255, CRYSTAL STRUCTURE OF THE PPARGAMMA-LBD COMPLEXED WITH A NEW ARYLOXY-3PHENYLPROPANOIC ACID
256, d3sp9A_, 0.9341, 1.30, 0.953, 270, 253, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
257, d2q6sA_, 0.9341, 1.39, 0.641, 269, 256, 2.4 ANGSTROM CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED TO BVT.13 WITHOUT CO-ACTIVATOR PEPTIDES
258, d4yt1B_, 0.9340, 0.81, 0.996, 254, 249, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT76
259, d2q8sB_, 0.9340, 1.13, 0.976, 257, 251, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
260, p5xmxA_, 0.9339, 1.15, 0.948, 254, 251, CO-CRYSTAL STRUCTURE OF INHIBITOR COMPOUND IN COMPLEX WITH HUMAN PPARDELTA LBD 
261, d3an4B_, 0.9339, 1.17, 0.643, 257, 252, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO4R
262, d2i4zB_, 0.9336, 1.09, 0.972, 257, 251, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). THIS STRUCTURE HAS BEEN OBTAINED FROM CRYSTALS SOAKED FOR 6 HOURS.
263, d5u41B_, 0.9330, 1.35, 0.949, 270, 253, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 16
264, d5u3zB_, 0.9330, 1.00, 0.645, 261, 251, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 10
265, d4e4qB_, 0.9329, 1.01, 0.645, 261, 251, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND FS214
266, d1k7lC_, 0.9329, 1.15, 0.956, 268, 251, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE.
267, d3g8iA_, 0.9327, 1.60, 0.643, 267, 255, ALEGLITAZAR A NEW POTENT AND BALANCED PPAR ALPHA/GAMMA AGONIST FOR THE TREATMENT OF TYPE II DIABETES
268, d3sp9B_, 0.9326, 1.19, 0.635, 254, 252, STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHA/DELTA AGONIST
269, d3ia6B_, 0.9326, 1.43, 0.641, 267, 256, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A PPAR GAMMA/ALPHA DUAL AGONIST
270, d3wj4B1, 0.9325, 1.10, 0.968, 255, 250, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN
271, d2i4pB_, 0.9325, 1.28, 0.964, 255, 252, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA AND THE PARTIAL AGONIST LT127 (UREIDOFIBRATE DERIVATIVE). STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 30 DAYS.
272, d5hykA_, 0.9324, 1.33, 0.949, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX PPARALPHA/AL26-29
273, d3peqB_, 0.9324, 1.15, 0.645, 255, 251, PPARD COMPLEXED WITH A PHENOXYACETIC ACID PARTIAL AGONIST
274, d5y2tB1, 0.9323, 1.40, 0.636, 257, 253, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN - LOBEGLITAZONE COMPLEX
275, d4r06A_, 0.9320, 1.09, 0.960, 258, 250, CRYSTAL STRUCTURE OF SR2067 BOUND TO PPARGAMMA
276, p4heeX_, 0.9319, 0.93, 0.984, 252, 249, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH COMPOUND 13
277, d3wj5B1, 0.9319, 0.90, 0.988, 251, 249, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN
278, d1nyxB_, 0.9317, 1.39, 0.964, 253, 252, LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH AN AGONIST
279, d5ttoB_, 0.9316, 1.36, 0.948, 258, 252, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1643
280, d2q59A_, 0.9316, 1.24, 0.964, 258, 251, CRYSTAL STRUCTURE OF PPARGAMMA LBD BOUND TO FULL AGONIST MRL20
281, d2zk2B_, 0.9315, 0.91, 0.996, 254, 249, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH GLUTATHION CONJUGATED 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
282, d1rdtD1, 0.9315, 1.14, 0.976, 263, 250, CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHA LIGAND BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER
283, d2vv2B_, 0.9313, 0.68, 1.000, 252, 247, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA
284, d4r6sB_, 0.9312, 1.23, 0.968, 257, 251, CRYSTAL STRUCTURE OF PPARGAMMMA IN COMPLEX WITH SR1663
285, d3wmhB_, 0.9310, 1.29, 0.964, 254, 251, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMMA SELECTIVE SYNTHETIC PARTIAL AGONIST MEKT75
286, d3vsoB_, 0.9310, 1.11, 0.980, 256, 250, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT21
287, d3vi8A_, 0.9310, 1.08, 0.976, 260, 250, HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST APHM13
288, d2znnA_, 0.9309, 1.25, 0.641, 258, 251, HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
289, d2xyxA_, 0.9308, 1.25, 0.641, 258, 251, NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY
290, d4xumB_, 0.9306, 1.05, 0.653, 261, 251, PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
291, d3vspB_, 0.9306, 1.36, 0.960, 260, 252, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MEKT28
292, d1i7iB_, 0.9306, 1.08, 0.972, 259, 250, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242
293, d4r2uD_, 0.9305, 1.15, 0.960, 258, 250, CRYSTAL STRUCTURE OF PPARGAMMA IN COMPLEX WITH SR1664
294, d2zk1B_, 0.9305, 1.26, 0.968, 257, 251, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214- PROSTAGLANDIN J2
295, d3an3B_, 0.9303, 1.12, 0.968, 263, 250, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A GAMMA SELECTIVE AGONIST MO3S
296, d4bcrA_, 0.9301, 1.10, 0.980, 256, 250, STRUCTURE OF PPARALPHA IN COMPLEX WITH WY14643
297, p6an1B_, 0.9293, 1.30, 0.637, 263, 251, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND AM-879
298, d5u3uA_, 0.9291, 1.26, 0.960, 253, 250, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 5
299, d2zk3B_, 0.9291, 1.33, 0.641, 255, 251, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 8-OXO- EICOSATETRAENOIC ACID
300, d3peqA_, 0.9290, 1.20, 0.968, 263, 250, PPARD COMPLEXED WITH A PHENOXYACETIC ACID PARTIAL AGONIST
301, d5y2oB1, 0.9289, 1.31, 0.645, 255, 251, STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN-PIOGLITAZONE COMPLEX
302, d4prgD_, 0.9287, 1.11, 0.972, 253, 249, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
303, d4e4kB_, 0.9287, 1.39, 0.949, 270, 253, CRYSTAL STRUCTURE OF PPARGAMMA WITH THE LIGAND JO21
304, d5lsgB_, 0.9286, 1.22, 0.956, 268, 251, PPARGAMMA COMPLEX WITH THE BETULINIC ACID
305, d2zk4B_, 0.9286, 1.22, 0.960, 260, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 15-OXO- EICOSATETRAENOIC ACID
306, d2zk5B_, 0.9285, 1.19, 0.968, 263, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH NITRO-233
307, d4jl4B_, 0.9284, 1.22, 0.968, 263, 250, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570 [(2S)-3-(BIPHENYL-4-YL)-2-(BIPHENYL-4-YLOXY)PROPANOIC ACID]
308, d5u40B_, 0.9283, 1.18, 0.960, 267, 250, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 15
309, d3adwB_, 0.9283, 1.37, 0.635, 259, 252, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE AND 15-OXO-EICOSATETRAENOIC ACID
310, d2xkwB_, 0.9283, 1.22, 0.972, 260, 250, LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE
311, d2vsrB_, 0.9283, 1.41, 0.968, 256, 251, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE
312, d2zvtB_, 0.9282, 1.39, 0.968, 255, 250, CYS285SER MUTANT PPARGAMMA LIGAND-BINDING DOMAIN COMPLEXED WITH 15-DEOXY-DELTA1214-PROSTAGLANDIN J2
313, d4r06B_, 0.9281, 1.21, 0.972, 263, 250, CRYSTAL STRUCTURE OF SR2067 BOUND TO PPARGAMMA
314, d2zk6B_, 0.9280, 1.25, 0.964, 252, 250, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH C8-BODIPY
315, d3dy6B_, 0.9277, 1.23, 0.960, 262, 250, PPARDELTA COMPLEXED WITH AN ANTHRANILIC ACID PARTIAL AGONIST
316, d3d5fB_, 0.9276, 1.14, 0.640, 255, 250, CRYSTAL STRUCTURE OF PPAR-DELTA COMPLEX
317, d4ci5B_, 0.9275, 1.25, 0.644, 254, 250, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR GAMMA AGONIST
318, p3dzyD2, 0.9273, 1.42, 0.960, 260, 252, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH ROSIGLITAZONE 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
319, p6f2lB_, 0.9272, 0.80, 0.984, 252, 247, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND THE LIGAND LJ570: STRUCTURE OBTAINED FROM CRYSTALS OF THE APO-FORM SOAKED FOR 15 DAYS.
320, d4prgB_, 0.9271, 1.31, 0.968, 255, 250, PARTIAL AGONIST PPAR GAMMA COCRYSTAL
321, d4jazB_, 0.9269, 1.40, 0.945, 270, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA LBD AND TRANS- RESVERATROL
322, d3advB_, 0.9269, 1.21, 0.964, 267, 250, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH SEROTONIN
323, p5aztA_, 0.9266, 1.31, 0.960, 257, 250, TERNARY COMPLEX OF HPPARALPHA LIGAND BINDING DOMAIN 17-OXODHA AND A SRC1 PEPTIDE
324, d2znpA_, 0.9266, 1.44, 0.627, 261, 252, HUMAN PPAR DELTA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP204
325, d2awhA_, 0.9258, 1.27, 0.641, 259, 251, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
326, d5u41A_, 0.9257, 1.34, 0.651, 254, 252, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 16
327, d3r8aA_, 0.9254, 1.08, 0.644, 260, 250, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A COMPOUND WITH DUAL PPAR GAMMA AGONISM AND ANGIOTENSIN II TYPE I RECEPTOR ANTAGONISM ACTIVITY
328, d3adxB_, 0.9251, 1.21, 0.960, 251, 249, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN AND NITRO-233
329, d5hzcA_, 0.9249, 1.22, 0.968, 251, 249, CRYSTAL STRUCTURE OF THE COMPLEX PPARGAMMA/AL26-29
330, d3x1hB_, 0.9249, 0.76, 0.988, 251, 246, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-OXO- TRICOSAHEXAENOIC ACID
331, d2q6sB_, 0.9248, 1.36, 0.968, 254, 249, 2.4 ANGSTROM CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED TO BVT.13 WITHOUT CO-ACTIVATOR PEPTIDES
332, p6c5tA_, 0.9245, 1.43, 0.948, 253, 249, PPARG LBD BOUND TO SR11023 
333, d5u3yB_, 0.9243, 1.29, 0.964, 257, 249, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 9
334, d3adsB_, 0.9242, 1.37, 0.641, 255, 251, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN
335, p6c5qA_, 0.9241, 1.23, 0.968, 251, 249, PPARG LBD BOUND TO SR10171 
336, d4ci4A_, 0.9233, 1.32, 0.964, 265, 249, STRUCTURAL BASIS FOR GL479 A DUAL PEROXISOME PROLIFERATOR- ACTIVATED RECEPTOR ALPHA AGONIST
337, d2q59B_, 0.9233, 0.80, 0.638, 248, 246, CRYSTAL STRUCTURE OF PPARGAMMA LBD BOUND TO FULL AGONIST MRL20
338, d5u44A_, 0.9225, 1.27, 0.968, 253, 248, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 13
339, d2vv0B_, 0.9225, 1.39, 0.640, 257, 250, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA
340, p5aztB_, 0.9224, 1.29, 0.956, 252, 249, TERNARY COMPLEX OF HPPARALPHA LIGAND BINDING DOMAIN 17-OXODHA AND A SRC1 PEPTIDE
341, d2bawA_, 0.9222, 0.91, 0.640, 251, 247, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
342, d4o8fB_, 0.9220, 1.09, 0.649, 250, 248, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA MUTANT R357A AND ROSIGLITAZONE
343, d3d5fA_, 0.9219, 0.85, 0.996, 249, 246, CRYSTAL STRUCTURE OF PPAR-DELTA COMPLEX
344, d3aduB_, 0.9211, 1.39, 0.648, 254, 250, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE
345, d3adtB_, 0.9210, 1.31, 0.964, 261, 249, HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-HYDROXY-INDOLE ACETATE
346, d3pbaB_, 0.9208, 1.32, 0.956, 257, 249, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MONOSULFATE TETRABROMO-BISPHENOL A (MONOTBBPA)
347, d3et0B1, 0.9207, 1.32, 0.968, 249, 248, STRUCTURE OF PPARGAMMA WITH 3-(5-METHOXY-1H-INDOL-3-YL)- PROPIONIC ACID
348, p3t03B_, 0.9202, 1.07, 0.943, 257, 247, CRYSTAL STRUCTURE OF PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A NOVEL PARTIAL AGONIST GQ-16
349, d2znoB_, 0.9200, 0.88, 0.996, 249, 246, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703
350, d2hwrB_, 0.9192, 1.26, 0.968, 251, 248, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
351, d2hwqB_, 0.9192, 1.27, 0.960, 253, 247, STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS
352, d4oj4A_, 0.9183, 1.26, 0.968, 253, 247, CRYSTAL STRUCTURE OF V290M PPARGAMMA MUTANT IN COMPLEX WITH DICLOFENAC
353, d2awhB_, 0.9183, 1.29, 0.964, 260, 247, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
354, d5u40A_, 0.9182, 1.10, 0.649, 250, 248, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 15
355, d2bawB_, 0.9179, 1.21, 0.635, 257, 249, HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1
356, d3oswB_, 0.9162, 0.93, 0.659, 248, 246, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRABROMO-BISPHENOL A (TBBPA)
357, d5u3xB_, 0.9148, 1.23, 0.959, 248, 246, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 8
358, d4xtaA_, 0.9146, 0.99, 0.654, 252, 246, MECHANISMS OF PPARGAMMA ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
359, d3po9B_, 0.9144, 0.95, 0.984, 248, 245, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPROPYLTIN
360, d5u3uB_, 0.9130, 1.52, 0.960, 249, 248, HUMAN PPARDELTA LIGAND-BINDING DOMAIN IN COMPLEXED WITH SPECIFIC AGONIST 5
361, d2j14A_, 0.9115, 1.10, 0.645, 250, 245, 345-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2
362, d5wr1B_, 0.9114, 1.34, 0.649, 253, 248, COVALENT BOND FORMATION OF BIFUNCTIONAL LIGAND WITH HPPARG-LBD
363, d4l98B_, 0.9114, 1.31, 0.967, 246, 245, CRYSTAL STRUCTURE OF THE COMPLEX OF F360L PPARGAMMA MUTANT WITH THE LIGAND LT175
364, d5wqxB_, 0.9110, 1.79, 0.940, 258, 250, COVALENT BOND FORMATION OF SYNTHETIC LIGAND WITH HPPARG-LBD
365, d5wr0B_, 0.9107, 1.33, 0.967, 246, 245, HUISGEN CYCLOADDITION FOR PPARG-LBD LABELING BY SOAKING METHOD
366, d1zeoB_, 0.9106, 1.33, 0.967, 246, 245, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST
367, d2vv4B_, 0.9105, 1.27, 0.963, 247, 245, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE
368, d5azvB_, 0.9102, 1.36, 0.963, 247, 245, CRYSTAL STRUCTURE OF HPPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 17-OXODHA
369, d2vv3B_, 0.9094, 1.35, 0.967, 246, 245, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-OXODHA
370, d2vstB_, 0.9094, 1.37, 0.967, 246, 245, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)- HODE
371, d3oz0A_, 0.9090, 1.64, 0.955, 248, 247, PPAR DELTA IN COMPLEX WITH AZPPARD02
372, d4l96A_, 0.9088, 1.65, 0.633, 260, 248, STRUCTURE OF THE COMPLEX BETWEEN THE F360L PPARGAMMA MUTANT AND THE LIGAND LT175 (SPACE GROUP I222)
373, d3feiA_, 0.9088, 1.73, 0.948, 260, 251, DESIGN AND BIOLOGICAL EVALUATION OF NOVEL BALANCED DUAL PPARA/G AGONISTS
374, d3osiB_, 0.9086, 1.03, 0.648, 246, 244, CRYSTAL STRUCTURE OF PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH TETRACHLORO-BISPHENOL A (TCBPA)
375, d3vjhB_, 0.9084, 1.25, 0.967, 245, 244, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL35
376, d2prgB_, 0.9080, 1.39, 0.959, 246, 245, LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA
377, d2j14B_, 0.9071, 0.93, 0.992, 246, 242, 345-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2
378, d2p4yA_, 0.9044, 1.28, 0.650, 251, 246, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA-LIGAND BINDING DOMAIN COMPLEXED WITH AN INDOLE-BASED MODULATOR
379, d4pvuB_, 0.9034, 0.93, 0.996, 244, 242, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE R ENANTIOMER OF MBX-102 (METAGLIDASEN)
380, d3vjiB_, 0.9031, 1.16, 0.967, 252, 243, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH JKPL53
381, d2pobB_, 0.9031, 1.50, 0.963, 245, 244, PPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A FARGLITAZAR ANALOGUE GW4709
382, d4pwlB_, 0.9022, 1.11, 0.971, 247, 242, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPARGAMMA-LBD AND THE S ENANTIOMER OF MBX-102 (METAGLIDASEN)
383, d3b0qB_, 0.9016, 1.17, 0.959, 252, 243, HUMAN PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH MCC555
384, d2q5pB_, 0.9011, 1.50, 0.967, 245, 244, CRYSTAL STRUCTURE OF PPARGAMMA BOUND TO PARTIAL AGONIST MRL24
385, d3b0rB_, 0.8992, 1.43, 0.947, 245, 243, HUMAN PPAR GAMMA LIGAND BINDING DMAIN COMPLEXED WITH GW9662 IN A COVALENT BONDED FORM
386, d4em9B_, 0.8988, 1.58, 0.967, 245, 244, HUMAN PPAR GAMMA IN COMPLEX WITH NONANOIC ACIDS
387, d5f9bB_, 0.8980, 1.41, 0.959, 243, 242, X-RAY CRYSTAL STRUCTURE OF PPARGAMMA IN THE COMPLEX WITH CAULOPHYLLOGENIN
388, d1kkqB_, 0.8962, 1.11, 0.954, 250, 241, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
389, p5xmxB_, 0.8960, 1.86, 0.609, 269, 248, CO-CRYSTAL STRUCTURE OF INHIBITOR COMPOUND IN COMPLEX WITH HUMAN PPARDELTA LBD 
390, d1kkqD_, 0.8953, 1.29, 0.647, 245, 241, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
391, d5hzcB_, 0.8944, 1.75, 0.607, 269, 247, CRYSTAL STRUCTURE OF THE COMPLEX PPARGAMMA/AL26-29
392, d1kkqA_, 0.8940, 1.22, 0.954, 250, 241, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
393, d1kkqC_, 0.8939, 1.88, 0.617, 269, 248, CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF
394, d4emaB_, 0.8920, 1.78, 0.611, 269, 247, HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH ROSIGLITAZONE
395, d4xtaB_, 0.8893, 1.27, 0.942, 244, 241, MECHANISMS OF PPARGAMMA ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
396, d2vv1B_, 0.8848, 1.12, 0.962, 243, 239, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA
397, d3r8aB1, 0.8821, 1.36, 0.971, 239, 238, X-RAY CRYSTAL STRUCTURE OF THE NUCLEAR HORMONE RECEPTOR PPAR-GAMMA IN A COMPLEX WITH A COMPOUND WITH DUAL PPAR GAMMA AGONISM AND ANGIOTENSIN II TYPE I RECEPTOR ANTAGONISM ACTIVITY
398, d3x1iB_, 0.8778, 1.47, 0.954, 238, 238, HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXO- TETRACOSAHEXAENOIC ACID
399, d2q6rA_, 0.8756, 1.33, 0.970, 237, 236, CRYSTAL STRUCTURE OF PPAR GAMMA COMPLEXED WITH PARTIAL AGONIST SF147
400, p6enqB_, 0.8755, 0.65, 0.987, 235, 232, STRUCTURE OF HUMAN PPAR GAMMA LBD IN COMPLEX WITH LANIFIBRANOR (IVA337)
401, d2q5gA_, 0.8728, 0.65, 1.000, 232, 232, LIGAND BINDING DOMAIN OF PPAR DELTA RECEPTOR IN COMPLEX WITH A PARTIAL AGONIST
402, d4l98A_, 0.8637, 1.61, 0.633, 244, 237, CRYSTAL STRUCTURE OF THE COMPLEX OF F360L PPARGAMMA MUTANT WITH THE LIGAND LT175
403, d2q5gB_, 0.8624, 1.47, 0.949, 244, 234, LIGAND BINDING DOMAIN OF PPAR DELTA RECEPTOR IN COMPLEX WITH A PARTIAL AGONIST
404, d2p4yB_, 0.8349, 1.04, 0.651, 235, 232, CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA-LIGAND BINDING DOMAIN COMPLEXED WITH AN INDOLE-BASED MODULATOR
405, d2qmvA_, 0.8316, 1.35, 0.964, 227, 225, HIGH RESOLUTION STRUCTURE OF PEROXISONE PROLIFERATION-ACTIVATED RECEPTOR GAMMA AND CHARACTERISATION OF ITS INTERACTION WITH THE CO- ACTIVATOR TRANSCRIPTIONAL INTERMEDIARY FACTOR 2
406, d1s0xA1, 0.8195, 2.80, 0.914, 270, 255, CRYSTAL STRUCTURE OF THE HUMAN RORALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH CHOLESTEROL SULFATE AT 2.2A
407, p4s15B_, 0.8172, 2.30, 0.256, 249, 238, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORALPHA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
408, p5iz0G_, 0.8116, 2.43, 0.243, 250, 239, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
409, p5iz0B_, 0.8104, 2.43, 0.243, 250, 239, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
410, p4wpfA_, 0.8082, 2.40, 0.223, 246, 238, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PHENYL SULFONAMIDE AGONIST
411, d1k4wA_, 0.8082, 2.36, 0.224, 245, 237, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR BETA LIGAND-BINDING DOMAIN IN THE ACTIVE CONFORMATION
412, p4wpfD_, 0.8080, 2.54, 0.223, 246, 238, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PHENYL SULFONAMIDE AGONIST
413, p4s15A_, 0.8078, 2.31, 0.237, 244, 236, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORALPHA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
414, d5vb3A1, 0.8076, 2.55, 0.223, 246, 238, X-RAY STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN + SRC2 PEPTIDE
415, d5vb5A1, 0.8057, 2.35, 0.246, 244, 236, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN INVERSE AGONIST AND SRC2 PEPTIDE
416, p5vqlA_, 0.8051, 2.58, 0.223, 249, 238, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH A INVERSE AGONIST AND SRC2 PEPTIDE 
417, d1n83A1, 0.8049, 2.62, 0.223, 249, 238, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE ORPHAN NUCLEAR HORMONE RECEPTOR ROR(ALPHA)-LBD AND CHOLESTEROL
418, d5vb6A1, 0.8040, 2.62, 0.223, 259, 238, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN INVERSE AGONIST AND SRC2 PEPTIDE
419, d4ymqA1, 0.8036, 2.24, 0.258, 241, 233, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT + SRC2 PEPTIDE WITH A BENZOTHIADIAZOLE DIOXIDE INVERSE AGONIST
420, d1nq7A_, 0.8036, 2.63, 0.223, 249, 238, CHARACTERIZATION OF LIGANDS FOR THE ORPHAN NUCLEAR RECEPTOR RORBETA
421, d5g46A1, 0.8029, 2.43, 0.225, 244, 236, LIGAND COMPLEX OF RORG LBD
422, p5yp5A_, 0.8028, 2.40, 0.237, 244, 236, CRYSTAL STRUCTURE OF RORGAMMA COMPLEXED WITH SRC2 AND COMPOUND 5D
423, p4xt9A_, 0.8028, 2.39, 0.226, 243, 235, RORGAMMA (263-509) COMPLEXED WITH GSK2435341A AND SRC2
424, d1n4hA_, 0.8028, 2.38, 0.226, 243, 235, CHARACTERIZATION OF LIGANDS FOR THE ORPHAN NUCLEAR RECEPTOR RORBETA
425, d5x8wA_, 0.8022, 2.38, 0.226, 243, 235, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN.
426, p5vqkA_, 0.8022, 2.39, 0.237, 244, 236, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH A INVERSE AGONIST AND SRC2 PEPTIDE 
427, d5nu1A_, 0.8022, 2.51, 0.220, 244, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
428, p5yp6A_, 0.8021, 2.56, 0.224, 256, 237, RORGAMMA (263-509) COMPLEXED WITH SRC2 AND COMPOUND 6
429, d5x8uA_, 0.8021, 2.46, 0.225, 245, 236, CRYSTAL STRUCTURE OF THE WILD HUMAN ROR GAMMA LIGAND BINDING DOMAIN.
430, d5vb7A1, 0.8021, 2.38, 0.226, 243, 235, X-RAY CO-STRUCTURE OF NUCLEAR RECEPTOR ROR-GAMMAT LIGAND BINDING DOMAIN WITH AN AGONIST AND SRC2 PEPTIDE
431, p5ejvB_, 0.8018, 2.51, 0.225, 244, 236, RORY IN COMPLEX WITH T090131718 AND COACTIVATOR PEPTIDE EBI96
432, d5g45A1, 0.8016, 2.65, 0.223, 249, 238, LIGAND COMPLEX OF RORG LBD
433, d5g43A1, 0.8016, 2.45, 0.225, 245, 236, LIGAND COMPLEX OF RORG LBD
434, p6fzuA_, 0.8015, 2.41, 0.226, 243, 235, RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ( CPD-1 ) AND RIP140 PEPTIDE AT 1.80A 
435, p6fx0A_, 0.8013, 2.40, 0.226, 243, 235, STRUCTURE-BASED DESIGN OF TRIFAROTENE (CD5789); A POTENT AND SELECTIVE RAR GAMMA AGONIST FOR THE TREATMENT OF ACNE 
436, d5ntwD_, 0.8012, 2.46, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
437, d5aphA1, 0.8012, 2.49, 0.245, 238, 233, LIGAND COMPLEX OF RORG LBD
438, d5apjA1, 0.8009, 2.47, 0.225, 245, 236, LIGAND COMPLEX OF RORG LBD
439, p4nieB_, 0.8004, 2.41, 0.226, 243, 235, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH SMALL MOLECULE LIGAND
440, p6g07D_, 0.8000, 2.41, 0.226, 243, 235, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
441, d5g42A1, 0.8000, 2.47, 0.225, 245, 236, LIGAND COMPLEX OF RORG LBD
442, d5g44A1, 0.7999, 2.49, 0.225, 245, 236, LIGAND COMPLEX OF RORG LBD
443, p4wlbB_, 0.7999, 2.43, 0.226, 243, 235, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PARTIAL INVERSE AGONIST COMPOUND
444, p4dm8B_, 0.7998, 2.44, 0.226, 243, 235, CRYSTAL STRUCTURE OF RARB LBD IN COMPLEX WITH 9CIS RETINOIC ACID
445, d5ntnC_, 0.7996, 2.43, 0.230, 248, 235, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
446, d4dm6B_, 0.7992, 2.44, 0.249, 239, 233, CRYSTAL STRUCTURE OF RARB LBD HOMODIMER IN COMPLEX WITH TTNPB
447, d3l0lB_, 0.7991, 2.50, 0.225, 245, 236, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
448, p6g07A_, 0.7987, 2.48, 0.245, 239, 233, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
449, p6g05B_, 0.7987, 2.43, 0.226, 248, 235, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-2  AND RIP140 PEPTIDE AT 1.90A 
450, d3lbdA_, 0.7985, 2.50, 0.225, 245, 236, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO 9-CIS RETINOIC ACID
451, d5ntwC_, 0.7982, 2.50, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
452, p4jyhA_, 0.7982, 2.47, 0.246, 237, 232, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE AGONIST BMS948 [4-{[(8-PHENYLNAPHTHALEN-2-YL)CARBONYL]AMINO}BENZOIC ACID]
453, p5ejvA_, 0.7981, 2.50, 0.225, 245, 236, RORY IN COMPLEX WITH T090131718 AND COACTIVATOR PEPTIDE EBI96
454, p4s14A_, 0.7981, 2.46, 0.245, 239, 233, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORGAMMA LIGAND- BINDING DOMAIN IN COMPLEX WITH 4ALPHA-CABOXYL 4BETA-METHYL- ZYMOSTEROL (4ACD8)
455, p5iz0A_, 0.7980, 2.44, 0.226, 245, 235, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
456, d4lbdA_, 0.7977, 2.54, 0.224, 245, 237, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO THE SYNTHETIC AGONIST BMS961
457, d5ntnA_, 0.7976, 2.51, 0.225, 244, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
458, d3l0jA_, 0.7976, 2.48, 0.246, 237, 232, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
459, d5nu1B_, 0.7975, 2.51, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
460, p5iz0D_, 0.7975, 2.47, 0.226, 243, 235, RORGAMMA IN COMPLEX WITH AGONIST BIO592 AND COACTIVATOR EBI96
461, d5ntwA_, 0.7973, 2.53, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
462, d5ntnB_, 0.7973, 2.46, 0.226, 243, 235, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
463, d1exxA_, 0.7971, 2.51, 0.225, 245, 236, ENANTIOMER DISCRIMINATION ILLUSTRATED BY CRYSTAL STRUCTURES OF THE HUMAN RETINOIC ACID RECEPTOR HRARGAMMA LIGAND BINDING DOMAIN: THE COMPLEX WITH THE INACTIVE S-ENANTIOMER BMS270395.
464, p6fzuB_, 0.7970, 2.46, 0.226, 244, 235, RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ( CPD-1 ) AND RIP140 PEPTIDE AT 1.80A 
465, d5ntiC_, 0.7970, 2.45, 0.251, 236, 231, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
466, d2lbdA_, 0.7965, 2.51, 0.225, 245, 236, LIGAND-BINDING DOMAIN OF THE HUMAN RETINOIC ACID RECEPTOR GAMMA BOUND TO ALL-TRANS RETINOIC ACID
467, p4jygA_, 0.7963, 2.55, 0.225, 245, 236, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH AGONIST BMS411 [4- {[(55-DIMETHYL-8-PHENYL-56-DIHYDRONAPHTHALEN-2-YL) CARBONYL]AMINO}BENZOIC ACID]
468, p4jyiA_, 0.7961, 2.50, 0.246, 237, 232, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE PARTIAL AGONIST BMS641 [3-CHLORO-4-[(E)-2-(55-DIMETHYL-8-PHENYL-56- DIHYDRONAPHTHALEN-2-YL)ETHENYL]BENZOIC ACID]
469, d4dm6A1, 0.7960, 2.48, 0.245, 239, 233, CRYSTAL STRUCTURE OF RARB LBD HOMODIMER IN COMPLEX WITH TTNPB
470, p6g07C_, 0.7957, 2.49, 0.245, 239, 233, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
471, d1fcyA_, 0.7956, 2.45, 0.250, 239, 232, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARBETA/GAMMA- SELECTIVE RETINOID CD564
472, p4nieA_, 0.7955, 2.59, 0.224, 246, 237, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH SMALL MOLECULE LIGAND
473, p4jyhB_, 0.7955, 2.49, 0.247, 236, 231, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE AGONIST BMS948 [4-{[(8-PHENYLNAPHTHALEN-2-YL)CARBONYL]AMINO}BENZOIC ACID]
474, p3kytA_, 0.7955, 2.54, 0.225, 245, 236, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
475, d5ntiA_, 0.7948, 2.56, 0.249, 239, 233, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
476, p4wlbA_, 0.7943, 2.47, 0.226, 243, 235, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PARTIAL INVERSE AGONIST COMPOUND
477, d5ntiB_, 0.7941, 2.56, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
478, p4jygB_, 0.7941, 2.50, 0.226, 248, 235, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH AGONIST BMS411 [4- {[(55-DIMETHYL-8-PHENYL-56-DIHYDRONAPHTHALEN-2-YL) CARBONYL]AMINO}BENZOIC ACID]
479, d1exaA_, 0.7941, 2.52, 0.226, 244, 235, ENANTIOMER DISCRIMINATION ILLUSTRATED BY CRYSTAL STRUCTURES OF THE HUMAN RETINOIC ACID RECEPTOR HRARGAMMA LIGAND BINDING DOMAIN: THE COMPLEX WITH THE ACTIVE R-ENANTIOMER BMS270394.
480, d1fcxA_, 0.7935, 2.59, 0.249, 240, 233, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARGAMMA-SELECTIVE RETINOID BMS184394
481, d5ntwB_, 0.7934, 2.48, 0.251, 236, 231, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
482, d5m24A_, 0.7933, 2.47, 0.248, 235, 230, RARG MUTANT-S371E
483, p4jyiB_, 0.7924, 2.55, 0.225, 245, 236, CRYSTAL STRUCTURE OF RARBETA LBD IN COMPLEX WITH SELECTIVE PARTIAL AGONIST BMS641 [3-CHLORO-4-[(E)-2-(55-DIMETHYL-8-PHENYL-56- DIHYDRONAPHTHALEN-2-YL)ETHENYL]BENZOIC ACID]
484, d3l0lA_, 0.7922, 2.39, 0.248, 236, 230, CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH NATURAL LIGAND
485, d1fd0A_, 0.7917, 2.61, 0.249, 239, 233, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE RARGAMMA-SELECTIVE RETINOID SR11254
486, d1fczA_, 0.7909, 2.52, 0.226, 247, 235, ISOTYPE SELECTIVITY OF THE HUMAN RETINOIC ACID NUCLEAR RECEPTOR HRAR: THE COMPLEX WITH THE PANAGONIST RETINOID BMS181156
487, p6g07B_, 0.7898, 2.37, 0.249, 235, 229, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-9  AND RIP140 PEPTIDE AT 1.66A 
488, p6g05A_, 0.7893, 2.38, 0.249, 235, 229, RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST  CPD-2  AND RIP140 PEPTIDE AT 1.90A 
489, d5ntnD_, 0.7879, 2.60, 0.225, 245, 236, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
490, p3a9eB_, 0.7876, 2.59, 0.229, 245, 236, CRYSTAL STRUCTURE OF A MIXED AGONIST-BOUND RAR-ALPHA AND ANTAGONIST- BOUND RXR-ALPHA HETERODIMER LIGAND BINDING DOMAINS
491, p4dm8A_, 0.7869, 2.56, 0.226, 244, 235, CRYSTAL STRUCTURE OF RARB LBD IN COMPLEX WITH 9CIS RETINOIC ACID
492, d3falD_, 0.7857, 2.66, 0.245, 239, 233, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
493, d5hjpB1, 0.7856, 2.47, 0.252, 238, 230, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
494, d5i4vE1, 0.7854, 2.36, 0.261, 242, 226, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
495, d5ntiD_, 0.7851, 2.43, 0.251, 243, 227, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
496, d3uvvA1, 0.7850, 2.41, 0.247, 236, 227, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE THYROID RECEPTOR:RETINOID X RECEPTOR COMPLEXED WITH 33 5 TRIIODO-L- THYRONINE AND 9-CIS RETINOIC ACID
497, d5i4vA_, 0.7849, 2.62, 0.226, 244, 235, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
498, d1xdkF_, 0.7849, 2.84, 0.258, 249, 236, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
499, d1xdkB_, 0.7849, 2.79, 0.243, 260, 230, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
500, d1nq1A1, 0.7847, 2.79, 0.243, 260, 230, TR RECEPTOR MUTATIONS CONFERRING HORMONE RESISTANCE AND REDUCED COREPRESSOR RELEASE EXHIBIT DECREASED STABILITY IN THE NTERMINAL LBD
501, d5kyjE1, 0.7843, 2.54, 0.251, 245, 231, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
502, d5kyaE1, 0.7842, 2.54, 0.251, 245, 231, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
503, d5kyaA1, 0.7842, 2.54, 0.251, 245, 231, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
504, d3fc6D_, 0.7839, 2.85, 0.254, 250, 236, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
505, p4zo1X_, 0.7836, 2.33, 0.248, 235, 226, CRYSTAL STRUCTURE OF THE T3-BOUND TR-BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH RXR-ALPHA
506, d3fc6B_, 0.7836, 2.61, 0.246, 242, 228, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
507, d5hjpD1, 0.7834, 2.36, 0.248, 235, 226, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
508, d2aclB1, 0.7834, 2.52, 0.269, 241, 227, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
509, d3falB_, 0.7833, 2.86, 0.250, 242, 236, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
510, d5kyjA1, 0.7828, 2.41, 0.270, 241, 226, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
511, p4dqmC_, 0.7828, 2.44, 0.257, 235, 226, REVEALING A MARINE NATURAL PRODUCT AS A NOVEL AGONIST FOR RETINOIC ACID RECEPTORS WITH A UNIQUE BINDING MODE AND ANTITUMOR ACTIVITY
512, d2aclH2, 0.7827, 2.32, 0.271, 241, 225, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
513, p4nqaI1, 0.7824, 2.39, 0.256, 238, 227, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
514, d3kmrA_, 0.7822, 2.64, 0.246, 242, 228, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH AN AGONIST LIGAND (AM580) AND A COACTIVATOR FRAGMENT
515, d1nq0A1, 0.7822, 2.49, 0.250, 234, 228, TR RECEPTOR MUTATIONS CONFERRING HORMONE RESISTANCE AND REDUCED COREPRESSOR RELEASE EXHIBIT DECREASED STABILITY IN THE NTERMINAL LBD
516, p4dqmA_, 0.7821, 2.67, 0.268, 243, 228, REVEALING A MARINE NATURAL PRODUCT AS A NOVEL AGONIST FOR RETINOIC ACID RECEPTORS WITH A UNIQUE BINDING MODE AND ANTITUMOR ACTIVITY
517, d2aclF2, 0.7818, 2.43, 0.252, 240, 226, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
518, d1nq2A1, 0.7816, 2.47, 0.250, 234, 228, TWO RTH MUTANTS WITH IMPAIRED HORMONE BINDING
519, d1xzxX1, 0.7812, 2.88, 0.254, 250, 236, THYROXINE-THYROID HORMONE RECEPTOR INTERACTIONS
520, d1p8dA_, 0.7809, 2.48, 0.254, 234, 228, X-RAY CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN WITH 24(S)25- EPOXYCHOLESTEROL
521, d4oztE_, 0.7808, 2.45, 0.265, 241, 226, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (PONA CRYSTAL)
522, d3l0eA_, 0.7808, 2.92, 0.250, 251, 236, X-RAY CRYSTAL STRUCTURE OF A POTENT LIVER X RECEPTOR MODULATOR
523, d2aclD2, 0.7805, 2.84, 0.251, 247, 235, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
524, p4nqaB1, 0.7804, 2.47, 0.251, 240, 227, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
525, d1y0xX1, 0.7802, 2.16, 0.259, 238, 224, THYROXINE-THYROID HORMONE RECEPTOR INTERACTIONS
526, d4rakB_, 0.7795, 2.16, 0.259, 238, 224, CRYSTAL STRUCTURE OF NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2 (LXRB) COMPLEXED WITH PARTIAL AGONIST
527, p4dk8C_, 0.7789, 2.64, 0.263, 243, 228, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST 5
528, d5k13A_, 0.7788, 2.41, 0.267, 241, 225, CRYSTAL STRUCTURE OF THE RAR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST
529, d1xapA_, 0.7787, 2.37, 0.258, 240, 225, STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOIC ACID RECEPTOR BETA
530, p3ipuA_, 0.7785, 2.84, 0.247, 247, 235, X-RAY STRUCTURE OF BENZISOXAZOLE UREA SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
531, p3ipuB_, 0.7784, 2.35, 0.258, 232, 225, X-RAY STRUCTURE OF BENZISOXAZOLE UREA SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
532, d1p8dB_, 0.7775, 2.26, 0.259, 229, 224, X-RAY CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN WITH 24(S)25- EPOXYCHOLESTEROL
533, d2nxxE_, 0.7773, 2.67, 0.249, 235, 229, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
534, d1pq6B_, 0.7773, 2.40, 0.257, 232, 226, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
535, d1pq6A_, 0.7773, 2.45, 0.257, 238, 226, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
536, d3kfcA_, 0.7767, 2.39, 0.267, 235, 225, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
537, d2nxxH_, 0.7767, 2.37, 0.249, 239, 225, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
538, d4ypqA_, 0.7761, 2.15, 0.251, 234, 223, CRYSTAL STRUCTURE OF THE ROR(GAMMA)T LIGAND BINDING DOMAIN IN COMPLEX WITH 4-(1-(2-CHLORO-6-(TRIFLUOROMETHYL)BENZOYL)-1H-INDAZOL-3-YL) BENZOIC ACID
539, d1bsxB_, 0.7761, 2.67, 0.250, 241, 228, STRUCTURE AND SPECIFICITY OF NUCLEAR RECEPTOR-COACTIVATOR INTERACTIONS
540, d1bsxA_, 0.7761, 2.37, 0.253, 232, 225, STRUCTURE AND SPECIFICITY OF NUCLEAR RECEPTOR-COACTIVATOR INTERACTIONS
541, d3kfcD_, 0.7759, 2.42, 0.253, 233, 225, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
542, d2nxxG_, 0.7757, 2.18, 0.251, 234, 223, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
543, d2nxxF_, 0.7757, 2.87, 0.222, 243, 234, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
544, d5lwpA1, 0.7754, 2.86, 0.251, 243, 235, DISCOVERY OF PHENOXYINDAZOLES AND PHENYLTHIOINDAZOLES AS RORG INVERSE AGONISTS
545, d2pinB_, 0.7753, 2.86, 0.251, 243, 235, THYROID RECEPTOR BETA IN COMPLEX WITH INHIBITOR
546, d3d57B_, 0.7752, 2.44, 0.253, 233, 225, TR VARIANT D355R
547, d1pqcA_, 0.7752, 2.09, 0.252, 233, 222, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
548, d1pq9A_, 0.7752, 2.09, 0.252, 233, 222, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
549, d3kfcB_, 0.7744, 3.03, 0.230, 242, 235, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
550, p4dk8A_, 0.7743, 2.91, 0.247, 250, 235, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST 5
551, d3d57A_, 0.7743, 2.92, 0.247, 248, 235, TR VARIANT D355R
552, d1pqcC_, 0.7741, 2.55, 0.257, 232, 226, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
553, d1pq9C_, 0.7741, 2.55, 0.257, 232, 226, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
554, d5jy3B_, 0.7737, 2.34, 0.250, 232, 224, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
555, d1pqcB_, 0.7737, 2.34, 0.250, 233, 224, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
556, d1pq9B_, 0.7732, 2.95, 0.247, 245, 235, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
557, d2pinA_, 0.7731, 2.17, 0.257, 231, 222, THYROID RECEPTOR BETA IN COMPLEX WITH INHIBITOR
558, d3imyA_, 0.7730, 2.17, 0.257, 231, 222, STRUCTURE OF TR-BETA BOUND TO SELECTIVE THYROMIMETIC GC-1
559, d3m7rA_, 0.7722, 2.20, 0.260, 230, 223, CRYSTAL STRUCTURE OF VDR H305Q MUTANT
560, d1z5xE_, 0.7722, 2.47, 0.258, 238, 225, HEMIPTERAN ECDYSONE RECEPTOR LIGAND-BINDING DOMAIN COMPLEXED WITH PONASTERONE A
561, d1s19A_, 0.7719, 2.49, 0.258, 238, 225, CRYSTAL STRUCTURE OF VDR LIGAND BINDING DOMAIN COMPLEXED TO CALCIPOTRIOL.
562, d5jy3D_, 0.7716, 2.96, 0.247, 245, 235, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
563, p5uanB2, 0.7715, 2.86, 0.253, 248, 233, CRYSTAL STRUCTURE OF MULTI-DOMAIN RAR-BETA-RXR-ALPHA HETERODIMER ON DNA
564, d1naxA_, 0.7713, 2.84, 0.252, 253, 230, THYROID RECEPTOR BETA1 IN COMPLEX WITH A BETA-SELECTIVE LIGAND
565, d5k6eB_, 0.7710, 2.21, 0.242, 237, 223, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0654919
566, d2hb8A_, 0.7710, 2.62, 0.259, 253, 228, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA-METHYL CALCITRIOL
567, d3tkcA_, 0.7709, 2.20, 0.261, 227, 222, DESIGN SYNTHESIS EVALUATION AND STRUCTURE OF VITAMIN D ANALOGUES WITH FURAN SIDE CHAINS
568, d3ogtA_, 0.7709, 2.47, 0.252, 232, 226, DESIGN CHEMICAL SYNTHESIS FUNCTIONAL CHARACTERIZATION AND CRYSTAL STRUCTURE OF THE SIDECHAIN ANALOGUE OF 125-DIHYDROXYVITAMIN D3.
569, d1txiA_, 0.7708, 2.94, 0.247, 250, 235, CRYSTAL STRUCTURE OF THE VDR LIGAND BINDING DOMAIN COMPLEXED TO TX522
570, d1s0zA_, 0.7708, 2.78, 0.224, 234, 232, CRYSTAL STRUCTURE OF THE VDR LBD COMPLEXED TO SEOCALCITOL.
571, d3x36A_, 0.7707, 2.64, 0.263, 254, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 78-CIS-1A25-DIHYDROXY-19-NORVITAMIN D3
572, d1nuoA_, 0.7707, 2.79, 0.258, 254, 229, TWO RTH MUTANTS WITH IMPAIRED HORMONE BINDING
573, d4pa2A_, 0.7706, 2.79, 0.258, 254, 229,  
574, d3kpzA_, 0.7703, 2.64, 0.263, 253, 228, CRYSTAL STRUCTURE OF A NOVEL VITAMIN D3 ANALOGUE ZK203278 SHOWING DISSOCIATED PROFILE
575, d5gt4A_, 0.7698, 2.63, 0.263, 253, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R2S3R5Z7E14BETA17ALPHA)-2-CYANOPROPOXY- 910-SECOCHOLESTA-5710-TRIENE-1325-TRIOL
576, d4g2iA_, 0.7698, 2.64, 0.268, 254, 228, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
577, d3wwrA_, 0.7697, 2.92, 0.252, 247, 234, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1-((((1S2R6RZ)-26-DIHYDROXY-4-((E)-2-((1R 3AS7AR)-1-((R)-6-HYDROXY-6-METHYLHEPTAN-2-YL)-7A-METHYLHEXAHYDRO-1H- INDEN-4(2H)-YLIDENE)ETHYLIDENE)-3-METHYLENECYCLOHEXYL)OXY)METHYL) CYCLOPROPANECARBONITRILE
578, d2j4aA_, 0.7697, 2.64, 0.268, 255, 228, HUMAN THYROID HORMONE RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH KB131084
579, d2hb7A_, 0.7697, 2.80, 0.253, 253, 229, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA(3- HYDROXY-1-PROPYL) CALCITRIOL
580, d6bn6A_, 0.7696, 2.65, 0.268, 255, 228, IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS
581, p5ysyA_, 0.7696, 2.81, 0.253, 253, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R;2R;3R)-5-[(E)-2-{(1R;3AS;7AR)-1-[(R)-6- HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-2;3;3A;6;7;7A-HEXAHYDRO-1H- INDEN-4-YL}VINYL]-2-(3-HYDROXYPROPYL)CYCLOHEX-4-ENE-1;3-DIOL 
582, d3b0tA1, 0.7694, 2.65, 0.268, 254, 228, HUMAN VDR LIGAND BINDING DOMAIN IN COMPLEX WITH MAXACALCITOL
583, d3aurA_, 0.7694, 2.97, 0.251, 250, 235, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YNE-DIENE TYPE ANALOG OF ACTIVE 14-EPI-2BETA- METHYL-19-NORVITAMIN D3
584, d3a3zX_, 0.7693, 2.65, 0.268, 254, 228, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND 2ALPHA-METHYL-AMCR277A(C23S)
585, d3cs4A_, 0.7692, 2.37, 0.227, 228, 225, STRUCTURE-BASED DESIGN OF A SUPERAGONIST LIGAND FOR THE VITAMIN D NUCLEAR RECEPTOR
586, p5yt2A_, 0.7691, 2.79, 0.258, 255, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH (1R;2S;3R)-5-[(E)-2-{(1R;3AS;7AR)-1-[(R)-6- HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-2;3;3A;6;7;7A-HEXAHYDRO-1H- INDEN-4-YL}VINYL]-2-(3-HYDROXYPROPYL)CYCLOHEX-4-ENE-1;3-DIOL 
587, d4itfA_, 0.7691, 2.66, 0.268, 253, 228, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1ALPHA25-DIHYDROXY-2ALPHA-[2-(1H-TETRAZOLE-1- YL)ETHYL]VITAMIN D3
588, d3cs6A_, 0.7690, 2.66, 0.268, 253, 228, STRUCTURE-BASED DESIGN OF A SUPERAGONIST LIGAND FOR THE VITAMIN D NUCLEAR RECEPTOR
589, d3x31A_, 0.7689, 2.80, 0.253, 255, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 78-CIS-14-EPI-1A25-DIHYDROXY-19-NORVITAMIN D3
590, d3a78A_, 0.7689, 2.81, 0.258, 254, 229, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE NATURAL METABOLITE 1ALPHA25-DIHYDROXY-3-EPI-VITAMIN D3
591, d1upvA_, 0.7689, 2.66, 0.268, 255, 228, CRYSTAL STRUCTURE OF THE HUMAN LIVER X RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST
592, d3a40X_, 0.7688, 2.74, 0.266, 253, 229, CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND 2ALPHA-METHYL-AMCR277B(C23R)
593, p3a2iA_, 0.7688, 2.82, 0.258, 254, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR (H305F) LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647
594, d1ie9A_, 0.7688, 2.81, 0.258, 254, 229, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D LIGAND BINDING DOMAIN BOUND TO MC1288
595, p4g21A_, 0.7687, 2.67, 0.263, 255, 228, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
596, p4g1zA_, 0.7687, 2.34, 0.261, 232, 222, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
597, d3auqA_, 0.7687, 2.81, 0.258, 255, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YNE-DIENE TYPE ANALOG OF ACTIVE 14-EPI-2ALPHA- METHYL-19-NORVITAMIN D3
598, p5v39A_, 0.7686, 2.66, 0.272, 253, 228, CRYSTAL STRUCTURE OF HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A VDRM
599, p5ow7A_, 0.7686, 2.81, 0.253, 255, 229, VDR COMPLEX
600, d3ax8A_, 0.7686, 2.81, 0.253, 255, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 15ALPHA-METHOXY-1ALPHA25-DIHYDROXYVITAMIN D3
601, d5c4tA_, 0.7685, 2.96, 0.242, 239, 231, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
602, p4g1dA_, 0.7685, 2.86, 0.248, 239, 230, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
603, p3o1eA_, 0.7685, 2.72, 0.266, 253, 229, STRUCTURE-FUNCTION OF GEMINI DERIVATIVES WITH TWO DIFFERENT SIDE CHAINS AT C-20 GEMINI-0072 AND GEMINI-0097.
604, d1n46A_, 0.7683, 2.62, 0.269, 251, 227, CRYSTAL STRUCTURE OF HUMAN TR BETA LIGAND-BINDING DOMAIN COMPLEXED WITH A POTENT SUBTYPE-SELECTIVE THYROMIMETIC
605, d3p8xA_, 0.7682, 2.78, 0.253, 240, 229, SYNTHESIS STRUCTURE AND BIOLOGICAL ACTIVITY OF DES-SIDE CHAIN ANALOGUES OF 1ALPHA25-DIHYDROXYVITAMIN D3 WITH SUBSTITUENTS AT C-18
606, d1pq6D_, 0.7682, 2.81, 0.258, 253, 229, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
607, p6fo7A_, 0.7681, 3.02, 0.222, 241, 234, VITAMIN D NUCLEAR RECEPTOR COMPLEX 3 
608, d5c4oA_, 0.7681, 2.88, 0.248, 239, 230, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
609, d1upwA_, 0.7681, 2.90, 0.257, 239, 230, CRYSTAL STRUCTURE OF THE HUMAN LIVER X RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST
610, d1q4xA_, 0.7681, 2.87, 0.253, 248, 233, CRYSTAL STRUCTURE OF HUMAN THYROID HORMONE RECEPTOR BETA LBD IN COMPLEX WITH SPECIFIC AGONIST GC-24
611, d3vhwA_, 0.7679, 2.83, 0.258, 255, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 4-MP
612, d5ntqA_, 0.7677, 2.19, 0.259, 227, 220, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
613, d4iteA_, 0.7675, 2.83, 0.253, 239, 229, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1ALPHA25-DIHYDROXY-2ALPHA-[2-(2H-TETRAZOL-2- YL)ETHYL]VITAMIN D3
614, d3jzcA_, 0.7673, 2.97, 0.223, 241, 233, CRYSTAL STRUCTURE OF TR-BETA BOUND TO THE SELECTIVE THYROMIMETIC TRIAC
615, p5lgaA_, 0.7672, 2.36, 0.261, 232, 222, STRUCTURAL ANALYSIS AND BIOLOGICAL ACTIVITIES OF BXL0124 A GEMINI ANALOG OF VITAMIN D
616, d3a2jA_, 0.7672, 2.96, 0.252, 239, 234, CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR (H305F/H397F) LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647
617, p5ow9A_, 0.7671, 2.68, 0.268, 254, 228, VITAMIN D RECEPTOR COMPLEX
618, d4wqpA_, 0.7671, 2.53, 0.220, 234, 227, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A BENZYL SULFONAMIDE INVERSE AGONIST
619, d3v3qB1, 0.7671, 2.68, 0.263, 253, 228, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH ETHYL 2-[234 TRIMETHOXY-6(1-OCTANOYL)PHENYL]ACETATE
620, d3ilzA1, 0.7668, 2.95, 0.250, 244, 232, STRUCTURE OF TR-ALFA BOUND TO SELECTIVE THYROMIMETIC GC-1 IN P212121 SPACE GROUP
621, p5nmaA_, 0.7666, 2.91, 0.257, 238, 230, STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF VITAMIN D ANALOGS WITH OXOLANE GROUP IN THEIR SIDE CHAIN
622, d1n46B_, 0.7666, 2.83, 0.258, 253, 229, CRYSTAL STRUCTURE OF HUMAN TR BETA LIGAND-BINDING DOMAIN COMPLEXED WITH A POTENT SUBTYPE-SELECTIVE THYROMIMETIC
623, p3ipsB_, 0.7665, 2.94, 0.251, 239, 231, X-RAY STRUCTURE OF BENZISOXAZOLE SYNTHETIC AGONIST BOUND TO THE LXR- ALPHA
624, p5nmbA_, 0.7664, 2.69, 0.225, 234, 227, 
625, d1db1A_, 0.7664, 2.88, 0.210, 238, 229, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D COMPLEXED TO VITAMIN D
626, p5mx7A_, 0.7661, 3.06, 0.263, 259, 236, struct.pdbx_descriptor               Vitamin D3 receptor A; Nuclear receptor coactivator 1 (E.C.2.3.1.48)  
627, d3gwsX_, 0.7660, 3.06, 0.263, 259, 236, CRYSTAL STRUCTURE OF T3-BOUND THYROID HORMONE RECEPTOR
628, d2hasA_, 0.7660, 2.80, 0.253, 239, 229, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA-(1- PROPOXY) CALCITRIOL
629, d1navA1, 0.7660, 2.80, 0.254, 239, 232, THYROID RECEPTOR ALPHA IN COMPLEX WITH AN AGONIST SELECTIVE FOR THYROID RECEPTOR BETA1
630, d4qm0A_, 0.7659, 2.23, 0.273, 226, 220, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A TERTIARY SULFONAMIDE INVERSE AGONIST
631, p5aviC_, 0.7658, 2.97, 0.255, 238, 231, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 4
632, d5apkB_, 0.7658, 2.65, 0.264, 250, 227, LIGAND COMPLEX OF RORG LBD
633, p4q0aC_, 0.7657, 2.76, 0.259, 238, 228, VITAMIN D RECEPTOR COMPLEX WITH LITHOCHOLIC ACID
634, d2hamA_, 0.7656, 2.85, 0.251, 243, 231, CRYSTAL STRUCTURE OF VDR LBD COMPLEXED TO 2ALPHA-PROPYL- CALCITRIOL
635, p5e7vA_, 0.7655, 2.72, 0.268, 253, 228, POTENT VITAMIN D RECEPTOR AGONIST
636, d5c4uA_, 0.7653, 2.92, 0.272, 251, 232, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
637, d5c4sA_, 0.7653, 2.61, 0.221, 234, 226, IDENTIFICATION OF A NOVEL ALLOSTERIC BINDING SITE FOR RORGT INHIBITORS
638, d4lnwA1, 0.7652, 2.22, 0.264, 226, 220, CRYSTAL STRUCTURE OF TR-ALPHA BOUND TO T3 IN A SECOND SITE
639, p5hjsB_, 0.7651, 2.68, 0.225, 236, 227, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
640, d3wgpA_, 0.7651, 2.81, 0.249, 239, 229, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
641, d2harA_, 0.7651, 2.73, 0.268, 253, 228, CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2 ALPHA-(3- HYDROXY-1-PROPOXY) CALCITRIOL
642, p5hjsA_, 0.7649, 2.91, 0.257, 239, 230, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
643, d3w0cA_, 0.7649, 2.93, 0.224, 241, 232, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
644, p5b5bA_, 0.7648, 2.91, 0.224, 241, 232, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-2627- DIPHENYL-19-NOR-125-DIHYDROXYVITAMIN D3
645, p6b31A_, 0.7647, 3.00, 0.265, 256, 234, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 2 
646, d1ie8A_, 0.7647, 2.24, 0.273, 226, 220, CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D LIGAND BINDING DOMAIN BOUND TO KH1060
647, d3az3A_, 0.7646, 2.67, 0.264, 250, 227, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
648, p5nkyA_, 0.7645, 2.72, 0.268, 252, 228, STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF VITAMIN D ANALOGS WITH OXOLANE GROUP IN THEIR SIDE CHAIN
649, p5avlA_, 0.7645, 2.23, 0.273, 226, 220, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 32B
650, d3w0aA_, 0.7645, 2.68, 0.264, 250, 227, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
651, d3v3eB_, 0.7645, 2.95, 0.260, 249, 231, CRYSTAL STRUCTURE OF THE HUMAN NUR77 LIGAND-BINDING DOMAIN
652, p5b5bD_, 0.7644, 2.46, 0.222, 228, 225, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-2627- DIPHENYL-19-NOR-125-DIHYDROXYVITAMIN D3
653, d3jzbA1, 0.7644, 2.82, 0.254, 250, 228, CRYSTAL STRUCTURE OF TR-ALFA BOUND TO THE SELECTIVE THYROMIMETIC TRIAC
654, p6cvhA_, 0.7643, 2.69, 0.264, 250, 227, IDENTIFICATION AND BIOLOGICAL EVALUATION OF THIAZOLE-BASED INVERSE AGONISTS OF RORGT 
655, d3az2A_, 0.7643, 2.87, 0.258, 238, 229, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
656, p5zweA_, 0.7641, 2.50, 0.261, 224, 222, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING A VINYL KETONE GROUP VIA CONJUGATE ADDITION REACTION 
657, p6fo9A_, 0.7640, 2.68, 0.264, 250, 227, VITAMIN D NUCLEAR RECEPTOR COMPLEX 2 
658, d4kziB_, 0.7639, 2.79, 0.203, 237, 227, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH DPDO
659, p3w0iA_, 0.7639, 2.56, 0.270, 240, 226, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
660, d2zxnA_, 0.7639, 3.01, 0.265, 256, 234, A NEW CLASS OF VITAMIN D RECEPTOR LIGANDS THAT INDUCE STRUCTURAL REARRANGEMENT OF THE LIGAND-BINDING POCKET
661, d4lnxA1, 0.7638, 2.52, 0.222, 227, 225, CRYSTAL STRUCTURE OF TR-ALPHA BOUND TO T4 IN A SECOND SITE
662, p3wt7A_, 0.7638, 2.69, 0.264, 250, 227, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22R-BUTYL-2-METHYLIDENE- 2627-DIMETHYL-1924-DINOR-1 25-DIHYDROXYVITAMIN D3
663, p3vt5A_, 0.7637, 2.78, 0.269, 240, 227, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
664, p3o1dA_, 0.7637, 2.83, 0.253, 239, 229, STRUCTURE-FUNCTION STUDY OF GEMINI DERIVATIVES WITH TWO DIFFERENT SIDE CHAINS AT C-20 GEMINI-0072 AND GEMINI-0097.
665, p4fhhA_, 0.7635, 2.82, 0.211, 234, 227, DEVELOPMENT OF SYNTHETICALLY ACCESSIBLE NON-SECOSTEROIDAL HYBRID MOLECULES COMBINING VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITION
666, p3w0jA_, 0.7635, 2.77, 0.266, 242, 229, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
667, d2h6wX_, 0.7634, 2.79, 0.268, 240, 228,  
668, p5xzhA_, 0.7633, 3.02, 0.265, 256, 234, VITAMIN D RECEPTOR WITH A SYNTHETIC LIGAND ADRO2 
669, p3ipsA_, 0.7632, 2.74, 0.273, 240, 227, X-RAY STRUCTURE OF BENZISOXAZOLE SYNTHETIC AGONIST BOUND TO THE LXR- ALPHA
670, d4rzgB_, 0.7631, 2.69, 0.269, 240, 227, CRYSTAL STRUCTURE ANALYSIS OF THE DNPA-BOUNDED NUR77 LIGAND BINDING DOMAIN
671, d1rkgA_, 0.7631, 2.89, 0.252, 240, 230, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2MBISP AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
672, p3vt6A_, 0.7630, 2.91, 0.257, 239, 230, CRYSTAL STRUCTURE OF RAT VDR-LBD WITH 2-SUBSTITUTED-16-ENE-22-THIA- 1ALPHA25-DIHYDROXY-2627-DIMETHYL-19-NORVITAMIN D3
673, p5aviA_, 0.7629, 2.83, 0.266, 242, 229, CRYSTAL STRUCTURE OF LXRALPHA IN COMPLEX WITH TERT-BUTYL BENZOATE ANALOG COMPOUND 4
674, p2hc4A_, 0.7628, 2.85, 0.252, 242, 230, CRYSTAL STRUCTURE OF THE LBD OF VDR OF DANIO RERIO IN COMPLEX WITH CALCITRIOL
675, p4ia1A_, 0.7627, 2.80, 0.268, 239, 228, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
676, p4g2hA_, 0.7627, 2.23, 0.274, 224, 219, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
677, d1xv9D_, 0.7627, 2.63, 0.204, 235, 225, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
678, d1dkfB_, 0.7627, 2.79, 0.263, 241, 228, CRYSTAL STRUCTURE OF A HETERODIMERIC COMPLEX OF RAR AND RXR LIGAND-BINDING DOMAINS
679, d4whgB_, 0.7626, 2.73, 0.269, 240, 227, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 3
680, p3wtqA_, 0.7626, 2.31, 0.264, 228, 220, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-2-METHYLIDENE- 19-NOR-1A25-DIHYDROXYVITAMIN D3
681, d3w0yA_, 0.7626, 3.02, 0.251, 239, 231, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
682, d3az1A_, 0.7626, 3.12, 0.246, 239, 232, CRYSTAL STRUCTURE ANALYSIS OF VITAMIN D RECEPTOR
683, p5zwfA_, 0.7625, 3.08, 0.247, 239, 231, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING A ENONE WITH A BETA METHYL GROUP VIA CONJUGATE ADDITION REACTION 
684, p5owdA_, 0.7625, 2.92, 0.226, 246, 230, VITAMIN D RECEPTOR COMPLEX
685, p4rujA_, 0.7625, 2.67, 0.241, 232, 224, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-VD COMPLEX
686, d3afrA_, 0.7625, 2.65, 0.204, 232, 225, CRYSTAL STRUCTURE OF VDR-LBD/22S-BUTYL-1A24R-DIHYDROXYVITAMIN D3 COMPLEX
687, d2h79A1, 0.7625, 2.75, 0.264, 240, 227, CRYSTAL STRUCTURE OF HUMAN TR ALPHA BOUND T3 IN ORTHORHOMBIC SPACE GROUP
688, p5gicA_, 0.7624, 2.72, 0.260, 250, 227, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-2P
689, p3w5pA_, 0.7624, 2.85, 0.254, 250, 228, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
690, p4g20A_, 0.7623, 2.71, 0.274, 237, 226, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
691, d5k74A_, 0.7622, 2.84, 0.263, 238, 228, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0655870
692, p3w5qA_, 0.7622, 3.00, 0.243, 240, 230, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
693, p3vt4A_, 0.7622, 2.76, 0.269, 240, 227, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
694, p5xpoA_, 0.7621, 3.14, 0.260, 256, 235, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25-(HYDROXYPHENYL)-2- METHYLIDENE-19;26;27-TRINOR-25-OXO-1-HYDROXYVITAMIN D3 
695, p4ummG_, 0.7621, 2.63, 0.278, 237, 227, THE CRYO-EM STRUCTURE OF THE PALINDROMIC DNA-BOUND USP-ECR NUCLEAR RECEPTOR REVEALS AN ASYMMETRIC ORGANIZATION WITH ALLOSTERIC DOMAIN POSITIONING
696, d1r1kD_, 0.7621, 2.77, 0.264, 240, 227, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO PONASTERONE A
697, d5k38A_, 0.7620, 2.87, 0.263, 237, 228, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN
698, p5gieA_, 0.7619, 2.54, 0.228, 227, 224, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4P (P21 FORM)
699, p6b31B_, 0.7618, 2.71, 0.274, 240, 226, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 2 
700, p5zwiA_, 0.7618, 2.80, 0.269, 240, 227, INTERACTION BETWEEN VITAMIN D RECEPTOR (VDR) AND A LIGAND HAVING A DIENONE GROUP 
701, p5b41A_, 0.7617, 2.66, 0.274, 239, 226, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 2-METHYLIDENE-19-NOR-1A 25-DIHYDROXYVITAMIN D3
702, p4ruoX_, 0.7617, 2.49, 0.241, 236, 224, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-GEMINI COMPLEX
703, p4fhiA_, 0.7617, 2.49, 0.241, 236, 224, DEVELOPMENT OF SYNTHETICALLY ACCESSIBLE NON-SECOSTEROIDAL HYBRID MOLECULES COMBINING VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITION
704, p3dr1A_, 0.7617, 2.56, 0.228, 227, 224, SIDE-CHAIN FLUORINE ATOMS OF NON-STEROIDAL VITAMIN D3 ANALOGS STABILIZE HELIX 12 OF VITAMIN D RECEPTOR
705, d2zlaA_, 0.7617, 2.79, 0.268, 251, 228, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
706, p6fodA_, 0.7616, 2.44, 0.223, 227, 224, VITAMIN D NUCLEAR RECEPTOR COMPLEX 1 
707, p3vruA_, 0.7616, 2.76, 0.273, 240, 227, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-METHYLIDENE-1924-DINOR- 1ALPHA25-DIHYDROXY VITAMIND3
708, p2hcdA_, 0.7616, 2.78, 0.269, 239, 227, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE VITAMIN D NUCLEAR RECEPTOR IN COMPLEX WITH GEMINI AND A COACTIVATOR PEPTIDE
709, p4ia3A_, 0.7614, 3.07, 0.242, 239, 231, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
710, p2hbhA_, 0.7614, 2.88, 0.262, 238, 229, CRYSTAL STRUCTURE OF VITAMIN D NUCLEAR RECEPTOR LIGAND BINDING DOMAIN BOUND TO A LOCKED SIDE-CHAIN ANALOG OF CALCITRIOL AND SRC-1 PEPTIDE
711, d2h77A_, 0.7614, 3.12, 0.241, 240, 232, CRYSTAL STRUCTURE OF HUMAN TR ALPHA BOUND T3 IN MONOCLINIC SPACE GROUP
712, p3w5rA_, 0.7613, 2.80, 0.269, 238, 227, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
713, d5k74B_, 0.7612, 2.86, 0.253, 239, 229, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0655870
714, d5k3nD_, 0.7612, 2.67, 0.270, 238, 226, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
715, p5awkA_, 0.7612, 3.01, 0.248, 239, 230, CRYSTAL STRUCTURE OF VDR-LBD/PARTIAL AGONIST COMPLEX: 22S-ETHYL ANALOGUE
716, p4ia2A_, 0.7612, 3.00, 0.248, 239, 230, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
717, p5zwhA_, 0.7611, 2.87, 0.253, 239, 229, COVALENT BOND FORMATION BETWEEN HISTIDINE OF VITAMIN D RECEPTOR (VDR) AND A FULL AGONIST HAVING AN ENE-YNONE GROUP VIA CONJUGATE ADDITION REACTION 
718, p4rupA_, 0.7611, 3.11, 0.261, 251, 234, CRYSTAL STRUCTURE OF ZVDR L337H MUTANT-GEMINI72 COMPLEX
719, d4reeB_, 0.7611, 2.89, 0.271, 242, 229, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 6
720, p3w5tA_, 0.7611, 2.56, 0.228, 227, 224, CRYSTAL STRUCTURE OF COMPLEXES OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN WITH LITHOCHOLIC ACID DERIVATIVES
721, p3vrwA_, 0.7611, 2.49, 0.231, 228, 225, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 22S-BUTYL-2-METHYLIDENE-26 27-DIMETHYL-1924-DINOR-1ALPHA25-DIHYDROXYVITAMIN D3
722, p3ipqA_, 0.7611, 2.85, 0.268, 240, 228, X-RAY STRUCTURE OF GW3965 SYNTHETIC AGONIST BOUND TO THE LXR-ALPHA
723, p2zxmA_, 0.7611, 3.14, 0.241, 239, 232, A NEW CLASS OF VITAMIN D RECEPTOR LIGANDS THAT INDUCE STRUCTURAL REARRANGEMENT OF THE LIGAND-BINDING POCKET
724, p3w0hA_, 0.7610, 2.72, 0.279, 237, 226, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
725, p3w0gA_, 0.7610, 3.06, 0.242, 239, 231, CRYSTAL STRUCTURE OF RAT VDR LIGAND BINDING DOMAIN IN COMPLEX WITH NOVEL NONSECOSTEROIDAL LIGANDS
726, d1xvpD_, 0.7610, 2.79, 0.208, 233, 226, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
727, d3a2hA_, 0.7609, 2.83, 0.272, 242, 228, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH TEI-9647 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
728, p4dk7C_, 0.7608, 2.70, 0.274, 238, 226, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH FULL AGONIST 1
729, p4dk7A_, 0.7608, 2.05, 0.272, 220, 217, CRYSTAL STRUCTURE OF LXR LIGAND BINDING DOMAIN IN COMPLEX WITH FULL AGONIST 1
730, d1xvpB_, 0.7608, 2.91, 0.266, 240, 229, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
731, p3wt5A_, 0.7607, 2.80, 0.263, 247, 228, A MIXED POPULATION OF ANTAGONIST AND AGONIST BINDING CONFORMERS IN A SINGLE CRYSTAL EXPLAINS PARTIAL AGONISM AGAINST VITAMIN D RECEPTOR: ACTIVE VITAMIN D ANALOGUES WITH 22R-ALKYL GROUP
732, p4g1yA_, 0.7606, 2.83, 0.266, 242, 229, STRUCTURAL BASIS FOR THE ACCOMMODATION OF BIS- AND TRIS-AROMATIC DERIVATIVES IN VITAMIN D NUCLEAR RECEPTOR
733, d2o4rA1, 0.7606, 2.91, 0.222, 246, 230, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH VITIII 17-20E AND THE NR2 BOX OF DRIP 205
734, p3vrvA_, 0.7605, 2.77, 0.268, 239, 228, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-METHYLIDENE-2627- DIMETHYL-1924-DINOR-1ALPHA25-DIHYDROXYVITAMIN D3
735, d2zlcA_, 0.7605, 2.27, 0.256, 224, 219, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
736, p5gidA_, 0.7604, 2.40, 0.255, 229, 220, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4 (C2 FORM)
737, p5xpnA_, 0.7603, 2.95, 0.226, 246, 230, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25RS-(HYDROXYPHENYL)-25- METHOXY-2-METHYLIDENE-19;26;27-TRINOR-1-HYDROXYVITAMIN D3 
738, p5xpmA_, 0.7603, 2.83, 0.276, 240, 228, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-25RS- (HYDROXYPHENYL)-25-METHOXY-2-METHYLIDENE-19;26;27-TRINOR-1- HYDROXYVITAMIN D3 
739, d2zmjA_, 0.7603, 3.03, 0.248, 239, 230, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
740, d1rk3A_, 0.7603, 2.76, 0.264, 240, 227, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 125-DIHYDROXYVITAMIN D3 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
741, p5awjA_, 0.7602, 2.72, 0.270, 237, 226, CRYSTAL STRUCTURE OF VDR-LBD/PARTIAL AGONIST COMPLEX: 22S-HEXYL ANALOGUE
742, d2zfxA_, 0.7601, 2.77, 0.269, 240, 227, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YR301 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
743, d1rkhA_, 0.7601, 2.60, 0.279, 237, 226, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2AM20R AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
744, p3vjsA_, 0.7600, 2.69, 0.274, 239, 226, VITAMIN D RECEPTOR COMPLEX WITH A CARBORANE COMPOUND
745, d5k3lD_, 0.7599, 2.71, 0.273, 239, 227, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
746, d2zl9A_, 0.7598, 2.81, 0.269, 240, 227, 2-SUBSTITUTED-16-ENE-22-THIA-1ALPHA25-DIHYDROXY-2627- DIMETHYL-19-NORVITAMIN D3 ANALOGS: SYNTHESIS BIOLOGICAL EVALUATION AND CRYSTAL STRUCTURE
747, d1uhlB1, 0.7595, 2.78, 0.269, 239, 227, CRYSTAL STRUCTURE OF THE LXRALFA-RXRBETA LBD HETERODIMER
748, d5k38B_, 0.7594, 2.77, 0.276, 240, 228, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN
749, p3vjtA_, 0.7593, 2.75, 0.269, 241, 227, VITAMIN D RECEPTOR COMPLEX WITH A CARBORANE COMPOUND
750, d5k6eA_, 0.7592, 2.90, 0.268, 242, 228, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH SBI0654919
751, d4kzmB_, 0.7592, 2.87, 0.268, 239, 228, CRYSTAL STRUCTURE OF TR3 LBD S553A MUTANT
752, d2zmiA_, 0.7592, 2.40, 0.224, 226, 223, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
753, p6fobA_, 0.7591, 2.71, 0.270, 238, 226, VITAMIN D RECEPTOR COMPLEX 5 
754, d5k3lB_, 0.7591, 2.15, 0.259, 218, 216, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
755, p4ynkA_, 0.7591, 2.49, 0.224, 226, 223, CRYSTAL STRUCTURE OF VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH A 19-NORVITAMIN D COMPOUND
756, p6fo81_, 0.7590, 2.84, 0.269, 238, 227, VITAMIN D NUCLEAR RECEPTOR COMPLEX 4 
757, p3vtbA_, 0.7590, 2.52, 0.223, 226, 224, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 25-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK1
758, p4ia7A_, 0.7589, 2.54, 0.215, 230, 223, DIASTEREOTOPIC AND DEUTERIUM EFFECTS IN GEMINI
759, d2o4jA1, 0.7589, 2.84, 0.266, 242, 229, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH VITIII 17-20Z AND THE NR2 BOX OF DRIP 205
760, p3vtdA_, 0.7588, 2.98, 0.249, 238, 229, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 26-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK4
761, p3vtcA_, 0.7588, 2.41, 0.229, 226, 223, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO A PARTIAL AGONIST 26-ADAMANTYL-23-YNE-19-NORVITAMMIN D ADTK3
762, p5xppA_, 0.7587, 2.90, 0.263, 240, 228, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 25RS-(HYDROXYPHENYL)-2- METHYLIDENE-19;26;27-TRINOR-1;25-DIHYDROXYVITAMIN D3 
763, d2zmhA_, 0.7587, 2.81, 0.260, 236, 227, CRYSTAL STRUCTURE OF RAT VITAMIN D RECEPTOR BOUND TO ADAMANTYL VITAMIN D ANALOGS: STRUCTURAL BASIS FOR VITAMIN D RECEPTOR ANTAGONISM AND/OR PARTIAL AGONISM
764, d4refB_, 0.7585, 2.80, 0.264, 240, 227, CRYSTAL STRUCTURE OF TR3 LBD_L449W IN COMPLEX WITH MOLECULE 2
765, d1rjkA_, 0.7585, 3.00, 0.245, 238, 229, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 2MD AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
766, p5h1eA_, 0.7584, 2.79, 0.269, 240, 227, INTERACTION BETWEEN VITAMIN D RECEPTOR AND COACTIVATOR PEPTIDE SRC2-3
767, d1xlsF_, 0.7583, 2.68, 0.274, 240, 226, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
768, d1xlsG_, 0.7582, 2.81, 0.272, 240, 228, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
769, d1xlsH_, 0.7581, 2.72, 0.274, 239, 226, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
770, d1xlsE_, 0.7581, 2.78, 0.273, 240, 227, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
771, p3vt3A_, 0.7577, 2.87, 0.211, 235, 227, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH R270L MUTATION
772, d1xv9B_, 0.7576, 2.82, 0.269, 239, 227, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
773, d5x8sA_, 0.7575, 2.72, 0.279, 239, 226, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH URSOLIC ACID.
774, p3vrtA_, 0.7575, 2.80, 0.211, 242, 227, VDR LIGAND BINDING DOMAIN IN COMPLEX WITH 2-MEHYLIDENE-19252627- TETRANOR-1ALPHA24-DIHYDROXYVITAMIND3
775, d5x8sB_, 0.7574, 2.80, 0.211, 242, 227, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH URSOLIC ACID.
776, d4rzeB_, 0.7574, 2.80, 0.211, 242, 227, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN L437W D594E MUTANT
777, d5k3nA_, 0.7572, 2.80, 0.211, 242, 227, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
778, d4rzfB_, 0.7572, 2.71, 0.271, 239, 225, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN S441W MUTANT
779, d1r6gA_, 0.7571, 3.02, 0.225, 246, 231, CRYSTAL STRUCTURE OF THE THYROID HORMONE RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BETA SELECTIVE COMPOUND
780, d4whfB_, 0.7569, 3.02, 0.225, 246, 231, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH 1-(345- TRIHYDROXYPHENYL)DECAN-1-ONE
781, d5ufoA_, 0.7568, 2.78, 0.216, 235, 227, STRUCTURE OF RORGT BOUND TO
782, d5ntpA_, 0.7566, 2.69, 0.276, 238, 225, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
783, d5k3lC_, 0.7566, 2.79, 0.216, 232, 227, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
784, p5xzfA_, 0.7564, 2.59, 0.206, 229, 223, VITAMIN D RECEPTOR WITH A SYNTHETIC LIGAND ADRO1 
785, d5k3nC_, 0.7562, 2.56, 0.231, 228, 225, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
786, d5k3nB_, 0.7559, 2.70, 0.201, 232, 224, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH ML209
787, d2r40D_, 0.7558, 2.70, 0.257, 239, 226, CRYSTAL STRUCTURE OF 20E BOUND ECR/USP
788, d4qm0C1, 0.7557, 2.60, 0.202, 229, 223, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A TERTIARY SULFONAMIDE INVERSE AGONIST
789, d2o9iB_, 0.7545, 2.60, 0.224, 225, 223, CRYSTAL STRUCTURE OF THE HUMAN PREGNANE X RECEPTOR LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND T0901317
790, d1xvpA_, 0.7543, 2.78, 0.221, 230, 226, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
791, p4nqaA2, 0.7540, 2.44, 0.229, 226, 223, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
792, d4kzjB_, 0.7540, 2.71, 0.271, 237, 225, CRYSTAL STRUCTURE OF TR3 LBD L449W MUTANT
793, p5gieD_, 0.7539, 2.57, 0.231, 228, 225, CRYSTAL STRUCTURE OF VDR IN COMPLEX WITH DLAM-4P (P21 FORM)
794, d5k3lA_, 0.7538, 2.47, 0.224, 226, 223, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 444
795, p3aunA_, 0.7538, 2.53, 0.243, 233, 222, CRYSTAL STRUCTURE OF THE RAT VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YR335 AND A SYNTHETIC PEPTIDE CONTAINING THE NR2 BOX OF DRIP 205
796, p3wt6A_, 0.7537, 2.76, 0.214, 233, 224, A MIXED POPULATION OF ANTAGONIST AND AGONIST BINDING CONFORMERS IN A SINGLE CRYSTAL EXPLAINS PARTIAL AGONISM AGAINST VITAMIN D RECEPTOR: ACTIVE VITAMIN D ANALOGUES WITH 22R-ALKYL GROUP
797, p6eu9A_, 0.7532, 3.18, 0.247, 279, 227, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
798, d3hzfA1, 0.7531, 2.77, 0.220, 232, 227, STRUCTURE OF TR-ALFA BOUND TO SELECTIVE THYROMIMETIC GC-1 IN C2 SPACE GROUP
799, p4j5wB_, 0.7524, 2.71, 0.211, 232, 228, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
800, d1xv9A_, 0.7524, 2.58, 0.212, 229, 222, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
801, d4zomB_, 0.7521, 2.44, 0.277, 230, 220, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
802, d4nb6B_, 0.7520, 2.43, 0.234, 225, 222, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF RORC WITH T0901317
803, d5ntqB_, 0.7514, 2.71, 0.276, 238, 225, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
804, d4re8B_, 0.7513, 2.84, 0.269, 239, 227, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 5
805, p4j5wA_, 0.7513, 2.66, 0.272, 227, 224, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
806, d6bn6B1, 0.7505, 3.29, 0.266, 256, 233, IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS
807, d4zomA_, 0.7504, 3.13, 0.248, 293, 226, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
808, d2o9iA_, 0.7500, 2.77, 0.225, 232, 227, CRYSTAL STRUCTURE OF THE HUMAN PREGNANE X RECEPTOR LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND T0901317
809, d5m96B_, 0.7494, 2.46, 0.227, 222, 220, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW TRIAZOLO AND IMIDAZOLOPYRIDINE RORGT INVERSE AGONISTS
810, p3hc6A_, 0.7491, 2.31, 0.228, 222, 219, FXR WITH SRC1 AND GSK088
811, d1xv9C_, 0.7491, 2.40, 0.227, 223, 220, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND 5B-PREGNANE-320-DIONE.
812, p3hvlB_, 0.7489, 2.56, 0.217, 227, 221, TETHERED PXR-LBD/SRC-1P COMPLEXED WITH SR-12813
813, d4wqpB_, 0.7488, 3.32, 0.246, 294, 228, CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A BENZYL SULFONAMIDE INVERSE AGONIST
814, d5m96A_, 0.7487, 3.32, 0.246, 294, 228, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW TRIAZOLO AND IMIDAZOLOPYRIDINE RORGT INVERSE AGONISTS
815, d1fm6A_, 0.7486, 2.35, 0.228, 222, 219, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
816, p4j5xA_, 0.7485, 2.58, 0.217, 223, 221, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
817, d1xvpC_, 0.7485, 3.20, 0.242, 279, 227, CRYSTAL STRUCTURE OF CAR/RXR HETERODIMER BOUND WITH SRC1 PEPTIDE FATTY ACID AND CITCO
818, d4nb6A_, 0.7484, 2.44, 0.227, 223, 220, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF RORC WITH T0901317
819, p6bnsB_, 0.7483, 3.05, 0.296, 230, 226, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND 25A AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES
820, d1nrlB_, 0.7483, 2.89, 0.220, 232, 227, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND SR12813
821, d5ickB_, 0.7482, 3.23, 0.248, 289, 226, A UNIQUE BINDING MODEL OF FXR LBD WITH FEROLINE
822, d1ovlD_, 0.7481, 2.32, 0.229, 221, 218, CRYSTAL STRUCTURE OF NURR1 LBD
823, d5a86B_, 0.7480, 2.66, 0.224, 225, 223, STRUCTURE OF PREGNANE X RECEPTOR IN COMPLEX WITH A SPHINGOSINE 1-PHOSPHATE RECEPTOR 1 ANTAGONIST
824, d1fm6U_, 0.7478, 2.75, 0.217, 232, 226, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.
825, d1k74A_, 0.7477, 3.23, 0.251, 293, 227, THE 2.3 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN PPARGAMMA AND RXRALPHA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH GW409544 AND 9-CIS RETINOIC ACID AND CO-ACTIVATOR PEPTIDES.
826, d3hlvB_, 0.7474, 3.05, 0.223, 236, 229, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND 16-ALPHA-HYDROXY-ESTRONE ((8S9R13S14R 16R)-316-DIHYDROXY-13-METHYL-78911121415 16-OCTAHYDRO-6H- CYCLOPENTA[A]PHENANTHREN-17-ONE
827, d1ilhA_, 0.7473, 2.32, 0.229, 221, 218, CRYSTAL STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TO SR12813
828, d5apkA1, 0.7472, 3.13, 0.249, 283, 225, LIGAND COMPLEX OF RORG LBD
829, d1pqcD_, 0.7468, 3.08, 0.253, 275, 225, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317
830, d1fm9A_, 0.7467, 3.02, 0.281, 229, 224, THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.
831, d1pq9D_, 0.7464, 2.48, 0.214, 228, 220, HUMAN LXR BETA HORMONE RECEPTOR COMPLEXED WITH T0901317 COMPLEX
832, d1ilgA_, 0.7461, 2.94, 0.256, 274, 223, CRYSTAL STRUCTURE OF APO HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN
833, d4jgvB_, 0.7458, 2.76, 0.217, 232, 226, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH THPN
834, p3ctbB_, 0.7457, 2.77, 0.221, 232, 226, TETHERED PXR-LBD/SRC-1P APOPROTEIN
835, p5di7B_, 0.7456, 2.85, 0.191, 240, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN METHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(4-HYDROXY-2-METHYLPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
836, p3gd2A_, 0.7456, 3.33, 0.250, 270, 228, ISOXAZOLE LIGAND BOUND TO FARNESOID X RECEPTOR (FXR)
837, d5x0rB_, 0.7454, 2.41, 0.228, 222, 219, CRYSTAL STRUCTURE OF PXR LBD COMPLEXED WITH SJB7
838, p5didB_, 0.7454, 2.31, 0.265, 219, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(23-DIFLUORO-4-HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1- OL
839, p4p6wA_, 0.7454, 2.77, 0.221, 232, 226, CRYSTAL STRUCTURE OF MOMETASONE FUROATE-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
840, p5iawA_, 0.7453, 2.32, 0.265, 219, 215, NOVEL NATURAL FXR MODULATOR WITH A UNIQUE BINDING MODE
841, d1ovlB_, 0.7452, 3.24, 0.251, 270, 227, CRYSTAL STRUCTURE OF NURR1 LBD
842, d4zjrB_, 0.7451, 2.64, 0.205, 226, 220, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
843, d1r20D_, 0.7451, 3.09, 0.246, 287, 224, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO THE SYNTHETIC AGONIST BYI06830
844, p5dziB_, 0.7450, 2.87, 0.191, 245, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
845, d5k3mB_, 0.7449, 2.99, 0.290, 227, 224, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH UUA
846, d4s0tB_, 0.7449, 3.16, 0.237, 257, 224, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND WITH ADNECTIN-1 AND COMPOUND-1
847, p5xuqA_, 0.7448, 2.88, 0.182, 245, 225, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH AN ANTAGONIST; 2- METHYLIDENE-19;26;27-TRINOR-22-(S)-BUTYL-1-HYDROXY-25-OXO-25-(1H- PYRROL-2-YL)- VITAMIN D3 
848, p3vt9A_, 0.7448, 2.60, 0.176, 252, 222, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
849, d1ovlE_, 0.7448, 2.96, 0.278, 228, 223, CRYSTAL STRUCTURE OF NURR1 LBD
850, d2qabB_, 0.7447, 2.89, 0.196, 233, 224, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH AN ETHYL INDAZOLE COMPOUND
851, d5ufrB_, 0.7446, 2.47, 0.220, 220, 218, STRUCTURE OF RORGT BOUND TO
852, p5tlvB_, 0.7441, 2.74, 0.239, 228, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(THIOPHENE-23-DIYL)BIS(3-FLUOROPHENOL)
853, p5didA_, 0.7441, 2.89, 0.196, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(23-DIFLUORO-4-HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1- OL
854, p4j5xB_, 0.7441, 2.45, 0.233, 222, 219, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
855, p5di7A_, 0.7440, 3.07, 0.253, 283, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN METHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR5S 7AS)-5-(4-HYDROXY-2-METHYLPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
856, d4x1gA_, 0.7440, 2.61, 0.277, 231, 220, CRYSTAL STRUCTURE OF THE HPXR-LBD IN COMPLEX WITH THE SYNTHETIC ESTROGEN 17ALPHA-ETHINYLESTRADIOL AND THE PESTICIDE TRANS-NONACHLOR
857, p5dl4B_, 0.7439, 2.75, 0.270, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(PHENYLAMINO)PHENYL]PROP-1-ENE-11-DIYL}DIPHENOL
858, d5aygB_, 0.7439, 2.92, 0.218, 247, 225, CRYSTAL STRUCTURE OF THE HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH 3G
859, d4xaoA_, 0.7439, 2.92, 0.218, 247, 225, CRYSTAL STRUCTURE OF THE HPXR-LBD OBTAINED IN PRESENCE OF THE PESTICIDE TRANS-NONACHLOR
860, p3vt8A_, 0.7438, 2.89, 0.191, 245, 225, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
861, d4j5xC_, 0.7437, 2.76, 0.213, 223, 221, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
862, d1m13A_, 0.7437, 2.89, 0.187, 242, 225, CRYSTAL STRUCTURE OF THE HUMAN PREGANE X RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH HYPERFORIN A CONSTITUENT OF ST. JOHN S WORT
863, p5xplA_, 0.7436, 2.94, 0.187, 244, 225, CRYSTAL STRUCTURE OF VDR-LBD COMPLEXED WITH 22S-BUTYL-25- HYDROXYPHENYL-2-METHYLIDENE-19;26;27-TRINOR-25-OXO-1-HYDROXYVITAMIN D3 
864, p5q1iA_, 0.7436, 3.02, 0.237, 293, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
865, d4zomC_, 0.7436, 2.92, 0.187, 241, 225, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
866, d4x1fA_, 0.7436, 2.92, 0.256, 279, 223, CRYSTAL STRUCTURE OF THE HPXR-LBD IN COMPLEX WITH THE SYNTHETIC ESTROGEN 17ALPHA-ETHINYLESTRADIOL
867, d2qa6B_, 0.7435, 2.90, 0.191, 240, 225, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA MUTANT 537S COMPLEXED WITH 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-13-DIOL
868, d1nrlA_, 0.7434, 2.39, 0.222, 219, 216, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH AN SRC-1 COACTIVATOR PEPTIDE AND SR12813
869, p3ctbA_, 0.7432, 3.03, 0.254, 275, 224, TETHERED PXR-LBD/SRC-1P APOPROTEIN
870, d2qr9B_, 0.7432, 2.76, 0.266, 233, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DERIVATIVE COMPOUND
871, d2p15B_, 0.7432, 2.50, 0.222, 238, 221, CRYSTAL STRUCTURE OF THE ER ALPHA LIGAND BINDING DOMAIN WITH THE AGONIST ORTHO-TRIFLUOROMETHYLPHENYLVINYL ESTRADIOL
872, d1xiuB_, 0.7431, 3.07, 0.253, 273, 225, CRYSTAL STRUCTURE OF THE AGONIST-BOUND LIGAND-BINDING DOMAIN OF BIOMPHALARIA GLABRATA RXR
873, d5a86A_, 0.7430, 2.93, 0.276, 237, 225, STRUCTURE OF PREGNANE X RECEPTOR IN COMPLEX WITH A SPHINGOSINE 1-PHOSPHATE RECEPTOR 1 ANTAGONIST
874, p5tn1B_, 0.7427, 2.90, 0.269, 227, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14SE)-17-((4- ISOPROPYLPHENYL)IMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
875, d3q95A_, 0.7427, 2.42, 0.230, 219, 217, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND ESTRIOL
876, d1qkuB_, 0.7427, 3.04, 0.250, 271, 224, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
877, d1qkuA_, 0.7427, 2.92, 0.182, 242, 225, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
878, p5t1zA_, 0.7425, 2.93, 0.256, 278, 223, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ETHOXYTRIPHENYLETHYLENE AND GRIP PEPTIDE
879, p3hvlA_, 0.7425, 3.03, 0.247, 287, 223, TETHERED PXR-LBD/SRC-1P COMPLEXED WITH SR-12813
880, d3p88A_, 0.7424, 2.95, 0.187, 242, 225, FXR BOUND TO ISOQUINOLINECARBOXYLIC ACID
881, d2qseB_, 0.7424, 2.96, 0.182, 242, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH BURNED MEAT COMPOUND 4-OH-PHIP
882, d5k3mA_, 0.7423, 2.37, 0.223, 224, 220, CRYSTAL STRUCTURE OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR (ROR) GAMMA LIGAND BINDING DOMAIN COMPLEX WITH UUA
883, d4j5xD_, 0.7423, 2.98, 0.251, 271, 223, CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
884, p5tn3B_, 0.7422, 2.97, 0.187, 245, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S)-17-((4- ISOPROPYLPHENYL)AMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
885, d1g50A_, 0.7422, 2.84, 0.183, 243, 224, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
886, d3dcuA_, 0.7421, 2.87, 0.182, 247, 225, FXR WITH SRC1 AND GSK8062
887, d5ickA_, 0.7420, 2.87, 0.182, 250, 225, A UNIQUE BINDING MODEL OF FXR LBD WITH FEROLINE
888, p5krlA_, 0.7419, 2.98, 0.187, 240, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(2-CHLORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
889, p4qe6A_, 0.7419, 3.02, 0.256, 287, 223, FXR WITH CDCA AND NCOA-2 PEPTIDE
890, d2yjaB_, 0.7418, 3.09, 0.289, 229, 225, STAPLED PEPTIDES BINDING TO ESTROGEN RECEPTOR ALPHA.
891, d2qabA_, 0.7418, 2.98, 0.187, 242, 225, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH AN ETHYL INDAZOLE COMPOUND
892, p5krmB_, 0.7416, 2.48, 0.233, 222, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(25-DIFLUORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
893, p5digA_, 0.7416, 2.53, 0.217, 239, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUOROMETHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S 3AR5S7AS)-5-[4-HYDROXY-2-(TRIFLUOROMETHYL)PHENYL]-7A- METHYLOCTAHYDRO-1H-INDEN-1-OL
894, d2qxmB_, 0.7416, 2.53, 0.217, 239, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO BURNED MEAT COMPOUND PHIP
895, p5krmA_, 0.7415, 2.92, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(25-DIFLUORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
896, p5drjB_, 0.7415, 2.86, 0.182, 247, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 3-METHYL 25-DIARYLTHIOPHENE-CORE LIGAND 44 -(3-METHYLTHIENE-25-DIYL)BIS(3-CHLOROPHENOL)
897, d4ny9A_, 0.7415, 3.11, 0.302, 229, 225, CRYSTAL STRUCTURE OF THE HUMAN PXR-LBD IN COMPLEX WITH N-{(2R)-1- [(4S)-4-(4-CHLOROPHENYL)-4-HYDROXY-33-DIMETHYLPIPERIDIN-1-YL]-3- METHYL-1-OXOBUTAN-2-YL}-3-HYDROXY-3-METHYLBUTANAMIDE
898, d3dctA_, 0.7415, 3.06, 0.295, 229, 224, FXR WITH SRC1 AND GW4064
899, d5ufrA_, 0.7414, 2.98, 0.182, 236, 225, STRUCTURE OF RORGT BOUND TO
900, p5tmrA_, 0.7414, 3.24, 0.276, 228, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (CYCLOHEXYLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
901, p5tm6B_, 0.7414, 2.98, 0.173, 245, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEXANOIC ACID
902, p5tm5A_, 0.7413, 2.97, 0.178, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 5-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)PENTANOIC ACID
903, p5tm3B_, 0.7413, 2.90, 0.187, 240, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 23-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
904, p5tltB_, 0.7412, 2.98, 0.191, 241, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OCTANE-18-DIYL BIS(23-BIS(4-HYDROXYPHENYL)PENTANOATE)
905, d3ruuA_, 0.7412, 2.98, 0.182, 242, 225, FXR WITH SRC1 AND GSK237
906, d1qkuC_, 0.7412, 2.96, 0.182, 237, 225, WILD TYPE ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
907, p4mg9A_, 0.7411, 2.93, 0.182, 242, 225, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BUTYLPARABEN
908, d2qnvA_, 0.7411, 2.96, 0.257, 260, 222, CRYSTAL STRUCTURE OF THE PREGNANE X RECEPTOR BOUND TO COLUPULONE
909, d2qgwB_, 0.7411, 3.11, 0.302, 229, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH A CHLORO-INDAZOLE COMPOUND
910, p5e19B_, 0.7409, 2.85, 0.213, 223, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE METHYL {4-[BIS(4-HYDROXYPHENYL) METHYLIDENE]CYCLOHEXYL}ACETATE
911, p5uhiA_, 0.7408, 2.92, 0.187, 242, 225, STRUCTURE OF RORGT BOUND TO
912, p5digB_, 0.7408, 2.81, 0.187, 243, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUOROMETHYL-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S 3AR5S7AS)-5-[4-HYDROXY-2-(TRIFLUOROMETHYL)PHENYL]-7A- METHYLOCTAHYDRO-1H-INDEN-1-OL
913, p6bnsA_, 0.7407, 2.95, 0.191, 239, 225, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR PEPTIDE AND COMPOUND 25A AKA BICYCLIC HEXAFLUOROISOPROPYL 2 ALCOHOL SULFONAMIDES
914, d4zjrC1, 0.7407, 2.92, 0.187, 243, 225, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
915, d2qgwA_, 0.7407, 2.97, 0.191, 240, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH A CHLORO-INDAZOLE COMPOUND
916, d1xlsC_, 0.7407, 3.11, 0.289, 229, 225, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
917, d1xlsB_, 0.7407, 2.82, 0.183, 247, 224, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
918, p5tmqB_, 0.7406, 2.97, 0.187, 241, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE 4-BROMOPHENYL 44  - DIHYDROXY-[11 :2 1  -TERPHENYL]-4 -SULFONATE
919, p5dieA_, 0.7406, 2.90, 0.258, 249, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR 5S7AS)-7A-METHYL-5-(235-TRIFLUORO-4-HYDROXYPHENYL)OCTAHYDRO-1H- INDEN-1-OL
920, p4iwfA_, 0.7406, 2.98, 0.187, 242, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC OXIME-DERIVATIVE
921, d1xlsD_, 0.7406, 2.95, 0.191, 238, 225, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
922, d1xlsA_, 0.7406, 2.73, 0.214, 223, 220, CRYSTAL STRUCTURE OF THE MOUSE CAR/RXR LBD HETERODIMER BOUND TO TCPOBOP AND 9CRA AND A TIF2 PEPTIDE CONTAING THE THIRD LXXLL MOTIFS
923, p5e1cB_, 0.7405, 2.90, 0.187, 242, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE DIMETHYL {(1S)-3-[BIS(4- HYDROXYPHENYL)METHYLIDENE]CYCLOHEXYL}PROPANEDIOATE
924, d2qgtB_, 0.7405, 2.87, 0.253, 286, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO AN ETHER ESTRADIOL COMPOUND
925, p5tmuA_, 0.7404, 2.48, 0.226, 219, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(CYCLOHEPTYLIDENEMETHYLENE)DIPHENOL
926, p5tlvA_, 0.7404, 2.98, 0.178, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(THIOPHENE-23-DIYL)BIS(3-FLUOROPHENOL)
927, d2qgtA_, 0.7404, 2.96, 0.221, 232, 226, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO AN ETHER ESTRADIOL COMPOUND
928, p5tlxB_, 0.7403, 2.96, 0.221, 232, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
929, p5dmfA_, 0.7403, 2.93, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}PROP-1-ENE-11- DIYL)DIPHENOL
930, d4xhdA_, 0.7403, 2.98, 0.178, 236, 225, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH COMPOUND-1
931, d3hlvA_, 0.7403, 3.01, 0.182, 236, 225, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND 16-ALPHA-HYDROXY-ESTRONE ((8S9R13S14R 16R)-316-DIHYDROXY-13-METHYL-78911121415 16-OCTAHYDRO-6H- CYCLOPENTA[A]PHENANTHREN-17-ONE
932, p5tn6A_, 0.7402, 2.96, 0.221, 232, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE SPIRO BC-ESTRADIOL (1S1 S3A S7A S)-7A -METHYL- 1 22 33 3A 4 6 7 7A -DECAHYDRO-15 -SPIROBI[INDENE]-1 5- DIOL
933, p5tn3A_, 0.7402, 2.96, 0.221, 232, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S)-17-((4- ISOPROPYLPHENYL)AMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
934, p5tmoB_, 0.7401, 2.97, 0.187, 241, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE PHENYL 44  -DIHYDROXY- [11 :2 1  -TERPHENYL]-4 -SULFONATE
935, p5dueB_, 0.7401, 2.95, 0.182, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PARA-HYDROXYL-SUBSTITUTED SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG 4-HYDROXYPHENYL (1S2S4S5S6R 7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7-THIABICYCLO[2.2.1]HEPTANE-2- SULFONATE 7-OXIDE
936, p4ppsB_, 0.7401, 2.85, 0.187, 241, 224, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN A-CD RING ESTROGEN DERIVATIVE
937, p3rvfA_, 0.7401, 2.99, 0.187, 239, 225, FXR WITH SRC1 AND GSK2034
938, d3bejA_, 0.7401, 2.99, 0.191, 237, 225, STRUCTURE OF HUMAN FXR IN COMPLEX WITH MFA-1 AND CO- ACTIVATOR PEPTIDE
939, p4iqrF2, 0.7400, 2.94, 0.187, 242, 225, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
940, p3rutA_, 0.7400, 2.91, 0.179, 236, 224, FXR WITH SRC1 AND GSK359
941, d2qa6A_, 0.7400, 2.87, 0.258, 268, 221, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA MUTANT 537S COMPLEXED WITH 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-13-DIOL
942, d5u2bC_, 0.7399, 2.88, 0.192, 240, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
943, p5q0zC_, 0.7399, 2.96, 0.178, 236, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
944, p5krcB_, 0.7399, 3.02, 0.182, 238, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH ZEARALENONE
945, d3l03B_, 0.7399, 2.95, 0.191, 239, 225, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTETROL (ESTRA-135(10)-TRIENE-315 ALPHA 16ALPHA17BETA-TETROL)
946, p3kmzA_, 0.7399, 3.00, 0.196, 242, 225, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH THE INVERSE AGONIST BMS493 AND A COREPRESSOR FRAGMENT
947, p5q1gA_, 0.7398, 2.99, 0.182, 236, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
948, d5ntkA_, 0.7398, 3.07, 0.290, 228, 224, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
949, p5uhiB_, 0.7397, 2.82, 0.286, 224, 220, STRUCTURE OF RORGT BOUND TO
950, p5tn4B_, 0.7397, 2.49, 0.218, 227, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ACD-RING ESTROGEN (S)-5-(4-HYDROXY-35- DIMETHYLPHENYL)-23-DIHYDRO-1H-INDEN-1-OL
951, p5tlgB_, 0.7397, 3.10, 0.289, 229, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-44  -DIHYDROXY-3 -((HYDROXYIMINIO)METHYL)-[11 :2  1  -TERPHENYL]-4 -OLATE
952, p4znhA_, 0.7397, 2.92, 0.183, 243, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-FLUORO-SUBSTITUTED OBHS DERIVATIVE
953, d3bejB_, 0.7397, 2.93, 0.188, 244, 223, STRUCTURE OF HUMAN FXR IN COMPLEX WITH MFA-1 AND CO- ACTIVATOR PEPTIDE
954, d2zkcA1, 0.7397, 3.30, 0.265, 230, 226, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH BISPHENOL Z
955, p5tn8B_, 0.7396, 2.98, 0.182, 238, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-4-OLATE
956, p3uuaA_, 0.7396, 3.00, 0.187, 242, 225, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-AF
957, d1ovlA_, 0.7396, 2.61, 0.236, 221, 216, CRYSTAL STRUCTURE OF NURR1 LBD
958, p5tlpA_, 0.7395, 3.12, 0.274, 224, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-BSC ANALOG 3-FLUOROPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE AND 3-METHYL-6-PHENYL-3H- IMIDAZO[45-B]PYRIDIN-2-AMINE
959, p5duhA_, 0.7395, 2.68, 0.209, 225, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-3 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-3-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
960, p4zn7B_, 0.7395, 2.85, 0.213, 223, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DIETHYLSTILBESTROL
961, p5tmzB_, 0.7393, 2.96, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S17S)-16-(3- METHOXYBENZYL)-13-METHYL-78911121314151617-DECAHYDRO-6H- CYCLOPENTA[A]PHENANTHRENE-317-DIOL
962, p5q14C_, 0.7392, 2.84, 0.183, 236, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
963, p5dxkB_, 0.7392, 3.00, 0.191, 239, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(9S)-BICYCLO[3.3.1]NON-9- YLMETHANEDIYL]DIPHENOL
964, d4s0tA_, 0.7391, 3.14, 0.278, 228, 223, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND WITH ADNECTIN-1 AND COMPOUND-1
965, p4pppB_, 0.7391, 2.64, 0.214, 226, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH FLUORO-RESVERATROL
966, p3kmzB_, 0.7391, 2.73, 0.188, 235, 223, CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH THE INVERSE AGONIST BMS493 AND A COREPRESSOR FRAGMENT
967, p5q13A_, 0.7390, 2.87, 0.187, 241, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
968, p5dkgB_, 0.7390, 2.55, 0.220, 226, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A T-BUTYL-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 - [2-(4-TERT-BUTYLPHENYL)PROP-1-ENE-11-DIYL]DIPHENOL
969, p5egvB_, 0.7389, 2.87, 0.179, 234, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX THE 34-DIARYL-FURAN DERIVATIVE 3-CHLORANYL-4-[4-(2- CHLORANYL-4-OXIDANYL-PHENYL)FURAN-3-YL]PHENOL
970, d5x0rA_, 0.7387, 2.94, 0.183, 236, 224, CRYSTAL STRUCTURE OF PXR LBD COMPLEXED WITH SJB7
971, p5tn7A_, 0.7387, 2.98, 0.182, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-3 -FLUORO-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[1 1 -BIPHENYL]-4-OLATE
972, d4reeA_, 0.7387, 2.85, 0.187, 243, 224, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 6
973, d2zasA_, 0.7387, 3.30, 0.265, 230, 226, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 4-ALPHA-CUMYLPHENOL A BISPHENOL A DERIVATIVE
974, d1g50B_, 0.7387, 2.89, 0.192, 239, 224, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
975, p5q10A_, 0.7386, 3.11, 0.256, 279, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
976, p6br3A_, 0.7385, 2.77, 0.188, 235, 223, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST TAK-828.
977, p4mg8A_, 0.7385, 2.64, 0.236, 221, 216, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALANOL
978, p4iqrE2, 0.7385, 3.44, 0.274, 232, 230, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
979, p3vt7A_, 0.7385, 2.93, 0.187, 240, 224, CRYSTAL STRUCTURES OF RAT VDR-LBD WITH W282R MUTATION
980, p5dxrB_, 0.7384, 2.78, 0.185, 232, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- METHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
981, d3hc5A_, 0.7384, 2.93, 0.243, 237, 218, FXR WITH SRC1 AND GSK826
982, d3erdA_, 0.7384, 2.96, 0.178, 236, 225, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DIETHYLSTILBESTROL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
983, p5tn1A_, 0.7383, 2.89, 0.200, 234, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14SE)-17-((4- ISOPROPYLPHENYL)IMINO)-13-METHYL-78911121314151617- DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
984, p5q12A_, 0.7383, 2.67, 0.213, 227, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
985, p5tmvB_, 0.7382, 2.92, 0.187, 246, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS ANALOG 4-IODOPHENYL (1S2R4S)-56-BIS(4- HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
986, p5q0pC_, 0.7382, 2.88, 0.281, 227, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
987, p5dl4A_, 0.7382, 2.35, 0.224, 216, 214, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(PHENYLAMINO)PHENYL]PROP-1-ENE-11-DIYL}DIPHENOL
988, p4iwcA_, 0.7382, 2.87, 0.188, 240, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC THIOPHENE-DERIVATIVE
989, d2gp7B_, 0.7382, 2.63, 0.218, 228, 220, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
990, p5q0wA_, 0.7380, 2.70, 0.274, 230, 219, LIGAND BINDING TO FARNESOID-X-RECEPTOR
991, p5dz1B_, 0.7380, 2.94, 0.173, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-ETHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
992, p3uudA_, 0.7380, 3.13, 0.289, 229, 225, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ESTRADIOL
993, p5kccA_, 0.7379, 2.91, 0.179, 245, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONAMIDE (OBHS-N)
994, p4dmaA_, 0.7379, 2.83, 0.193, 245, 223, CRYSTAL STRUCTURE OF ERA LBD IN COMPLEX WITH RU100132
995, d3erdB_, 0.7379, 3.11, 0.281, 228, 224, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DIETHYLSTILBESTROL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
996, d3r8dA_, 0.7378, 2.82, 0.189, 239, 222, ACTIVATION OF THE HUMAN NUCLEAR XENOBIOTIC RECEPTOR PXR BY THE REVERSE TRANSCRIPTASE-TARGETED ANTI-HIV DRUG PNU-142721
997, d1zh7A_, 0.7378, 3.32, 0.265, 230, 226, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
998, p5q0rA_, 0.7377, 2.88, 0.184, 237, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
999, p5du5B_, 0.7377, 3.01, 0.178, 236, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
1000, p4p6xK_, 0.7377, 2.53, 0.215, 225, 219, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1001, p5dtvB_, 0.7376, 3.14, 0.277, 228, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIMETHYL-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
1002, d3b0wB_, 0.7376, 2.94, 0.182, 241, 225, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH DIGOXIN
1003, p5tmsB_, 0.7375, 2.95, 0.192, 240, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (BICYCLO[3.3.1]NONAN-9-YLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
1004, p5drmA_, 0.7375, 2.93, 0.192, 237, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 25-DIARYLTHIOPHENE-CORE LIGAND 44 - THIENE-25-DIYLBIS(3-CHLOROPHENOL)
1005, p4iwcB_, 0.7375, 2.98, 0.182, 238, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC THIOPHENE-DERIVATIVE
1006, p5dxmB_, 0.7374, 2.85, 0.184, 237, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 3-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(4-HYDROXYPHENYL)METHYL]PHENOL
1007, p4ppsA_, 0.7374, 2.82, 0.255, 264, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN A-CD RING ESTROGEN DERIVATIVE
1008, d4s0sA_, 0.7373, 2.88, 0.179, 243, 223, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH ADNECTIN-1
1009, p4p6xC_, 0.7373, 2.90, 0.279, 224, 219, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1010, d2gp7C_, 0.7373, 2.99, 0.192, 235, 224, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
1011, d4zjrD1, 0.7372, 2.90, 0.180, 255, 222, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
1012, d4s0sB_, 0.7372, 2.92, 0.192, 238, 224, STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN WITH ADNECTIN-1
1013, d2gp7A_, 0.7372, 2.41, 0.223, 217, 215, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
1014, p5dugA_, 0.7371, 2.84, 0.188, 243, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
1015, d2gp7D_, 0.7371, 3.11, 0.182, 239, 225, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN
1016, d2zbsA_, 0.7370, 2.91, 0.193, 240, 223, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN APO FORM
1017, d1skxA_, 0.7370, 2.95, 0.192, 237, 224, STRUCTURAL DISORDER IN THE COMPLEX OF HUMAN PXR AND THE MACROLIDE ANTIBIOTIC RIFAMPICIN
1018, d5aygA_, 0.7369, 2.89, 0.188, 238, 223, CRYSTAL STRUCTURE OF THE HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH 3G
1019, p5q1hE_, 0.7368, 2.95, 0.258, 273, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1020, d1pcgB_, 0.7368, 2.91, 0.180, 255, 222, HELIX-STABILIZED CYCLIC PEPTIDES AS SELECTIVE INHIBITORS OF STEROID RECEPTOR-COACTIVATOR INTERACTIONS
1021, p5tn7B_, 0.7367, 2.48, 0.220, 224, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-3 -FLUORO-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[1 1 -BIPHENYL]-4-OLATE
1022, p5q1hA_, 0.7367, 2.42, 0.223, 217, 215, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1023, d5ethB_, 0.7367, 2.96, 0.258, 273, 221, RORY IN COMPLEX WITH INVERSE AGONIST 3.
1024, p5tllA_, 0.7366, 2.48, 0.220, 224, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-2-CHLORO-4 -HYDROXY-4-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-3-OLATE
1025, p4tuzA_, 0.7366, 2.88, 0.184, 234, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALENOL
1026, p5u2dA_, 0.7365, 2.48, 0.220, 224, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
1027, p5tluB_, 0.7365, 2.64, 0.218, 227, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PEG-LINKED DIMERIC ESTROGEN EE2-(EG)6-EE2-AMINE
1028, p5q1bA_, 0.7365, 2.97, 0.249, 242, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1029, p3uu7A_, 0.7365, 2.37, 0.224, 217, 214, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-A
1030, d2qr9A_, 0.7365, 3.26, 0.267, 230, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DERIVATIVE COMPOUND
1031, p5tn5B_, 0.7364, 2.95, 0.187, 243, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE AC-RING ESTROGEN (1S3AS5S7AS)-5-(4- HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
1032, p5t1zB_, 0.7364, 2.98, 0.183, 235, 224, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ETHOXYTRIPHENYLETHYLENE AND GRIP PEPTIDE
1033, d4zjrA_, 0.7364, 3.25, 0.267, 229, 225, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 48
1034, d2p15A_, 0.7364, 2.61, 0.211, 221, 218, CRYSTAL STRUCTURE OF THE ER ALPHA LIGAND BINDING DOMAIN WITH THE AGONIST ORTHO-TRIFLUOROMETHYLPHENYLVINYL ESTRADIOL
1035, d1zkyB_, 0.7364, 2.95, 0.183, 235, 224, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-3M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1036, d1gwqA_, 0.7364, 3.05, 0.187, 235, 224, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE CORE AND TIF2 NRBOX2 PEPTIDE
1037, p4znvB_, 0.7363, 3.04, 0.187, 246, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHOXY-SUBSTITUTED OBHS DERIVATIVE
1038, d2qw4A1, 0.7363, 2.95, 0.192, 238, 224, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1039, p5tlfA_, 0.7362, 3.28, 0.262, 230, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CONSTRAINED WAY DERIVATIVE 4-(2-(3-METHYLBUT-2-EN- 1-YL)-7-(TRIFLUOROMETHYL)-2H-INDAZOL-3-YL)BENZENE-13-DIOL
1040, p5q0oA_, 0.7362, 2.92, 0.184, 237, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1041, p4p6xI_, 0.7362, 2.86, 0.179, 242, 223, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1042, d3q95B_, 0.7362, 2.95, 0.183, 235, 224, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND ESTRIOL
1043, d1ot7A_, 0.7362, 2.93, 0.188, 238, 223, STRUCTURAL BASIS FOR 3-DEOXY-CDCA BINDING AND ACTIVATION OF FXR
1044, d1gwrB_, 0.7362, 2.43, 0.223, 217, 215, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-OESTRADIOL AND TIF2 NRBOX3 PEPTIDE
1045, p5q16C_, 0.7361, 2.86, 0.179, 242, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1046, p5q0xA_, 0.7361, 2.91, 0.197, 242, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1047, p4mgdA_, 0.7361, 2.74, 0.180, 243, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH HPTE
1048, d2qzoB_, 0.7361, 3.03, 0.187, 243, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH WAY-169916
1049, d2gpoA_, 0.7361, 2.85, 0.226, 230, 221, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A SYNTHETIC PEPTIDE FROM RIP140
1050, p5w4rB_, 0.7360, 3.07, 0.182, 237, 225, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1051, p5dxbA_, 0.7360, 3.34, 0.265, 230, 226, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P1 AND ESTRADIOL
1052, p4zn7A_, 0.7360, 2.86, 0.176, 255, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DIETHYLSTILBESTROL
1053, p4p6xG_, 0.7360, 2.98, 0.193, 251, 223, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1054, p5q0mA_, 0.7359, 2.98, 0.193, 251, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1055, p5q0jC_, 0.7359, 3.23, 0.281, 229, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1056, p5iawB_, 0.7359, 2.98, 0.179, 239, 224, NOVEL NATURAL FXR MODULATOR WITH A UNIQUE BINDING MODE
1057, d2e2rA_, 0.7359, 3.25, 0.267, 230, 225, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH BISPHENOL A
1058, d1m2zD_, 0.7359, 2.81, 0.271, 222, 218, CRYSTAL STRUCTURE OF A DIMER COMPLEX OF THE HUMAN GLUCOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEXAMETHASONE AND A TIF2 COACTIVATOR MOTIF
1059, d1gwqB_, 0.7359, 2.87, 0.185, 240, 222, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE CORE AND TIF2 NRBOX2 PEPTIDE
1060, d3fs1A_, 0.7358, 2.94, 0.197, 235, 223, CRYSTAL STRUCTURE OF HNF4A LBD IN COMPLEX WITH THE LIGAND AND THE COACTIVATOR PGC-1A FRAGMENT
1061, d2a3iA_, 0.7358, 2.49, 0.211, 224, 218, STRUCTURAL AND BIOCHEMICAL MECHANISMS FOR THE SPECIFICITY OF HORMONE BINDING AND COACTIVATOR ASSEMBLY BY MINERALOCORTICOID RECEPTOR
1062, p5tmrB_, 0.7357, 2.33, 0.215, 217, 214, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (CYCLOHEXYLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
1063, p5q0vC_, 0.7357, 2.95, 0.188, 231, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1064, p5ei1A_, 0.7357, 2.88, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- IODANYL-IMIDAZO[12-A]PYRIDIN-6-OL
1065, p5dziA_, 0.7357, 3.02, 0.175, 254, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1066, d1x7eB_, 0.7357, 3.01, 0.279, 223, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH WAY-244
1067, p5dlrB_, 0.7356, 3.28, 0.262, 230, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-ETHYLENE COMPOUND 44 -(2-PHENYLETHENE-11-DIYL) DIPHENOL
1068, p5q0jA_, 0.7355, 3.13, 0.281, 227, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1069, p5q0iA_, 0.7355, 2.77, 0.208, 227, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1070, p5kceB_, 0.7355, 2.77, 0.208, 227, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL 2-CHLOROBENZYL OBHS-N DERIVATIVE
1071, p5dmfB_, 0.7355, 2.66, 0.183, 253, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}PROP-1-ENE-11- DIYL)DIPHENOL
1072, p5q18A_, 0.7354, 2.65, 0.186, 242, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1073, d1gwrA_, 0.7354, 2.81, 0.225, 230, 222, HUMAN OESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-OESTRADIOL AND TIF2 NRBOX3 PEPTIDE
1074, d1e3kA_, 0.7354, 2.81, 0.225, 230, 222, HUMAN PROGESTERON RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
1075, p5tmlB_, 0.7353, 2.98, 0.148, 253, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND (E)-6-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)HEX-5-ENOIC ACID
1076, p5dieB_, 0.7353, 2.99, 0.183, 237, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIFLUORO-SUBSTITUTED A-CD RING ESTROGEN DERIVATIVE (1S3AR 5S7AS)-7A-METHYL-5-(235-TRIFLUORO-4-HYDROXYPHENYL)OCTAHYDRO-1H- INDEN-1-OL
1077, d4zjwB_, 0.7353, 3.25, 0.267, 230, 225, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 16
1078, d4a2jA_, 0.7353, 2.86, 0.185, 232, 222, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA- SUBSTITUTED STEROIDS
1079, p5q1dA_, 0.7352, 2.87, 0.185, 235, 222, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1080, p5q0zA_, 0.7352, 2.85, 0.188, 238, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1081, p4mgbA_, 0.7352, 2.84, 0.185, 240, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH TCBPA
1082, d1osvA1, 0.7352, 3.35, 0.261, 230, 226, STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR
1083, p5tlyB_, 0.7351, 3.03, 0.284, 227, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
1084, p5q19C_, 0.7351, 2.97, 0.185, 239, 222, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1085, p5eitB_, 0.7351, 2.81, 0.180, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- (TRIFLUOROMETHYL)IMIDAZO[12-A]PYRIDIN-6-OL
1086, p4tuzB_, 0.7351, 3.36, 0.265, 230, 226, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALENOL
1087, p4mg5A_, 0.7351, 2.79, 0.189, 238, 222, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH CHLORDECONE
1088, d3okhA_, 0.7351, 2.76, 0.155, 251, 220, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 2-(4-CHLOROPHENYL)-1- [(1S)-1-CYCLOHEXYL-2-(CYCLOHEXYLAMINO)-2-OXOETHYL]-1H-BENZIMIDAZOLE- 6-CARBOXYLIC ACID
1089, p4p6xE_, 0.7350, 2.90, 0.184, 241, 223, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1090, p4ivwB_, 0.7350, 2.95, 0.184, 235, 223, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 6B
1091, d3l03A_, 0.7350, 2.76, 0.209, 222, 220, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTETROL (ESTRA-135(10)-TRIENE-315 ALPHA 16ALPHA17BETA-TETROL)
1092, d3fxvA1, 0.7350, 2.77, 0.155, 250, 220, IDENTIFICATION OF AN N-OXIDE PYRIDINE GW4064 ANALOGUE AS A POTENT FXR AGONIST
1093, p5q1dC_, 0.7349, 3.28, 0.262, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1094, p5dueA_, 0.7349, 3.42, 0.264, 230, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PARA-HYDROXYL-SUBSTITUTED SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG 4-HYDROXYPHENYL (1S2S4S5S6R 7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7-THIABICYCLO[2.2.1]HEPTANE-2- SULFONATE 7-OXIDE
1095, p4p6xA_, 0.7349, 2.86, 0.185, 239, 222, CRYSTAL STRUCTURE OF CORTISOL-BOUND GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN
1096, d1pk5A_, 0.7349, 3.17, 0.283, 228, 223, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR LRH-1
1097, p5tmzA_, 0.7348, 2.97, 0.193, 236, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ESTRADIOL DERIVATIVE (8S9S13S14S17S)-16-(3- METHOXYBENZYL)-13-METHYL-78911121314151617-DECAHYDRO-6H- CYCLOPENTA[A]PHENANTHRENE-317-DIOL
1098, p5q0kA_, 0.7348, 3.28, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1099, d3v3eA_, 0.7348, 2.80, 0.185, 235, 222, CRYSTAL STRUCTURE OF THE HUMAN NUR77 LIGAND-BINDING DOMAIN
1100, d2b1vB_, 0.7348, 2.93, 0.197, 241, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1101, d1x7eA_, 0.7348, 2.92, 0.193, 239, 223, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH WAY-244
1102, p5tmwB_, 0.7347, 3.05, 0.286, 227, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS DERIVATIVE 4-ACETAMIDOPHENYL (1S2R4S)-56- BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
1103, p5tllB_, 0.7347, 2.93, 0.176, 255, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-2-CHLORO-4 -HYDROXY-4-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-3-OLATE
1104, d4zomD_, 0.7347, 2.84, 0.189, 238, 222, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 4J.
1105, d4apuB_, 0.7347, 2.98, 0.192, 235, 224, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA-SUBSTITUTED STEROID
1106, p5q0yA_, 0.7346, 2.78, 0.272, 221, 217, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1107, p5dugB_, 0.7346, 3.28, 0.262, 230, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-2 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-2-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
1108, p4pp6A_, 0.7346, 2.83, 0.189, 235, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RESVERATROL
1109, d1e3kB_, 0.7346, 2.88, 0.176, 252, 222, HUMAN PROGESTERON RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
1110, p5q0sC_, 0.7345, 3.01, 0.183, 242, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1111, p1zdtB_, 0.7345, 2.83, 0.185, 236, 222, THE CRYSTAL STRUCTURE OF HUMAN STEROIDOGENIC FACTOR-1
1112, d3q97A_, 0.7344, 2.93, 0.279, 224, 219, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND TWO ISOMERS OF ETHOXY TRIPHENYLETHYLENE
1113, d3f5cA_, 0.7344, 2.97, 0.204, 234, 225, STRUCTURE OF DAX-1:LRH-1 COMPLEX
1114, d1m2zA_, 0.7344, 2.92, 0.197, 241, 223, CRYSTAL STRUCTURE OF A DIMER COMPLEX OF THE HUMAN GLUCOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEXAMETHASONE AND A TIF2 COACTIVATOR MOTIF
1115, d1g50C_, 0.7344, 2.81, 0.194, 238, 222, CRYSTAL STRUCTURE OF A WILD TYPE HER ALPHA LBD AT 2.9 ANGSTROM RESOLUTION
1116, p5tn5A_, 0.7343, 2.82, 0.185, 240, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE AC-RING ESTROGEN (1S3AS5S7AS)-5-(4- HYDROXYPHENYL)-7A-METHYLOCTAHYDRO-1H-INDEN-1-OL
1117, p5tlxA_, 0.7343, 2.87, 0.180, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
1118, p5tldB_, 0.7343, 2.33, 0.225, 215, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL
1119, p5q1aC_, 0.7343, 2.75, 0.150, 250, 220, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1120, p4iw6B_, 0.7343, 3.26, 0.267, 230, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 7B
1121, d3okiC1, 0.7343, 2.84, 0.185, 234, 222, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N2-DICYCLOHEXYLETHANAMIDE
1122, d1zh7B_, 0.7343, 2.85, 0.185, 234, 222, STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP
1123, d1a28B_, 0.7343, 2.73, 0.150, 249, 220, HORMONE-BOUND HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN
1124, p5q16A_, 0.7342, 3.27, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1125, p5q15C_, 0.7342, 2.74, 0.176, 239, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1126, d4whgA_, 0.7342, 3.01, 0.193, 243, 223, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 3
1127, p5q1bC_, 0.7341, 2.87, 0.185, 243, 222, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1128, p5kriA_, 0.7341, 2.82, 0.177, 255, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16B-BENZYL 17B-ESTRADIOL
1129, d4kzmA_, 0.7341, 2.83, 0.188, 244, 223, CRYSTAL STRUCTURE OF TR3 LBD S553A MUTANT
1130, d3k22A_, 0.7341, 2.89, 0.185, 235, 222, GLUCOCORTICOID RECEPTOR WITH BOUND ALANINAMIDE 10 WITH TIF2 PEPTIDE
1131, d1pduA1, 0.7339, 3.02, 0.184, 234, 223, LIGAND-BINDING DOMAIN OF DROSOPHILA ORPHAN NUCLEAR RECEPTOR DHR38
1132, d5x8xE_, 0.7338, 2.95, 0.193, 235, 223, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
1133, p5q1aA_, 0.7338, 3.19, 0.268, 229, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1134, d3q97B_, 0.7338, 2.89, 0.189, 235, 222, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND TWO ISOMERS OF ETHOXY TRIPHENYLETHYLENE
1135, d2faiA_, 0.7338, 3.26, 0.268, 229, 224, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-2M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1136, d5x8qE_, 0.7337, 2.92, 0.179, 243, 223, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
1137, p5q19A_, 0.7337, 2.78, 0.150, 249, 220, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1138, p5q0sA_, 0.7337, 3.27, 0.267, 230, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1139, d1ereA_, 0.7337, 3.31, 0.271, 229, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1140, p5q18C_, 0.7336, 2.89, 0.201, 234, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1141, d4re8A_, 0.7336, 3.31, 0.262, 230, 225, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH MOLECULE 5
1142, d1zucB_, 0.7336, 2.84, 0.180, 234, 222, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE NONSTEROIDAL AGONIST TANAPROGET
1143, d1ereB_, 0.7336, 2.94, 0.201, 233, 224, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1144, d5u2bA_, 0.7335, 2.86, 0.181, 250, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1145, p5q15A_, 0.7335, 2.97, 0.228, 229, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1146, p5drjA_, 0.7335, 2.68, 0.211, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 3-METHYL 25-DIARYLTHIOPHENE-CORE LIGAND 44 -(3-METHYLTHIENE-25-DIYL)BIS(3-CHLOROPHENOL)
1147, d1ereD_, 0.7335, 3.29, 0.267, 230, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1148, d5x8xA_, 0.7334, 2.98, 0.188, 240, 223, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
1149, d5x8qA_, 0.7334, 2.95, 0.184, 233, 223, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
1150, p5q0yC_, 0.7334, 2.71, 0.206, 228, 218, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1151, p5dk9B_, 0.7334, 3.29, 0.267, 230, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 4 4 -{2-[3-(PHENYLAMINO)PHENYL]BUT-1-ENE-11-DIYL}DIPHENOL
1152, d3v3qA1, 0.7334, 3.28, 0.267, 230, 225, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH ETHYL 2-[234 TRIMETHOXY-6(1-OCTANOYL)PHENYL]ACETATE
1153, d3g8oB_, 0.7334, 2.71, 0.186, 235, 221, PROGESTERONE RECEPTOR WITH BOUND PYRROLIDINE 1
1154, d1ereF_, 0.7334, 3.28, 0.267, 230, 225, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1155, p6br2A_, 0.7333, 2.91, 0.201, 233, 224, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL ISOQUINOLINE INVERSE AGONIST.
1156, p5tn4A_, 0.7333, 2.80, 0.150, 251, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ACD-RING ESTROGEN (S)-5-(4-HYDROXY-35- DIMETHYLPHENYL)-23-DIHYDRO-1H-INDEN-1-OL
1157, p5tlfB_, 0.7333, 2.71, 0.181, 235, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CONSTRAINED WAY DERIVATIVE 4-(2-(3-METHYLBUT-2-EN- 1-YL)-7-(TRIFLUOROMETHYL)-2H-INDAZOL-3-YL)BENZENE-13-DIOL
1158, p5kriB_, 0.7333, 2.85, 0.195, 242, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16B-BENZYL 17B-ESTRADIOL
1159, p5dxkA_, 0.7333, 3.28, 0.267, 230, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(9S)-BICYCLO[3.3.1]NON-9- YLMETHANEDIYL]DIPHENOL
1160, p5du5A_, 0.7333, 2.91, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
1161, d1ereC_, 0.7333, 2.71, 0.181, 235, 221, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1162, p5tmwA_, 0.7332, 2.68, 0.211, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS DERIVATIVE 4-ACETAMIDOPHENYL (1S2R4S)-56- BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
1163, d3omkC1, 0.7332, 2.72, 0.206, 228, 218, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYL-N-(2- METHYLPHENYL)ETHANAMIDE
1164, d2q6jA_, 0.7332, 3.29, 0.262, 230, 225, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED TO A B-N SUBSTITUTED LIGAND
1165, d1ereE_, 0.7332, 2.88, 0.194, 235, 222, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH 17BETA-ESTRADIOL
1166, d5ntkB_, 0.7331, 3.05, 0.213, 234, 225, STRUCTURAL STATES OF RORGT: X-RAY ELUCIDATION OF MOLECULAR MECHANISMS AND BINDING INTERACTIONS FOR NATURAL AND SYNTHETIC COMPOUNDS
1167, p5dx3A_, 0.7331, 2.76, 0.155, 250, 220, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P3 AND ESTRADIOL
1168, d4rzgA_, 0.7331, 2.71, 0.181, 235, 221, CRYSTAL STRUCTURE ANALYSIS OF THE DNPA-BOUNDED NUR77 LIGAND BINDING DOMAIN
1169, d3plzB_, 0.7331, 2.37, 0.221, 215, 213, HUMAN LRH1 LBD BOUND TO GR470
1170, d3e7cA_, 0.7331, 2.94, 0.180, 234, 222, GLUCOCORTICOID RECEPTOR LBD BOUND TO GSK866
1171, d2w8yA_, 0.7331, 2.86, 0.190, 235, 221, RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION
1172, p5tmtA_, 0.7330, 2.89, 0.194, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((13-DIHYDRO-2H-INDEN-2-YLIDENE)METHYLENE)DIPHENOL
1173, p5q1eA_, 0.7330, 2.90, 0.185, 234, 222, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1174, p5dz3B_, 0.7330, 2.70, 0.191, 231, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(FLUOROMETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1175, d2b1vA_, 0.7330, 2.72, 0.181, 235, 221, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1176, d1xj7A_, 0.7330, 2.99, 0.187, 240, 224, COMPLEX ANDROGEN RECEPTOR LBD AND RAC3 PEPTIDE
1177, p5q0uC_, 0.7329, 3.24, 0.268, 229, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1178, p5krhB_, 0.7329, 2.99, 0.183, 242, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16-BENZYLIDENE ESTRONE
1179, d4rzfA_, 0.7329, 2.72, 0.186, 235, 221, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN S441W MUTANT
1180, d3zr7A_, 0.7329, 2.80, 0.214, 225, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1181, d3d90B_, 0.7329, 2.95, 0.185, 231, 222, CRYSTAL STRUCTURE OF THE HUMAN PROGESTERONE RECEPTOR LIGAND- BINDING DOMAIN BOUND TO LEVONORGESTREL
1182, d5x8xC_, 0.7328, 2.97, 0.201, 233, 224, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
1183, p5q0qC_, 0.7328, 2.78, 0.189, 240, 222, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1184, p5z12A_, 0.7327, 2.85, 0.186, 248, 221, A STRUCTURE OF FXR/RXR 
1185, d2qa8A_, 0.7327, 2.80, 0.155, 250, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH GENISTEIN
1186, d1sr7B_, 0.7327, 2.97, 0.185, 237, 222, PROGESTERONE RECEPTOR HORMONE BINDING DOMAIN WITH BOUND MOMETASONE FUROATE
1187, p4mgaA_, 0.7326, 3.01, 0.268, 224, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH 4-TERT- OCTYLPHENOL
1188, d2faiB_, 0.7326, 3.00, 0.179, 238, 223, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-2M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1189, d1pzlA_, 0.7326, 3.00, 0.188, 233, 223, CRYSTAL STRUCTURE OF HNF4A LBD IN COMPLEX WITH THE LIGAND AND THE COACTIVATOR SRC-1 PEPTIDE
1190, p5kr9B_, 0.7325, 3.14, 0.142, 256, 226, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH COUMESTROL
1191, p5ei1B_, 0.7325, 3.28, 0.267, 230, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- IODANYL-IMIDAZO[12-A]PYRIDIN-6-OL
1192, p4qe8A_, 0.7325, 2.85, 0.189, 237, 222, FXR WITH DM175 AND NCOA-2 PEPTIDE
1193, d2g44A_, 0.7325, 2.93, 0.201, 233, 224, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M-G AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1194, d1x78B_, 0.7325, 2.79, 0.155, 250, 220, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-244
1195, d1tfcA_, 0.7325, 2.81, 0.159, 249, 220, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH A STEROID RECEPTOR COACTIVATOR-1 PEPTIDE
1196, d1pk5B_, 0.7325, 2.69, 0.211, 228, 218, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR LRH-1
1197, p5e14B_, 0.7324, 2.87, 0.289, 223, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- PHENYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1198, d3zrbB_, 0.7324, 3.13, 0.282, 223, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1199, d3k22B_, 0.7324, 2.74, 0.190, 229, 221, GLUCOCORTICOID RECEPTOR WITH BOUND ALANINAMIDE 10 WITH TIF2 PEPTIDE
1200, d2j7yA_, 0.7324, 2.75, 0.150, 249, 220, STRUCTURE OF 17-EPIESTRIOL-BOUND ESTROGEN RECEPTOR BETA LBD IN COMPLEX WITH LXXLL MOTIF FROM NCOA5
1201, d2j7xA_, 0.7324, 3.01, 0.188, 239, 223, STRUCTURE OF ESTRADIOL-BOUND ESTROGEN RECEPTOR BETA LBD IN COMPLEX WITH LXXLL MOTIF FROM NCOA5
1202, d2g5oA_, 0.7324, 2.94, 0.189, 242, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 2- (BUT-1-ENYL)-17BETA-ESTRADIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1203, d5x8qG_, 0.7323, 2.77, 0.226, 227, 221, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
1204, p5q13C_, 0.7323, 2.80, 0.186, 233, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1205, p5kr9A_, 0.7323, 2.84, 0.190, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH COUMESTROL
1206, p4tv1B_, 0.7323, 2.92, 0.288, 224, 219, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH PROPYLPARABEN
1207, p4qe8B_, 0.7323, 2.92, 0.194, 234, 222, FXR WITH DM175 AND NCOA-2 PEPTIDE
1208, d3zraA_, 0.7323, 2.61, 0.165, 228, 218, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1209, p5tm7B_, 0.7322, 2.74, 0.218, 226, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)HEPTANOIC ACID
1210, p5q0uA_, 0.7322, 2.84, 0.186, 236, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1211, p5dkbB_, 0.7322, 3.04, 0.184, 237, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-METHYLPHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(3-METHYLPHENYL)AMINO]PHENYL}BUT-1-ENE-11- DIYL)DIPHENOL
1212, d4kziA_, 0.7322, 2.80, 0.155, 250, 220, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH DPDO
1213, p5q0oC_, 0.7321, 2.91, 0.186, 250, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1214, p5e1cA_, 0.7321, 2.65, 0.174, 226, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE DIMETHYL {(1S)-3-[BIS(4- HYDROXYPHENYL)METHYLIDENE]CYCLOHEXYL}PROPANEDIOATE
1215, d3ommC1, 0.7321, 2.76, 0.173, 228, 220, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-FLUOROBENZOIC ACID
1216, d3hm1A_, 0.7321, 2.92, 0.198, 235, 222, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTRONE ((8R9S13S14S)-3-HYDROXY-13-METHYL- 7891112141516-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE)
1217, p5tmsA_, 0.7320, 2.73, 0.206, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE CYCLOFENIL-ASC DERIVATIVE ETHYL (E)-3-(4- (BICYCLO[3.3.1]NONAN-9-YLIDENE(4-HYDROXYPHENYL)METHYL)PHENYL)ACRYLATE
1218, p5krcA_, 0.7320, 3.48, 0.264, 230, 227, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH ZEARALENONE
1219, p5kd9A_, 0.7320, 2.84, 0.186, 236, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
1220, p5eitA_, 0.7320, 2.83, 0.186, 231, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE IMIDAZOPYRIDINE DERIVATIVE 2-(4-HYDROXYPHENYL)-3- (TRIFLUOROMETHYL)IMIDAZO[12-A]PYRIDIN-6-OL
1221, p5dwiA_, 0.7320, 2.88, 0.289, 223, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 2-CHLORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(2-CHLOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
1222, p5dweA_, 0.7320, 2.81, 0.155, 250, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-CHLORO-SUBSTITUTED TRIARYL-IMINE ANALOG 44 -[(2- CHLOROPHENYL)CARBONIMIDOYL]DIPHENOL
1223, p5tn6B_, 0.7319, 2.92, 0.185, 240, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE SPIRO BC-ESTRADIOL (1S1 S3A S7A S)-7A -METHYL- 1 22 33 3A 4 6 7 7A -DECAHYDRO-15 -SPIROBI[INDENE]-1 5- DIOL
1224, p5tmvA_, 0.7319, 3.31, 0.262, 230, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS ANALOG 4-IODOPHENYL (1S2R4S)-56-BIS(4- HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
1225, p5tm6A_, 0.7319, 2.97, 0.184, 232, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEXANOIC ACID
1226, p5q0pA_, 0.7319, 2.81, 0.216, 232, 222, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1227, p4iw8A_, 0.7319, 3.29, 0.267, 232, 225, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 9A
1228, d2qw4C_, 0.7319, 3.29, 0.267, 232, 225, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1229, p5tm8A_, 0.7318, 2.85, 0.180, 237, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEPTANOIC ACID
1230, p5kctA_, 0.7318, 3.26, 0.268, 229, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
1231, d5ixkB_, 0.7318, 2.98, 0.184, 232, 223, RORGAMMA IN COMPLEX WITH INVERSE AGONIST BIO399.
1232, p5dxrA_, 0.7318, 2.95, 0.180, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- METHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1233, d4rzeA_, 0.7318, 2.87, 0.186, 233, 221, CRYSTAL STRUCTURE ANALYSIS OF THE NUR77 LIGAND BINDING DOMAIN L437W D594E MUTANT
1234, d3hq5B_, 0.7318, 2.79, 0.186, 235, 221, PROGESTERONE RECEPTOR BOUND TO AN ALKYLPYRROLIDINE LIGAND.
1235, d3g8nB_, 0.7318, 2.85, 0.186, 234, 221,  
1236, d1zkyA_, 0.7318, 2.91, 0.189, 232, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-3M AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1237, p5q0vA_, 0.7317, 2.83, 0.190, 236, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1238, p5duhB_, 0.7317, 2.83, 0.181, 230, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SULFOXIDE-BRIDGED OXABICYCLIC HEPTENE SULFONATE (SOBHS)-3 ANALOG PHENYL (1S2S4S7S)-56-BIS(4-HYDROXY-3-METHYLPHENYL)-7- THIABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE 7-OXIDE
1239, p4znsB_, 0.7317, 3.07, 0.183, 236, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-FLUORO-SUBSTITUTED OBHS DERIVATIVE
1240, d3mnpA1, 0.7317, 2.89, 0.194, 234, 222, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY (A611V V708A E711G) MUTATIONS AT 1.50A
1241, d3bqdA_, 0.7317, 3.29, 0.267, 230, 225, DOUBLING THE SIZE OF THE GLUCOCORTICOID RECEPTOR LIGAND BINDING POCKET BY DEACYLCORTIVAZOL
1242, d2g5oB_, 0.7317, 2.85, 0.185, 239, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 2- (BUT-1-ENYL)-17BETA-ESTRADIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1243, d1a28A_, 0.7317, 2.76, 0.210, 227, 219, HORMONE-BOUND HUMAN PROGESTERONE RECEPTOR LIGAND-BINDING DOMAIN
1244, p6el7A_, 0.7316, 2.99, 0.189, 235, 222, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH COMPOUND 31
1245, p5tmqA_, 0.7316, 3.02, 0.184, 236, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE 4-BROMOPHENYL 44  - DIHYDROXY-[11 :2 1  -TERPHENYL]-4 -SULFONATE
1246, p5tm3A_, 0.7316, 2.64, 0.212, 220, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 23-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1247, p4tv1A_, 0.7316, 2.99, 0.179, 235, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH PROPYLPARABEN
1248, d3ookA1, 0.7316, 2.83, 0.198, 232, 222, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-35-DIFLUOROBENZOIC ACID
1249, p5tmoA_, 0.7315, 2.79, 0.150, 251, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE ARENE CORE OBHS DERIVATIVE PHENYL 44  -DIHYDROXY- [11 :2 1  -TERPHENYL]-4 -SULFONATE
1250, p5kraF_, 0.7315, 2.79, 0.150, 251, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
1251, p5dz0A_, 0.7315, 2.99, 0.188, 236, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-METHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
1252, p5dwiB_, 0.7315, 3.28, 0.267, 230, 225, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 2-CHLORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(2-CHLOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
1253, d3gn8A_, 0.7315, 2.85, 0.186, 233, 221, X-RAY CRYSTAL STRUCTURE OF ANCGR2 IN COMPLEX WITH DEXAMETHASONE
1254, d5x8qC_, 0.7314, 3.06, 0.188, 236, 223, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH ROCKOGENIN.
1255, p5tmuB_, 0.7314, 2.88, 0.155, 256, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -(CYCLOHEPTYLIDENEMETHYLENE)DIPHENOL
1256, p5q14A_, 0.7314, 2.66, 0.178, 253, 219, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1257, d3olfC1, 0.7314, 3.01, 0.193, 236, 223, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-METHYLBENZOIC ACID
1258, d1yucB_, 0.7314, 2.78, 0.150, 251, 220, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO PHOSPHOLIPID AND A FRAGMENT OF HUMAN SHP
1259, p6b30A_, 0.7313, 2.63, 0.179, 247, 218, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 1
1260, p5tlyA_, 0.7313, 2.90, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 34-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 11-DIOXIDE
1261, p5q0nA_, 0.7313, 2.84, 0.186, 231, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1262, p4oniA_, 0.7313, 3.03, 0.188, 233, 223, STRUCTURE OF HUMAN ORPHAN RECEPTOR LRH1 BOUND TO TWO BACTERIAL PHOSPHOLIPIDS
1263, d4apuA_, 0.7313, 3.16, 0.268, 229, 224, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA-SUBSTITUTED STEROID
1264, d3oofA1, 0.7313, 2.90, 0.185, 235, 222, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)BENZOIC ACID
1265, p5tlgA_, 0.7312, 3.06, 0.188, 237, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-44  -DIHYDROXY-3 -((HYDROXYIMINIO)METHYL)-[11 :2  1  -TERPHENYL]-4 -OLATE
1266, p5q1cA_, 0.7312, 3.06, 0.179, 236, 224, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1267, p5q0nC_, 0.7312, 2.89, 0.186, 231, 221, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1268, d3gn8B_, 0.7311, 2.76, 0.174, 249, 219, X-RAY CRYSTAL STRUCTURE OF ANCGR2 IN COMPLEX WITH DEXAMETHASONE
1269, d2w8yB_, 0.7311, 2.73, 0.206, 228, 218, RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION
1270, d2b1zA_, 0.7311, 2.91, 0.176, 235, 222, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17METHYL-17ALPHA-DIHYDROEQUILENIN AND A GLUCOC INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1271, d1mznE_, 0.7311, 3.29, 0.267, 230, 225, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1272, d1mznA_, 0.7311, 3.35, 0.271, 229, 225, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1273, p5nftA_, 0.7310, 2.71, 0.187, 240, 219, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH AZD5423
1274, d4a2jB_, 0.7310, 2.28, 0.217, 215, 212, PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA- SUBSTITUTED STEROIDS
1275, d3kbaB_, 0.7310, 2.88, 0.181, 233, 221, PROGESTERONE RECEPTOR BOUND TO SULFONAMIDE PYRROLIDINE PARTIAL AGONIST
1276, d3b0wA_, 0.7310, 3.20, 0.268, 229, 224, CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ROR(GAMMA)T LIGAND- BINDING DOMAIN IN COMPLEX WITH DIGOXIN
1277, d1ovlC_, 0.7310, 3.03, 0.184, 241, 223, CRYSTAL STRUCTURE OF NURR1 LBD
1278, p5g5wA_, 0.7309, 2.83, 0.150, 250, 220, DISCOVERY OF A NOVEL HIGHLY POTENT NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATOR SERIES MODULATORS
1279, d4kzjA_, 0.7309, 3.25, 0.272, 229, 224, CRYSTAL STRUCTURE OF TR3 LBD L449W MUTANT
1280, d1u3qB_, 0.7309, 2.74, 0.186, 229, 220, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
1281, d1p93A_, 0.7309, 3.26, 0.268, 229, 224, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
1282, p5q1cC_, 0.7308, 3.17, 0.265, 228, 223, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1283, p5hyrA_, 0.7308, 2.74, 0.183, 249, 219, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-SP2 AND ESTRADIOL
1284, d4zjwA_, 0.7308, 2.83, 0.155, 250, 220, RORGAMMA IN COMPLEX WITH INVERSE AGONIST 16
1285, p4oniB_, 0.7308, 2.85, 0.190, 232, 221, STRUCTURE OF HUMAN ORPHAN RECEPTOR LRH1 BOUND TO TWO BACTERIAL PHOSPHOLIPIDS
1286, p5dvsA_, 0.7307, 2.76, 0.227, 224, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-METHYL-SUBSTITUTED TRIARYL-IMINE 44 -[(2-METHYLPHENYL) CARBONIMIDOYL]DIPHENOL
1287, d3p89A_, 0.7307, 2.78, 0.227, 224, 220, FXR BOUND TO A QUINOLINECARBOXYLIC ACID
1288, p5kraE_, 0.7306, 2.76, 0.174, 248, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
1289, p4j24B_, 0.7306, 2.83, 0.150, 250, 220, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1290, d2b1zB_, 0.7306, 2.79, 0.150, 250, 220, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 17METHYL-17ALPHA-DIHYDROEQUILENIN AND A GLUCOC INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1291, p5kraB_, 0.7305, 2.42, 0.221, 215, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
1292, p5g3jA_, 0.7305, 2.62, 0.221, 223, 217, DISCOVERY OF NEW SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST LEADS
1293, d1x7rA_, 0.7305, 2.70, 0.174, 247, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED WITH GENISTEIN
1294, d1sqnB_, 0.7305, 2.88, 0.203, 231, 222, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN WITH BOUND NORETHINDRONE
1295, p5q1fA_, 0.7304, 2.72, 0.165, 227, 218, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1296, p4mg5B_, 0.7304, 2.91, 0.172, 247, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH CHLORDECONE
1297, d1zucA_, 0.7304, 3.16, 0.274, 228, 223, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH THE NONSTEROIDAL AGONIST TANAPROGET
1298, d1u3qA_, 0.7303, 3.00, 0.185, 231, 222, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
1299, p5z12D_, 0.7302, 2.57, 0.227, 219, 216, A STRUCTURE OF FXR/RXR 
1300, d4ltwA_, 0.7302, 2.79, 0.186, 242, 220, ANCESTRAL KETOSTEROID RECEPTOR-PROGESTERONE-MIFEPRISTONE COMPLEX
1301, d3oofC1, 0.7302, 2.88, 0.186, 231, 221, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)BENZOIC ACID
1302, p5q17A_, 0.7301, 2.93, 0.288, 223, 219, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1303, d2qh6A_, 0.7301, 2.74, 0.186, 228, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DIARYLETHYLENE COMPOUND
1304, d2p7aA_, 0.7301, 2.88, 0.164, 228, 220, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR G IN COMPLEX WITH 3-METHYL PHENOL
1305, p5q1hC_, 0.7300, 2.95, 0.203, 235, 222, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1306, p5drmB_, 0.7300, 2.92, 0.180, 240, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DICHLORO-SUBSTITUTED 25-DIARYLTHIOPHENE-CORE LIGAND 44 - THIENE-25-DIYLBIS(3-CHLOROPHENOL)
1307, p4qjrA_, 0.7300, 2.69, 0.178, 248, 219, CRYSTAL STRUCTURE OF HUMAN NUCLEAR RECEPTOR SF-1 (NR5A1) BOUND TO ITS HORMONE PIP3 AT 2.4 A RESOLUTION
1308, p4iu7A_, 0.7300, 2.61, 0.187, 235, 219, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 2B
1309, d3zraB_, 0.7300, 2.83, 0.150, 250, 220, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1310, d2qa8B_, 0.7300, 3.23, 0.268, 229, 224, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN MUTANT 537S COMPLEXED WITH GENISTEIN
1311, p6el6A_, 0.7299, 2.99, 0.189, 234, 222, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH COMPOUND 4
1312, p5dxmA_, 0.7299, 2.81, 0.155, 251, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 3-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(4-HYDROXYPHENYL)METHYL]PHENOL
1313, d4jgvA_, 0.7299, 2.72, 0.165, 226, 218, CRYSTAL STRUCTURE OF HUMAN NUR77 LIGAND-BINDING DOMAIN IN COMPLEX WITH THPN
1314, d3zrbA_, 0.7299, 3.06, 0.283, 223, 219, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1315, d3olfA1, 0.7299, 2.85, 0.140, 251, 221, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-METHYLBENZOIC ACID
1316, p5q1fC_, 0.7298, 3.38, 0.267, 229, 225, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1317, p4mgcB_, 0.7298, 3.10, 0.268, 224, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZOPHENONE-2
1318, p4mgcA_, 0.7298, 2.91, 0.186, 232, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZOPHENONE-2
1319, p4iu7B_, 0.7298, 2.61, 0.217, 223, 217, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 2B
1320, p5egvA_, 0.7297, 3.19, 0.269, 228, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX THE 34-DIARYL-FURAN DERIVATIVE 3-CHLORANYL-4-[4-(2- CHLORANYL-4-OXIDANYL-PHENYL)FURAN-3-YL]PHENOL
1321, p4dorB_, 0.7297, 2.73, 0.195, 235, 220, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN SHP BOX1
1322, p4qk4A_, 0.7296, 2.86, 0.176, 244, 222, CRYSTAL STRUCTURE OF HUMAN NUCLEAR RECEPTOR SF-1 (NR5A1) BOUND TO PIP2 AT 2.8 A RESOLUTION
1323, p4znuA_, 0.7295, 2.86, 0.176, 244, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHYL-SUBSTITUTED OBHS DERIVATIVE
1324, p4iqrB2, 0.7295, 3.04, 0.179, 235, 223, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
1325, d3g8oA_, 0.7295, 2.83, 0.150, 250, 220, PROGESTERONE RECEPTOR WITH BOUND PYRROLIDINE 1
1326, d1u3qD_, 0.7295, 3.01, 0.180, 234, 222, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
1327, p5wgqB_, 0.7293, 2.71, 0.174, 247, 218, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-BCP1 
1328, p5ufsA_, 0.7293, 2.92, 0.185, 234, 222, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH TRIAMCINOLONE ACETONIDE AND SHP COREGULATOR FRAGMENT
1329, p5gs4A_, 0.7293, 2.91, 0.202, 233, 223, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA IN COMPLEX WITH A STABILIZED PEPTIDE ANTAGONIST
1330, p5dydB_, 0.7293, 2.83, 0.150, 250, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(METHYLSULFANYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1331, p5ufsB_, 0.7292, 3.26, 0.272, 229, 224, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH TRIAMCINOLONE ACETONIDE AND SHP COREGULATOR FRAGMENT
1332, p4mg6B_, 0.7292, 3.20, 0.274, 229, 223, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZYLBUTYLPHTALATE
1333, d3ookC1, 0.7292, 2.95, 0.189, 234, 222, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-35-DIFLUOROBENZOIC ACID
1334, d2gppA_, 0.7292, 2.92, 0.189, 235, 222, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A RIP140 PEPTIDE AND SYNTHETIC LIGAND GSK4716
1335, p6eu9B_, 0.7291, 2.96, 0.180, 237, 222, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
1336, p5tltA_, 0.7291, 2.71, 0.187, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OCTANE-18-DIYL BIS(23-BIS(4-HYDROXYPHENYL)PENTANOATE)
1337, d3k23B_, 0.7291, 2.73, 0.187, 240, 219, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
1338, d4whfA_, 0.7290, 2.86, 0.176, 244, 222, CRYSTAL STRUCTURE OF TR3 LBD IN COMPLEX WITH 1-(345- TRIHYDROXYPHENYL)DECAN-1-ONE
1339, d3omkA1, 0.7290, 3.12, 0.184, 235, 223, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYL-N-(2- METHYLPHENYL)ETHANAMIDE
1340, d3hm1B_, 0.7290, 2.37, 0.223, 219, 215, CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTRONE ((8R9S13S14S)-3-HYDROXY-13-METHYL- 7891112141516-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE)
1341, d1ovlF_, 0.7290, 2.73, 0.160, 250, 219, CRYSTAL STRUCTURE OF NURR1 LBD
1342, p4pp6B_, 0.7289, 2.71, 0.165, 226, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH RESVERATROL
1343, p1yp0A_, 0.7289, 2.89, 0.186, 229, 221, STRUCTURE OF THE STEROIDOGENIC FACTOR-1 LIGAND BINDING DOMAIN BOUND TO PHOSPHOLIPID AND A SHP PEPTIDE MOTIF
1344, p5krlB_, 0.7288, 2.79, 0.183, 248, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE A-CD RING ESTROGEN (1S7AS)-5-(2-CHLORO-4- HYDROXYPHENYL)-7A-METHYL-233A477A-HEXAHYDRO-1H-INDEN-1-OL
1345, d2gppB_, 0.7288, 2.64, 0.178, 236, 219, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A RIP140 PEPTIDE AND SYNTHETIC LIGAND GSK4716
1346, d1p93D_, 0.7288, 2.71, 0.186, 231, 220, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
1347, d1p93C_, 0.7288, 2.79, 0.183, 248, 219, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
1348, p4fn9B_, 0.7287, 3.13, 0.184, 234, 223, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - PROGESTERONE COMPLEX
1349, d3okiA1, 0.7287, 3.36, 0.271, 229, 225, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4- CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N2-DICYCLOHEXYLETHANAMIDE
1350, p4iv2B_, 0.7286, 2.71, 0.216, 225, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 5A
1351, d2g44B_, 0.7286, 2.33, 0.283, 214, 212, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH OBCP-1M-G AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1352, d1sr7A_, 0.7286, 3.04, 0.185, 234, 222, PROGESTERONE RECEPTOR HORMONE BINDING DOMAIN WITH BOUND MOMETASONE FUROATE
1353, p5q0tA_, 0.7285, 2.93, 0.182, 247, 220, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1354, p4udcA_, 0.7285, 2.92, 0.203, 231, 222, GR IN COMPLEX WITH DEXAMETHASONE
1355, p4pppA_, 0.7285, 3.32, 0.263, 229, 224, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH FLUORO-RESVERATROL
1356, d1u9eB_, 0.7285, 3.04, 0.189, 236, 222, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-397
1357, p6el9A_, 0.7284, 2.44, 0.224, 220, 214, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH AZD9567
1358, p5krfA_, 0.7284, 2.90, 0.181, 230, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE DYNAMIC WAY DERIVATIVE 1A
1359, p5dybB_, 0.7284, 2.96, 0.180, 239, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -(34-DIHYDRONAPHTHALEN-2(1H)- YLIDENEMETHANEDIYL)DIPHENOL
1360, d1kv6B_, 0.7284, 2.79, 0.186, 228, 220, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ERR3 LIGAND- BINDING DOMAIN IN THE CONSTITUTIVELY ACTIVE CONFORMATION
1361, p5tm2B_, 0.7283, 2.66, 0.217, 224, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1362, p4j26B_, 0.7282, 2.83, 0.174, 247, 219, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1363, p5q1hG_, 0.7281, 2.84, 0.174, 247, 219, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1364, p4iqrA2, 0.7281, 2.81, 0.141, 249, 220, MULTI-DOMAIN ORGANIZATION OF THE HNF4ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA
1365, d5x8xG_, 0.7280, 3.28, 0.272, 229, 224, CRYSTAL STRUCTURE OF THE MUTANT HUMAN ROR GAMMA LIGAND BINDING DOMAIN WITH COMPOUND A.
1366, p5tldA_, 0.7280, 2.92, 0.180, 238, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL
1367, p4mgdB_, 0.7280, 2.82, 0.186, 234, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH HPTE
1368, p4iv4A_, 0.7280, 2.86, 0.150, 249, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 5B
1369, p4dmaB_, 0.7280, 3.03, 0.280, 222, 218, CRYSTAL STRUCTURE OF ERA LBD IN COMPLEX WITH RU100132
1370, d1zafB_, 0.7279, 2.76, 0.183, 248, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 3-BROMO-6-HYDROXY-2-(4-HYDROXY-PHENYL)-INDEN-1-ONE
1371, d1s9pD_, 0.7279, 2.71, 0.187, 228, 219, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
1372, p5q11A_, 0.7278, 2.59, 0.167, 228, 216, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1373, p5dxqA_, 0.7278, 2.70, 0.170, 247, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENEMETHANEDIYL]DIPHENOL
1374, p5dtvA_, 0.7278, 3.03, 0.185, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DIMETHYL-SUBSTITUTED 34-DIARYLTHIOPHENE DIOXIDE CORE LIGAND
1375, d3ollB_, 0.7278, 2.97, 0.190, 234, 221, CRYSTAL STRUCTURE OF PHOSPHORYLATED ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
1376, d3ollA_, 0.7278, 2.50, 0.213, 222, 216, CRYSTAL STRUCTURE OF PHOSPHORYLATED ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
1377, d1u3qC_, 0.7278, 2.93, 0.186, 231, 221, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH CL-272
1378, p5dwjA_, 0.7277, 2.98, 0.163, 229, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 4-FLUORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(4-FLUOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
1379, p5nfpA_, 0.7276, 3.19, 0.265, 229, 223, GLUCOCORTICOID RECEPTOR IN COMPLEX WITH BUDESONIDE
1380, p4mg7A_, 0.7276, 2.65, 0.225, 226, 218, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH FERUTININE
1381, d1p93B_, 0.7276, 2.73, 0.212, 224, 217, CRYSTAL STRUCTURE OF THE AGONIST FORM OF GLUCOCORTICOID RECEPTOR
1382, d5ixkA_, 0.7274, 2.75, 0.187, 230, 219, RORGAMMA IN COMPLEX WITH INVERSE AGONIST BIO399.
1383, d5ethA_, 0.7274, 3.00, 0.189, 234, 222, RORY IN COMPLEX WITH INVERSE AGONIST 3.
1384, d4refA_, 0.7274, 2.74, 0.187, 229, 219, CRYSTAL STRUCTURE OF TR3 LBD_L449W IN COMPLEX WITH MOLECULE 2
1385, p6br3B_, 0.7273, 2.92, 0.181, 235, 221, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST TAK-828.
1386, p5kcfA_, 0.7273, 2.69, 0.165, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-METHOXYBENZYL OBHS-N DERIVATIVE
1387, d2p7gA_, 0.7273, 2.61, 0.212, 225, 217, X-RAY STRUCTURE OF ESTROGEN RELATED RECEPTOR G IN COMPLEX WITH BISPHENOL A.
1388, d1zduA_, 0.7273, 2.94, 0.290, 221, 217, THE CRYSTAL STRUCTURE OF HUMAN LIVER RECEPTOR HOMOLOGUE-1
1389, d2q6jB_, 0.7272, 2.81, 0.186, 227, 220, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA COMPLEXED TO A B-N SUBSTITUTED LIGAND
1390, d1x76B_, 0.7272, 2.86, 0.186, 230, 220, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697
1391, d3ommA1, 0.7271, 2.96, 0.167, 233, 222, CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4- CHLOROPHENYL)-56-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2- CYCLOHEXYLACETYL}AMINO)-3-FLUOROBENZOIC ACID
1392, p5kcwA_, 0.7270, 2.96, 0.167, 234, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL OBHS-N DERIVATIVE
1393, p5dkbA_, 0.7270, 2.74, 0.165, 226, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-METHYLPHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -(2-{3-[(3-METHYLPHENYL)AMINO]PHENYL}BUT-1-ENE-11- DIYL)DIPHENOL
1394, d3olsA_, 0.7270, 2.87, 0.186, 231, 221, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
1395, p5gtrA_, 0.7269, 2.70, 0.179, 247, 218, ESTROGEN RECEPTOR ALPHA IN COMPLEX WITH A STABILIZED PEPTIDE ANTAGONIST 6
1396, p5e0xB_, 0.7269, 2.87, 0.186, 238, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-METHOXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1397, d3ltxB_, 0.7269, 2.83, 0.170, 245, 218,  
1398, d1e3gA_, 0.7269, 2.63, 0.213, 219, 216, HUMAN ANDROGEN RECEPTOR LIGAND BINDING IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)
1399, p5kroA_, 0.7268, 2.58, 0.219, 218, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE METHYL(PHENYL)AMINO-SUBSTITUTED ESTROGEN (8R9S 13S14S17S)-13-METHYL-17-(METHYL(PHENYL)AMINO)-7891112131415 1617-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
1400, p5e0xA_, 0.7268, 2.96, 0.203, 231, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-METHOXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1401, p4q13B_, 0.7268, 2.37, 0.218, 213, 211, APO ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT WITH A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1402, p4e2jA_, 0.7268, 3.03, 0.185, 236, 222, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH MOMETASONE FUROATE AND TIF-2 COACTIVATOR FRAGMENT
1403, d3k23C_, 0.7268, 2.59, 0.213, 222, 216, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
1404, d1yy4B1, 0.7268, 2.82, 0.192, 233, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 1-CHLORO-6-(4-HYDROXY-PHENYL)-NAPHTHALEN-2-OL
1405, d1x7jB_, 0.7268, 3.06, 0.180, 233, 222, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH GENISTEIN
1406, d1lv2A1, 0.7268, 2.60, 0.167, 225, 216, HEPATOCYTE NUCLEAR FACTOR 4 IS A TRANSCRIPTION FACTOR THAT CONSTITUTIVELY BINDS FATTY ACIDS
1407, p5dzhA_, 0.7267, 3.31, 0.268, 229, 224, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1408, d1pduB_, 0.7267, 2.72, 0.187, 233, 219, LIGAND-BINDING DOMAIN OF DROSOPHILA ORPHAN NUCLEAR RECEPTOR DHR38
1409, p5tmtB_, 0.7266, 2.92, 0.186, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((13-DIHYDRO-2H-INDEN-2-YLIDENE)METHYLENE)DIPHENOL
1410, p5e14A_, 0.7266, 2.74, 0.169, 229, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3R)-3- PHENYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1411, p4mg8B_, 0.7266, 2.68, 0.187, 236, 219, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ALPHA-ZEARALANOL
1412, p3uudB_, 0.7266, 2.85, 0.186, 230, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH ESTRADIOL
1413, p5krjB_, 0.7265, 2.99, 0.162, 227, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN A-NAPHTHYL SUBSTITUTED OBHS DERIVATIVE
1414, p4iwfB_, 0.7265, 2.99, 0.162, 227, 222, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A DYNAMIC OXIME-DERIVATIVE
1415, d4csjA_, 0.7265, 2.81, 0.145, 250, 220, THE DISCOVERY OF POTENT SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS SUITABLE FOR INHALATION
1416, d1kv6A_, 0.7265, 2.76, 0.187, 229, 219, X-RAY STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR ERR3 LIGAND- BINDING DOMAIN IN THE CONSTITUTIVELY ACTIVE CONFORMATION
1417, d1fbyA_, 0.7265, 2.80, 0.183, 230, 219, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID
1418, p5w4rA_, 0.7264, 2.75, 0.183, 226, 219, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1419, p5tn8A_, 0.7264, 2.72, 0.179, 246, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH (E)-4 -HYDROXY-3-((HYDROXYIMINIO)METHYL)-[11 - BIPHENYL]-4-OLATE
1420, p5krfB_, 0.7264, 2.65, 0.188, 246, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE DYNAMIC WAY DERIVATIVE 1A
1421, p5tm5B_, 0.7263, 2.61, 0.167, 225, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 5-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)PENTANOIC ACID
1422, p5tloB_, 0.7263, 2.74, 0.166, 225, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A SQUARIC ACID-LINKED DIMERIC ESTROGEN
1423, p4zi1A_, 0.7263, 2.71, 0.199, 222, 216, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH KB095285 AND CIA12 COACTIVATOR PEPTIDE
1424, d3omqA_, 0.7263, 3.05, 0.189, 235, 222, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1425, d3ompA_, 0.7263, 3.01, 0.215, 228, 223, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1426, d1u3rA_, 0.7263, 3.00, 0.189, 234, 222, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-338
1427, p5wgdA_, 0.7262, 3.05, 0.189, 232, 222, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-LP1 
1428, p5kcdA_, 0.7262, 2.92, 0.191, 234, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL SUBSTITUTED OBHS-N DERIVATIVE
1429, p5dkgA_, 0.7262, 2.90, 0.186, 235, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A T-BUTYL-SUBSTITUTED METHYL TRIARYL-ETHYLENE DERIVATIVE 44 - [2-(4-TERT-BUTYLPHENYL)PROP-1-ENE-11-DIYL]DIPHENOL
1430, p4fn9A_, 0.7262, 2.94, 0.177, 229, 220, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - PROGESTERONE COMPLEX
1431, p4e2jB_, 0.7262, 2.87, 0.186, 228, 220, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL GLUCOCORTICOID RECEPTOR 2 LIGAND BINDING DOMAIN IN COMPLEX WITH MOMETASONE FUROATE AND TIF-2 COACTIVATOR FRAGMENT
1432, d3d90A_, 0.7262, 2.75, 0.174, 247, 218, CRYSTAL STRUCTURE OF THE HUMAN PROGESTERONE RECEPTOR LIGAND- BINDING DOMAIN BOUND TO LEVONORGESTREL
1433, p5e0wA_, 0.7261, 2.50, 0.219, 222, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-HYDROXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1434, p3uuaB_, 0.7261, 2.27, 0.235, 217, 213, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-AF
1435, d3mneA1, 0.7261, 2.32, 0.218, 214, 211, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY F608S MUTATION AT 1.96A
1436, d2qseA_, 0.7261, 2.70, 0.188, 228, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH BURNED MEAT COMPOUND 4-OH-PHIP
1437, p5tluA_, 0.7260, 2.93, 0.186, 236, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PEG-LINKED DIMERIC ESTROGEN EE2-(EG)6-EE2-AMINE
1438, p4fneA_, 0.7260, 2.94, 0.177, 233, 220, X-RAY CRYSTAL STRUCTURE OF THE ANCESTRAL 3-KETO STEROID RECEPTOR - DOC COMPLEX
1439, d3mnoA1, 0.7260, 2.77, 0.183, 232, 219, CRYSTAL STRUCTURE OF THE AGONIST FORM OF MOUSE GLUCOCORTICOID RECEPTOR STABILIZED BY (A611V F608S) MUTATIONS AT 1.55A
1440, d1sqnA_, 0.7260, 2.88, 0.169, 230, 219, PROGESTERONE RECEPTOR LIGAND BINDING DOMAIN WITH BOUND NORETHINDRONE
1441, d3cldA_, 0.7259, 2.75, 0.169, 229, 219, LIGAND BINDING DOMAIN OF THE GLUCOCORTICOID RECEPTOR COMPLEXED WITH FLUTICAZONE FUROATE
1442, p1ymtA_, 0.7259, 2.75, 0.169, 229, 219, MOUSE SF-1 LBD
1443, d1l2iA_, 0.7259, 2.73, 0.164, 231, 219, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH (RR)-511-CIS-DIETHYL-561112- TETRAHYDROCHRYSENE-28-DIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1444, p4j26A_, 0.7258, 2.89, 0.183, 228, 219, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1445, d3omoA_, 0.7258, 2.94, 0.186, 231, 220, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1446, p1zdtA_, 0.7258, 2.86, 0.183, 231, 219, THE CRYSTAL STRUCTURE OF HUMAN STEROIDOGENIC FACTOR-1
1447, p5dy8A_, 0.7257, 2.85, 0.141, 250, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3- ETHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1448, p4pleA_, 0.7257, 2.73, 0.174, 247, 218, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1449, p4iw6A_, 0.7257, 2.95, 0.150, 247, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 7B
1450, d1yucA_, 0.7257, 2.93, 0.191, 234, 220, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO PHOSPHOLIPID AND A FRAGMENT OF HUMAN SHP
1451, d1tfcB_, 0.7257, 2.79, 0.192, 228, 219, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH A STEROID RECEPTOR COACTIVATOR-1 PEPTIDE
1452, p5krhA_, 0.7256, 2.67, 0.157, 252, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 16-BENZYLIDENE ESTRONE
1453, p5e19A_, 0.7256, 2.79, 0.183, 238, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE METHYL {4-[BIS(4-HYDROXYPHENYL) METHYLIDENE]CYCLOHEXYL}ACETATE
1454, d2b23B_, 0.7256, 2.78, 0.187, 229, 219, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1455, d3e7cB_, 0.7255, 2.85, 0.136, 247, 220, GLUCOCORTICOID RECEPTOR LBD BOUND TO GSK866
1456, d1ot7B_, 0.7255, 2.74, 0.157, 254, 217, STRUCTURAL BASIS FOR 3-DEOXY-CDCA BINDING AND ACTIVATION OF FXR
1457, p5wgqA_, 0.7254, 2.90, 0.155, 248, 220, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-BCP1 
1458, p4mgaB_, 0.7253, 2.94, 0.183, 243, 219, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH 4-TERT- OCTYLPHENOL
1459, d3cldB_, 0.7253, 2.81, 0.187, 235, 219, LIGAND BINDING DOMAIN OF THE GLUCOCORTICOID RECEPTOR COMPLEXED WITH FLUTICAZONE FUROATE
1460, p5e15B_, 0.7252, 3.02, 0.181, 233, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1461, p4mgbB_, 0.7251, 2.97, 0.164, 228, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH TCBPA
1462, d2qw4B_, 0.7251, 2.76, 0.169, 229, 219, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1463, p5dlrA_, 0.7250, 2.82, 0.177, 233, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-ETHYLENE COMPOUND 44 -(2-PHENYLETHENE-11-DIYL) DIPHENOL
1464, d2qw4D_, 0.7250, 3.01, 0.186, 233, 221, HUMAN NR4A1 LIGAND-BINDING DOMAIN
1465, p5dxpB_, 0.7249, 2.82, 0.187, 241, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 4-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(PHENYL)METHYL]PHENOL
1466, p4iw8B_, 0.7249, 3.02, 0.186, 233, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 9A
1467, p5kd9B_, 0.7248, 2.81, 0.187, 240, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
1468, p4zntA_, 0.7248, 2.70, 0.216, 225, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-BROMO-SUBSTITUTED OBHS DERIVATIVE
1469, p4mg9B_, 0.7247, 2.91, 0.191, 231, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BUTYLPARABEN
1470, p3uu7B_, 0.7247, 2.83, 0.182, 233, 220, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BISPHENOL-A
1471, d2qh6B_, 0.7247, 2.90, 0.191, 230, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH AN OXABICYCLIC DIARYLETHYLENE COMPOUND
1472, d2nv7B_, 0.7247, 2.92, 0.187, 245, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-555
1473, d4n1yB_, 0.7246, 3.31, 0.277, 229, 224, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
1474, d1l2iB_, 0.7246, 2.88, 0.182, 231, 220, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH (RR)-511-CIS-DIETHYL-561112- TETRAHYDROCHRYSENE-28-DIOL AND A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1475, p4znsA_, 0.7245, 3.11, 0.185, 233, 222, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-FLUORO-SUBSTITUTED OBHS DERIVATIVE
1476, p4iv4B_, 0.7245, 2.84, 0.179, 241, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 5B
1477, d1x7bB_, 0.7245, 3.01, 0.195, 233, 220, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH ERB-041
1478, p5krjA_, 0.7244, 3.04, 0.186, 232, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN A-NAPHTHYL SUBSTITUTED OBHS DERIVATIVE
1479, d1zafA_, 0.7244, 3.20, 0.238, 230, 223, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 3-BROMO-6-HYDROXY-2-(4-HYDROXY-PHENYL)-INDEN-1-ONE
1480, p6eu9D_, 0.7243, 3.00, 0.176, 233, 221, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
1481, p4pleG_, 0.7243, 2.86, 0.228, 227, 219, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1482, d5jmmB_, 0.7242, 2.83, 0.178, 230, 219, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BIOCHANIN A
1483, p5dx3B_, 0.7242, 3.04, 0.186, 233, 221, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P3 AND ESTRADIOL
1484, p4znwA_, 0.7242, 2.73, 0.184, 228, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 4-BROMO-SUBSTITUTED OBHS DERIVATIVE
1485, d3ry9B_, 0.7242, 2.85, 0.186, 229, 220, CRYSTAL STRUCTURE OF THE RESURRECTED ANCESTRAL GLUCOCORTICOID RECEPTOR 1 IN COMPLEX WITH DOC
1486, p5dy8B_, 0.7241, 2.87, 0.191, 230, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3- ETHYLCYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1487, p4pxmA_, 0.7241, 2.92, 0.191, 232, 220, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH ESTRADIOL AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1488, p5dxeA_, 0.7240, 2.81, 0.183, 228, 219, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P4 AND ESTRADIOL
1489, p4j24A_, 0.7240, 2.75, 0.166, 225, 217, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1490, d3ixpD_, 0.7240, 2.84, 0.164, 227, 220, CRYSTAL STRUCTURE OF THE ECDYSONE RECEPTOR BOUND TO BYI08346
1491, d2nv7A_, 0.7240, 2.78, 0.188, 231, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-555
1492, d1osvB1, 0.7240, 2.97, 0.190, 231, 221, STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR
1493, p4pxmB_, 0.7239, 2.92, 0.187, 232, 219, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH ESTRADIOL AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1494, d1u3rB_, 0.7239, 2.68, 0.166, 225, 217, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-338
1495, p6br2B_, 0.7238, 2.94, 0.186, 231, 220, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL ISOQUINOLINE INVERSE AGONIST.
1496, p5tm8B_, 0.7238, 2.74, 0.165, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENOXY)HEPTANOIC ACID
1497, p5kcuA_, 0.7238, 2.23, 0.279, 210, 208, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL ALPHA-NAPHTHYL OBHS-N DERIVATIVE
1498, p4ivwA_, 0.7238, 2.88, 0.186, 241, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH CONSTRAINED WAY-DERIVATIVE 6B
1499, d2pitA_, 0.7238, 3.07, 0.185, 233, 222, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1500, d1m7wA_, 0.7238, 2.61, 0.184, 224, 217, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1501, p5ehjB_, 0.7237, 3.08, 0.186, 234, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4AR8AR)-OCTAHYDRONAPHTHALEN- 2(1H)-YLIDENEMETHANEDIYL]DIPHENOL
1502, p4j24C_, 0.7237, 2.95, 0.151, 247, 219, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1503, d3zr7B_, 0.7237, 2.92, 0.187, 235, 219, STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS
1504, d1x7bA_, 0.7235, 2.86, 0.187, 230, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH ERB-041
1505, p5krkA_, 0.7234, 2.98, 0.191, 228, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((5-BROMO-23-DIHYDRO-1H-INDEN-1-YLIDENE) METHYLENE)DIPHENOL
1506, p5dxgA_, 0.7234, 2.75, 0.166, 225, 217, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P5
1507, p6cbzA_, 0.7233, 2.63, 0.247, 220, 215, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ESTRADIOL AND GRIP PEPTIDE
1508, d3plzA_, 0.7233, 2.72, 0.165, 228, 218, HUMAN LRH1 LBD BOUND TO GR470
1509, p5dxqB_, 0.7232, 3.30, 0.278, 228, 223, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENEMETHANEDIYL]DIPHENOL
1510, p5dz0B_, 0.7230, 2.69, 0.184, 226, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-METHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
1511, p4zntB_, 0.7230, 2.65, 0.167, 227, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 3-BROMO-SUBSTITUTED OBHS DERIVATIVE
1512, p5dxbB_, 0.7229, 2.38, 0.219, 212, 210, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P1 AND ESTRADIOL
1513, p4mg7B_, 0.7229, 2.77, 0.188, 228, 218, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH FERUTININE
1514, d1u3sA_, 0.7229, 2.77, 0.188, 226, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-797
1515, d3hq5A_, 0.7227, 3.04, 0.186, 234, 221, PROGESTERONE RECEPTOR BOUND TO AN ALKYLPYRROLIDINE LIGAND.
1516, d3g8nA_, 0.7227, 2.91, 0.145, 250, 220,  
1517, d5jjmA_, 0.7226, 2.36, 0.216, 223, 213, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
1518, p5dp0B_, 0.7226, 2.84, 0.187, 234, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 4 4 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}ETHENE-11-DIYL)DIPHENOL
1519, p5dmcB_, 0.7226, 2.75, 0.166, 225, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A NITRILE-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 33-BIS(4- HYDROXYPHENYL)-2-PHENYLPROP-2-ENENITRILE
1520, p4znhB_, 0.7226, 2.66, 0.157, 246, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-FLUORO-SUBSTITUTED OBHS DERIVATIVE
1521, p4rwvA_, 0.7226, 2.74, 0.165, 228, 218, CRYSTAL STRUCTURE OF PIP3 BOUND HUMAN NUCLEAR RECEPTOR LRH-1 (LIVER RECEPTOR HOMOLOG 1 NR5A2) IN COMPLEX WITH A CO-REGULATOR DAX-1 (NR0B1) PEPTIDE AT 1.86 A RESOLUTION
1522, p4dosA_, 0.7226, 2.91, 0.182, 228, 220, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO DLPC AND A FRAGMENT OF TIF-2
1523, d1yokA_, 0.7226, 2.85, 0.192, 228, 219, CRYSTAL STRUCTURE OF HUMAN LRH-1 BOUND WITH TIF-2 PEPTIDE AND PHOSPHATIDYLGLYCEROL
1524, p5dk9A_, 0.7225, 2.77, 0.188, 227, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A PHENYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 4 4 -{2-[3-(PHENYLAMINO)PHENYL]BUT-1-ENE-11-DIYL}DIPHENOL
1525, p4uddA_, 0.7225, 2.64, 0.189, 231, 217, GR IN COMPLEX WITH DESISOBUTYRYLCICLESONIDE
1526, p5dzhB_, 0.7224, 2.85, 0.183, 232, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1527, d1x78A_, 0.7224, 2.89, 0.183, 234, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-244
1528, p5tm7A_, 0.7223, 2.86, 0.188, 233, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND 7-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)HEPTANOIC ACID
1529, p5syzA_, 0.7223, 2.77, 0.188, 224, 218, HUMAN LIVER RECEPTOR HOMOLOGUE-1 (LRH-1) BOUND TO A RJW100 STEREOISOMER AND A FRAGMENT OF TIF-2
1530, d5jjmC_, 0.7223, 3.01, 0.191, 232, 220, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
1531, p4znvA_, 0.7223, 2.78, 0.165, 227, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHOXY-SUBSTITUTED OBHS DERIVATIVE
1532, d3l1bA1, 0.7223, 2.69, 0.157, 246, 216, COMPLEX STRUCTURE OF FXR LIGAND-BINDING DOMAIN WITH A TETRAHYDROAZEPINOINDOLE COMPOUND
1533, p4ivyB_, 0.7222, 2.69, 0.157, 246, 216, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 7A
1534, p4iv2A_, 0.7221, 2.95, 0.145, 252, 221, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 5A
1535, d2ocfA_, 0.7221, 2.92, 0.192, 232, 219, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND THE E2#23 FN3 MONOBODY
1536, p1yowA_, 0.7220, 2.96, 0.196, 231, 219, HUMAN STEROIDOGENIC FACTOR 1 LBD WITH BOUND CO-FACTOR PEPTIDE
1537, p6eu9C_, 0.7219, 2.92, 0.187, 227, 219, CRYSTAL STRUCTURE OF PLATYNEREIS DUMERILII RAR LIGAND-BINDING DOMAIN IN COMPLEX WITH ALL-TRANS RETINOIC ACID
1538, d4j5wD_, 0.7219, 2.85, 0.187, 242, 219, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
1539, d3wffA_, 0.7219, 2.85, 0.187, 242, 219, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 2B
1540, p5tm1B_, 0.7218, 2.85, 0.183, 236, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1541, d3fliA_, 0.7217, 3.02, 0.182, 230, 220, DISCOVERY OF XL335 A HIGHLY POTENT SELECTIVE AND ORALLY- ACTIVE AGONIST OF THE FARNESOID X RECEPTOR (FXR)
1542, d2pipL_, 0.7214, 2.86, 0.178, 249, 219, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1543, d1yyeB1, 0.7213, 2.89, 0.192, 235, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-202196
1544, p4zn9A_, 0.7211, 2.74, 0.165, 228, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
1545, p4pleE_, 0.7211, 2.98, 0.186, 234, 220, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1546, d1u3sB_, 0.7211, 3.05, 0.189, 237, 222, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-797
1547, p6b30B_, 0.7210, 2.96, 0.145, 250, 221, STRUCTURE OF RORGT IN COMPLEX WITH A NOVEL INVERSE AGONIST 1
1548, p5kctB_, 0.7210, 3.06, 0.181, 237, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-CHLOROBENZYL OBHS-N DERIVATIVE
1549, p4znwB_, 0.7210, 2.46, 0.290, 213, 210, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 4-BROMO-SUBSTITUTED OBHS DERIVATIVE
1550, d4j5wC1, 0.7210, 2.90, 0.192, 232, 219, CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX
1551, d3ozjA_, 0.7210, 2.99, 0.186, 231, 220, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA COMPLEXED WITH BIGELOVIN AND COACTIVATOR SRC-1
1552, d3uvvB_, 0.7209, 2.88, 0.187, 231, 219, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE THYROID RECEPTOR:RETINOID X RECEPTOR COMPLEXED WITH 33 5 TRIIODO-L- THYRONINE AND 9-CIS RETINOIC ACID
1553, p5dz1A_, 0.7208, 2.60, 0.176, 230, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4-ETHYLCYCLOHEXYLIDENE) METHANEDIYL]DIPHENOL
1554, p5kroB_, 0.7205, 2.52, 0.275, 217, 211, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE METHYL(PHENYL)AMINO-SUBSTITUTED ESTROGEN (8R9S 13S14S17S)-13-METHYL-17-(METHYL(PHENYL)AMINO)-7891112131415 1617-DECAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-3-OL
1555, d2pklA_, 0.7205, 2.28, 0.231, 227, 212, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1556, d2pivA_, 0.7205, 2.91, 0.173, 258, 220, ANDROGEN RECEPTOR WITH SMALL MOLECULE
1557, d1gs4A_, 0.7205, 2.80, 0.183, 226, 218, STRUCTURAL BASIS FOR THE GLUCOCORTICOID RESPONSE IN A MUTANT HUMAN ANDROGEN RECEPTOR (ARCCR) DERIVED FROM AN ANDROGEN-INDEPENDENT PROSTATE CANCER
1558, d5l7gA_, 0.7204, 3.09, 0.280, 221, 218, MCR IN COMPLEX WITH LIGAND
1559, d1t7fA_, 0.7204, 2.86, 0.146, 249, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A LXXLL MOTIF
1560, d1pcgA_, 0.7204, 2.76, 0.167, 224, 216, HELIX-STABILIZED CYCLIC PEPTIDES AS SELECTIVE INHIBITORS OF STEROID RECEPTOR-COACTIVATOR INTERACTIONS
1561, d1xnxA_, 0.7203, 3.07, 0.182, 237, 220, CRYSTAL STRUCTURE OF CONSTITUTIVE ANDROSTANE RECEPTOR
1562, d1t73A_, 0.7203, 2.78, 0.188, 241, 218, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXFF MOTIF
1563, d5jjmD_, 0.7202, 2.55, 0.168, 223, 214, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
1564, p3r5mA_, 0.7202, 2.29, 0.220, 212, 209, CRYSTAL STRUCTURE OF RXRALPHALBD COMPLEXED WITH THE AGONIST MAGNOLOL
1565, d3kbaA_, 0.7202, 2.77, 0.191, 226, 215, PROGESTERONE RECEPTOR BOUND TO SULFONAMIDE PYRROLIDINE PARTIAL AGONIST
1566, d1yjeA_, 0.7202, 2.78, 0.184, 228, 217, CRYSTAL STRUCTURE OF THE RNGFI-B LIGAND-BINDING DOMAIN
1567, p5q0qA_, 0.7201, 2.30, 0.231, 216, 212, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1568, d5jjmB_, 0.7201, 2.25, 0.237, 215, 211, CRYSTAL STRUCTURE OF HOMODIMERIC ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DHT AND LXXLL PEPTIDE
1569, d3ltxD_, 0.7201, 2.33, 0.235, 218, 213,  
1570, p5z12B_, 0.7200, 3.02, 0.186, 232, 220, A STRUCTURE OF FXR/RXR 
1571, d5l7hA1, 0.7200, 2.84, 0.183, 228, 218, MCR IN COMPLEX WITH LIGAND
1572, p5tm4A_, 0.7197, 2.89, 0.146, 249, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG 5-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)PENTANOIC ACID
1573, p4rmeA_, 0.7197, 2.86, 0.146, 249, 219, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB111 AND COACTIVATOR PEPTIDE GRIP-1
1574, d4n1yD_, 0.7197, 2.79, 0.147, 244, 218, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
1575, d2zy0C_, 0.7197, 2.66, 0.176, 247, 216, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1576, p5dz3A_, 0.7196, 2.99, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(FLUOROMETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1577, p5u2dB_, 0.7195, 2.82, 0.197, 232, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
1578, p5dksB_, 0.7195, 2.79, 0.207, 232, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-NAPHTHYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(NAPHTHALEN-1-YLAMINO)PHENYL]BUT-1-ENE-11- DIYL}DIPHENOL
1579, d4pf3A_, 0.7195, 2.96, 0.145, 250, 220, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 37A
1580, d2qxmA_, 0.7195, 2.94, 0.145, 249, 220, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO BURNED MEAT COMPOUND PHIP
1581, d2piwA_, 0.7195, 2.27, 0.237, 215, 211, ANDROGEN RECEPTOR WITH SMALL MOLECULE
1582, d1yy4A1, 0.7195, 2.74, 0.162, 243, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH 1-CHLORO-6-(4-HYDROXY-PHENYL)-NAPHTHALEN-2-OL
1583, p5e0wB_, 0.7194, 2.95, 0.218, 226, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(4-HYDROXYPHENYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1584, p5dwgA_, 0.7193, 2.99, 0.292, 221, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE TRIARYL-SUBSTITUTED IMINE ANALOG 4-{(E)-(4-HYDROXYPHENYL) [(2-METHYLPHENYL)IMINO]METHYL}BENZENE-13-DIOL
1585, p4nqaH2, 0.7193, 2.94, 0.145, 250, 220, CRYSTAL STRUCTURE OF LIGANDED HRXR-ALPHA/HLXR-BETA HETERODIMER ON DNA
1586, p4rmdA_, 0.7192, 2.86, 0.164, 226, 219, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB110 AND COACTIVATOR PEPTIDE GRIP-1
1587, p4q13A_, 0.7192, 2.45, 0.230, 217, 213, APO ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT WITH A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1588, d3zqtA_, 0.7192, 2.61, 0.177, 247, 215, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
1589, d3oapA_, 0.7192, 2.96, 0.179, 228, 218, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9-CIS RETINOIC ACID AND THE COACTIVATOR PEPTIDE GRIP-1
1590, d2pioA_, 0.7192, 2.20, 0.248, 214, 210, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1591, d1t76A_, 0.7192, 2.83, 0.164, 226, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A WXXVW MOTIF
1592, d1t63A_, 0.7192, 2.28, 0.232, 215, 211, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN WITH DHT AND A PEPTIDE DERIVED FROM ITS PHYSIOLOGICAL COACTIVATOR GRIP1 NR BOX3
1593, p5dydA_, 0.7191, 2.84, 0.183, 231, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[(3S)-3-(METHYLSULFANYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1594, p4mg6A_, 0.7191, 3.15, 0.181, 239, 221, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BENZYLBUTYLPHTALATE
1595, d1x7jA_, 0.7191, 2.87, 0.194, 227, 217, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH GENISTEIN
1596, d1t74A_, 0.7191, 3.03, 0.159, 249, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A WXXLF MOTIF
1597, p5dkeB_, 0.7190, 2.90, 0.188, 233, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-NAPHTHYL-SUBSTITUTED METHYL CIS-DIARYL-ETHYLENE COMPOUND 44 -[2-(NAPHTHALEN-2-YL)PROP-1-ENE-11-DIYL]DIPHENOL
1598, d2qpyA_, 0.7190, 2.83, 0.147, 248, 218, AR LBD WITH SMALL MOLECULE
1599, p4rmcA_, 0.7189, 2.72, 0.167, 225, 216, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB76 AND THE COACTIVATOR PEPTIDE GRIP-1
1600, d2b23A_, 0.7189, 2.94, 0.183, 230, 219, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN AND A GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1 NR BOX II PEPTIDE
1601, p4pleC_, 0.7188, 2.78, 0.189, 225, 217, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 BOUND TO AN E. COLI PHOSPHOLIPID AND A FRAGMENT OF TIF-2
1602, d4n1yA_, 0.7188, 2.53, 0.224, 223, 214, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
1603, d3ozjC_, 0.7188, 2.21, 0.248, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA COMPLEXED WITH BIGELOVIN AND COACTIVATOR SRC-1
1604, p3f7dA_, 0.7188, 2.89, 0.184, 226, 217, SF-1 LBD BOUND BY PHOSPHATIDYLCHOLINE
1605, d2zy0A_, 0.7188, 2.91, 0.146, 250, 219, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1606, d1t5zA_, 0.7188, 2.21, 0.248, 214, 210, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN (LBD) WITH DHT AND A PEPTIDE DERIVED FROM ITS PHYSIOLOGICAL COACTIVATOR ARA70
1607, p5tmlA_, 0.7187, 2.83, 0.147, 248, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC COMPOUND (E)-6-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)HEX-5-ENOIC ACID
1608, d2am9A_, 0.7187, 2.91, 0.146, 249, 219, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH TESTOSTERONE
1609, d1t65A_, 0.7187, 2.97, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN WITH DHT AND A PEPTIDE DERIVED FORM ITS PHYSIOLOGICAL COACTIVATOR GRIP1 NR BOX 2 BOUND IN A NON- HELICAL CONFORMATION
1610, d2yloA_, 0.7185, 2.83, 0.183, 225, 218, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
1611, p4zshA_, 0.7184, 2.99, 0.193, 233, 218, RXR LBD IN COMPLEX WITH 9-CIS-1314-DIHYDRORETINOIC ACID
1612, d2ylqA_, 0.7184, 2.71, 0.167, 225, 216, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
1613, p6cbzB_, 0.7183, 2.89, 0.146, 249, 219, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH ESTRADIOL AND GRIP PEPTIDE
1614, p5tloA_, 0.7183, 2.90, 0.179, 235, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A SQUARIC ACID-LINKED DIMERIC ESTROGEN
1615, p5dksA_, 0.7183, 2.86, 0.147, 248, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-NAPHTHYLAMINO-SUBSTITUTED ETHYL TRIARYL-ETHYLENE DERIVATIVE 44 -{2-[3-(NAPHTHALEN-1-YLAMINO)PHENYL]BUT-1-ENE-11- DIYL}DIPHENOL
1616, d2piqA_, 0.7183, 2.22, 0.248, 214, 210, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1617, d1xdkE_, 0.7183, 2.87, 0.188, 226, 218, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
1618, d1xdkA_, 0.7183, 2.94, 0.187, 239, 219, CRYSTAL STRUCTURE OF THE RARBETA/RXRALPHA LIGAND BINDING DOMAIN HETERODIMER IN COMPLEX WITH 9-CIS RETINOIC ACID AND A FRAGMENT OF THE TRAP220 COACTIVATOR
1619, d1t79A_, 0.7183, 2.95, 0.164, 226, 220, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXLW MOTIF
1620, d1m7wD_, 0.7183, 2.30, 0.237, 215, 211, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1621, p5kraA_, 0.7182, 2.98, 0.188, 237, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH DDT AND DDE
1622, p5dybA_, 0.7182, 2.28, 0.227, 215, 211, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -(34-DIHYDRONAPHTHALEN-2(1H)- YLIDENEMETHANEDIYL)DIPHENOL
1623, p4m8hA_, 0.7182, 3.00, 0.145, 250, 220, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (R)4-METHYL 9CUAB30 AND COACTIVATOR PEPTIDE GRIP- 3 1
1624, d2ambA_, 0.7182, 2.86, 0.188, 235, 218, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH TETRAHYDROGESTRINONE
1625, d3ltxA_, 0.7181, 2.93, 0.146, 250, 219,  
1626, d2yjdB_, 0.7181, 3.00, 0.145, 251, 220, STAPLED PEPTIDE BOUND TO ESTROGEN RECEPTOR BETA
1627, p4k6iA_, 0.7179, 2.94, 0.146, 250, 219, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH TARGRETIN AND THE COACTIVATOR PEPTIDE GRIP-1
1628, d1t7rA_, 0.7179, 2.14, 0.244, 213, 209, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXLF MOTIF
1629, p5wgdB_, 0.7178, 2.88, 0.147, 249, 218, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH ESTRADIOL AND SRC2-LP1 
1630, d3g0wA_, 0.7178, 2.70, 0.190, 223, 216, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH AN N-ARYL-OXAZOLIDIN 2-IMINE INHIBITOR
1631, d1x76A_, 0.7178, 2.77, 0.190, 229, 216, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697
1632, d1t7mA_, 0.7178, 2.71, 0.185, 225, 216, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH A FXXYF MOTIF
1633, p5kcdB_, 0.7177, 2.90, 0.146, 249, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL SUBSTITUTED OBHS-N DERIVATIVE
1634, d2piuA_, 0.7177, 2.32, 0.231, 217, 212, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1635, d2aa7A_, 0.7177, 2.32, 0.231, 217, 212, MINERALOCORTICOID RECEPTOR WITH BOUND DEOXYCORTICOSTERONE
1636, d1i37A_, 0.7177, 3.01, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH DIHYDROTESTOSTERONE
1637, p4oj9A_, 0.7176, 2.65, 0.219, 221, 215, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1638, d3ry9A_, 0.7176, 2.77, 0.184, 226, 217, CRYSTAL STRUCTURE OF THE RESURRECTED ANCESTRAL GLUCOCORTICOID RECEPTOR 1 IN COMPLEX WITH DOC
1639, p5kcfB_, 0.7175, 2.71, 0.190, 229, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL 4-METHOXYBENZYL OBHS-N DERIVATIVE
1640, d3vhvA1, 0.7175, 2.23, 0.248, 214, 210, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH NON-STEROIDAL ANTAGONIST
1641, p4rfwA_, 0.7174, 2.88, 0.147, 246, 218, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB70 AND THE COACTIVATOR PEPTIDE GRIP-1
1642, d2z4jA_, 0.7174, 2.96, 0.164, 226, 220, CRYSTAL STRUCTURE OF AR LBD WITH SHP PEPTIDE NR BOX 2
1643, d2hvcA_, 0.7174, 2.69, 0.172, 223, 215, THE CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN (LBD) OF HUMAN ANDROGEN RECEPTOR IN COMPLEX WITH A SELECTIVE MODULATOR LGD2226
1644, p4pojA_, 0.7173, 2.25, 0.243, 214, 210, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 7-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1645, d2pirA_, 0.7173, 3.01, 0.145, 250, 220, ANDROGEN RECEPTOR LBD WITH SMALL MOLECULE
1646, p5dp0A_, 0.7172, 2.65, 0.191, 222, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 4-FLUOROPHENYLAMINO-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 4 4 -(2-{3-[(4-FLUOROPHENYL)AMINO]PHENYL}ETHENE-11-DIYL)DIPHENOL
1647, p4pp5A_, 0.7172, 2.92, 0.146, 249, 219, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 5-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1648, p4j24D_, 0.7172, 2.73, 0.167, 225, 216, ESTROGEN RECEPTOR IN COMPLEX WITH PROLINE-FLANKED LXXLL PEPTIDES
1649, d2ylpA_, 0.7172, 2.92, 0.146, 249, 219, TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING
1650, d5jmmA_, 0.7171, 2.81, 0.189, 226, 217, CRYSTAL STRUCTURE OF HERA-LBD (Y537S) IN COMPLEX WITH BIOCHANIN A
1651, p4m8eA_, 0.7171, 2.85, 0.147, 248, 218, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH (S) 4-METHYL 9CUAB30 COACTIVATOR PEPTIDE GRIP-1
1652, p4k4jA_, 0.7171, 3.10, 0.173, 253, 220, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 9CUAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1653, p3v4aA_, 0.7171, 2.76, 0.147, 246, 217, STRUCTURE OF AR LBD WITH ACTIVATOR PEPTIDE AND SARM INHIBITOR 2
1654, d1t7tA_, 0.7171, 2.91, 0.146, 249, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH 5-ALPHA DIHYDROTESTOSTERONE
1655, p4zn9B_, 0.7170, 2.70, 0.167, 243, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONATE (OBHS)
1656, p5hyrB_, 0.7169, 2.74, 0.188, 227, 213, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-SP2 AND ESTRADIOL
1657, p5ehjA_, 0.7169, 2.78, 0.171, 253, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -[(4AR8AR)-OCTAHYDRONAPHTHALEN- 2(1H)-YLIDENEMETHANEDIYL]DIPHENOL
1658, p5dwjB_, 0.7169, 2.23, 0.248, 214, 210, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A RESORCINYL 4-FLUORO-SUBSTITUTED DIARYL-IMINE ANALOG 4-[(E)- [(4-FLUOROPHENYL)IMINO](4-HYDROXYPHENYL)METHYL]BENZENE-13-DIOL
1659, d3ltxC_, 0.7169, 2.87, 0.147, 248, 218,  
1660, d5toaB_, 0.7168, 2.98, 0.145, 250, 220, CRYSTAL STRUCTURE OF ER BETA BOUND TO ESTRADIOL
1661, p5dxeB_, 0.7168, 2.24, 0.248, 214, 210, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P4 AND ESTRADIOL
1662, p5kcwB_, 0.7167, 2.99, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-TRIFLUOROETHYL OBHS-N DERIVATIVE
1663, d4udbA_, 0.7167, 2.86, 0.179, 229, 218, MR IN COMPLEX WITH DESISOBUTYRYLCICLESONIDE
1664, d2pixA_, 0.7167, 2.23, 0.248, 214, 210, AR LBD WITH SMALL MOLECULE
1665, p5kccB_, 0.7166, 2.60, 0.169, 221, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH OXABICYCLIC HEPTENE SULFONAMIDE (OBHS-N)
1666, p5dweB_, 0.7166, 2.90, 0.147, 249, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-CHLORO-SUBSTITUTED TRIARYL-IMINE ANALOG 44 -[(2- CHLOROPHENYL)CARBONIMIDOYL]DIPHENOL
1667, d2aaxA_, 0.7166, 2.79, 0.190, 230, 216, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND CORTISONE
1668, d3rljA_, 0.7165, 2.24, 0.248, 214, 210, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-22
1669, d5l7eA_, 0.7164, 2.24, 0.248, 214, 210, MCR IN COMPLEX WITH LIGAND
1670, p4pp3A_, 0.7164, 2.80, 0.148, 244, 216, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 6-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1671, d1xnnA_, 0.7163, 3.03, 0.145, 250, 220, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT COMPLEX WITH (3A-ALPHA-4- ALPHA 7-ALPHA-7A-ALPHA-)-3A477A-TETRAHYDRO-2-(4-NITRO- 1-NAPHTHALENYL)-47-ETHANO-1H-ISOINDOLE-13(2H)-DIONE.
1672, d5u2bB_, 0.7161, 3.00, 0.183, 235, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1673, d4is8A_, 0.7161, 2.76, 0.190, 223, 216, DIVERGENT SEQUENCE TUNES LIGAND SENSITIVITY IN PHOSPHOLIPID-REGULATED HORMONE RECEPTORS
1674, d3l3zA1, 0.7161, 3.00, 0.183, 229, 218, CRYSTAL STRUCTURE OF DHT-BOUND ANDROGEN RECEPTOR IN COMPLEX WITH THE THIRD MOTIF OF STEROID RECEPTOR COACTIVATOR 3
1675, p5unjA_, 0.7159, 2.79, 0.185, 229, 216, STRUCTURE OF HUMAN LIVER RECEPTOR HOMOLOG 1 IN COMPLEX WITH PGC1A AND RJW100
1676, p2yjdA_, 0.7159, 2.85, 0.166, 224, 217, STAPLED PEPTIDE BOUND TO ESTROGEN RECEPTOR BETA
1677, d3l3xA1, 0.7158, 2.86, 0.157, 232, 216, CRYSTAL STRUCTURE OF DHT-BOUND ANDROGEN RECEPTOR IN COMPLEX WITH THE FIRST MOTIF OF STEROID RECEPTOR COACTIVATOR 3
1678, d3b5rA_, 0.7158, 2.72, 0.190, 222, 216, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM C-31
1679, d2aa6A_, 0.7157, 2.78, 0.182, 224, 214, MINERALOCORTICOID RECEPTOR S810L MUTANT WITH BOUND PROGESTERONE
1680, p4pohA_, 0.7156, 2.78, 0.171, 244, 217, CRYSTAL STRUCTURE OF HUMAN RETINOID X RECEPTOR ALPHA-LIGAND BINDING DOMAIN COMPLEX WITH 8-METHYL UAB30 AND THE COACTIVATOR PEPTIDE GRIP-1
1681, d4n1yC_, 0.7156, 2.87, 0.147, 248, 218, CRYSTAL STRUCTURE OF THE PACIFIC OYSTER ESTROGEN RECEPTOR LIGAND BINDING DOMAIN
1682, d3b65A_, 0.7156, 2.85, 0.189, 227, 217, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-24
1683, d2aaxB_, 0.7156, 2.77, 0.185, 229, 216, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND CORTISONE
1684, d1yyeA1, 0.7156, 3.26, 0.172, 261, 221, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-202196
1685, d4ok1A_, 0.7155, 3.26, 0.172, 261, 221, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1686, d1fbyB_, 0.7155, 2.92, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID
1687, p5w4vB_, 0.7154, 2.61, 0.178, 243, 214, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1688, d2nw4A_, 0.7154, 2.26, 0.248, 214, 210, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN COMPLEX WITH BMS-564929
1689, d2ab2B_, 0.7153, 2.84, 0.143, 247, 217, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND SPIRONOLACTONE
1690, d3wfgA_, 0.7152, 2.90, 0.194, 228, 217, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 2E
1691, p3v49A_, 0.7152, 2.70, 0.186, 230, 215, STRUCTURE OF AR LBD WITH ACTIVATOR PEPTIDE AND SARM INHIBITOR 1
1692, d3b66A_, 0.7151, 2.96, 0.147, 248, 218, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-21
1693, p5tmmA_, 0.7149, 2.69, 0.186, 227, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENYL)HEX-5-ENOIC ACID
1694, d5t8eA_, 0.7149, 2.61, 0.173, 223, 214, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS). PART II: OPTIMIZATION OF 4-(PYRROLIDIN- 1-YL)BENZONITRILE DERIVATIVES
1695, p5w4vA_, 0.7148, 3.04, 0.146, 249, 219, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1696, d2yhdA_, 0.7148, 2.92, 0.147, 247, 218, HUMAN ANDROGEN RECEPTOR IN COMPLEX WITH AF2 SMALL MOLECULE INHIBITOR
1697, d4hlwA_, 0.7147, 3.22, 0.164, 260, 220, TARGETING THE BINDING FUNCTION 3 (BF3) SITE OF THE HUMAN ANDROGEN RECEPTOR THROUGH VIRTUAL SCREENING. 2. DEVELOPMENT OF 2-((2- PHENOXYETHYL) THIO)-1H-BENZOIMIDAZOLE DERIVATIVES.
1698, d4is8B_, 0.7145, 2.27, 0.248, 214, 210, DIVERGENT SEQUENCE TUNES LIGAND SENSITIVITY IN PHOSPHOLIPID-REGULATED HORMONE RECEPTORS
1699, d2pnuA_, 0.7145, 2.84, 0.166, 224, 217, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH EM-5744
1700, p2zxzA_, 0.7144, 2.92, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO A SYNTHETIC AGONIST COMPOUND AND A COACTIVATOR PEPTIDE
1701, d4oktA_, 0.7142, 3.34, 0.163, 257, 221, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1702, d2q7lA_, 0.7142, 2.76, 0.167, 225, 216, THE ANDROGEN RECEPTOR PROSTATE CANCER MUTANT H874Y LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND A TIF2 BOX3 COACTIVATOR PEPTIDE 740-753
1703, d1u9eA_, 0.7142, 3.03, 0.146, 249, 219, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-397
1704, d1i38A_, 0.7142, 2.12, 0.240, 212, 208, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT COMPLEX WITH DIHYDROTESTOSTERONE
1705, p5tlmA_, 0.7141, 2.32, 0.217, 209, 207, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 4  -(THIOPHENE-235-TRIYL)TRIPHENOL
1706, d4udaA_, 0.7141, 2.90, 0.147, 248, 218, MR IN COMPLEX WITH DEXAMETHASONE
1707, d2ihqA_, 0.7141, 3.19, 0.159, 259, 220, CRYSTAL STRUCTURE OF THE RAT ANDROGEN RECEPTOR LIGAND BINDING DOMIAN COMPLEX WITH AN N-ARYL- HYDROXYBICYCLOHYDANTOIN
1708, p5dmcA_, 0.7140, 2.85, 0.170, 249, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A NITRILE-SUBSTITUTED TRIARYL-ETHYLENE DERIVATIVE 33-BIS(4- HYDROXYPHENYL)-2-PHENYLPROP-2-ENENITRILE
1709, d2ab2A_, 0.7140, 2.83, 0.148, 244, 216, MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND SPIRONOLACTONE
1710, d5toaA_, 0.7139, 2.93, 0.147, 247, 218, CRYSTAL STRUCTURE OF ER BETA BOUND TO ESTRADIOL
1711, d2aa5A_, 0.7138, 2.80, 0.191, 223, 215, MINERALOCORTICOID RECEPTOR WITH BOUND PROGESTERONE
1712, d4u4kA_, 0.7137, 3.00, 0.147, 249, 218,  
1713, p4pldA_, 0.7137, 2.34, 0.213, 209, 207, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN TIF-2
1714, d2aa2A_, 0.7136, 2.93, 0.147, 249, 218, MINERALOCORTICOID RECEPTOR WITH BOUND ALDOSTERONE
1715, d5t8jA_, 0.7134, 2.84, 0.148, 244, 216, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS). PART II: OPTIMIZATION OF 4-(PYRROLIDIN- 1-YL)BENZONITRILE DERIVATIVES
1716, d2aa6B_, 0.7134, 2.92, 0.189, 230, 217, MINERALOCORTICOID RECEPTOR S810L MUTANT WITH BOUND PROGESTERONE
1717, p5tlmB_, 0.7133, 2.89, 0.147, 245, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 4  -(THIOPHENE-235-TRIYL)TRIPHENOL
1718, p5mwyA_, 0.7133, 2.21, 0.239, 213, 209, THE STRUCTURE OF MR IN COMPLEX WITH EPLERENONE.
1719, p5mwpA_, 0.7133, 3.07, 0.146, 248, 219, THE STRUCTURE OF MR IN COMPLEX WITH AZD9977.
1720, p5mk4C_, 0.7133, 3.09, 0.151, 247, 218, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 7 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1721, d1oshA1, 0.7133, 2.64, 0.168, 223, 214, A CHEMICAL GENETIC AND STRUCTURAL ANALYSIS OF THE NUCLEAR BILE ACID RECEPTOR FXR
1722, d1mv9A_, 0.7133, 2.80, 0.147, 247, 217, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE EICOSANOID DHA (DOCOSA HEXAENOIC ACID) AND A COACTIVATOR PEPTIDE
1723, p5lyqA_, 0.7131, 2.77, 0.191, 226, 215, CRYSTAL STRUCTURE OF THE RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC SPIROKETAL AGONIST AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1724, d2q7jA_, 0.7131, 2.81, 0.172, 241, 215, THE WILD TYPE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND A TIF2 BOX 3 COACTIVATOR PEPTIDE 740-753
1725, p4ivyA_, 0.7129, 2.95, 0.147, 248, 218, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY-DERIVATIVE 7A
1726, d5v8qA_, 0.7128, 2.76, 0.191, 223, 215, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS): PART III
1727, p5kcuB_, 0.7128, 3.12, 0.174, 259, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-ETHYL ALPHA-NAPHTHYL OBHS-N DERIVATIVE
1728, p5cj6A_, 0.7128, 2.84, 0.158, 230, 215, CRYSTAL STRUCTURE OF A SELECTIVE ANDROGEN RECEPTOR MODULATOR BOUND TO THE LIGAND BINDING DOMAIN OF THE HUMAN ANDROGEN RECEPTOR
1729, d3olsB_, 0.7128, 3.06, 0.165, 255, 218, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN
1730, p5l11A_, 0.7127, 3.00, 0.146, 250, 219, HUMAN LIVER RECEPTOR HOMOLOGUE-1 (LRH-1) BOUND TO RJW100 AND A FRAGMENT OF TIF-2
1731, d3r5mC_, 0.7127, 2.84, 0.170, 239, 218, CRYSTAL STRUCTURE OF RXRALPHALBD COMPLEXED WITH THE AGONIST MAGNOLOL
1732, d3b67A_, 0.7127, 3.14, 0.164, 252, 219, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM C-23
1733, p5uanA2, 0.7125, 3.02, 0.147, 249, 218, CRYSTAL STRUCTURE OF MULTI-DOMAIN RAR-BETA-RXR-ALPHA HETERODIMER ON DNA
1734, p2ylyA_, 0.7125, 3.14, 0.178, 259, 219, SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS.
1735, p4znuB_, 0.7123, 2.80, 0.190, 227, 216, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH A 2-METHYL-SUBSTITUTED OBHS DERIVATIVE
1736, d1r5kA_, 0.7123, 2.74, 0.172, 244, 215, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
1737, d3b68A_, 0.7122, 2.69, 0.173, 243, 214, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH SARM S-4
1738, d3omqB_, 0.7121, 2.31, 0.238, 215, 210, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1739, p5vo4A_, 0.7120, 2.33, 0.288, 213, 208, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH 5-(2-FLUORO-4-HYDROXYPHENYL)-1-METHYL-1H-PYRROLE-2- CARBONITRILE
1740, d3ompB_, 0.7119, 2.21, 0.245, 214, 208, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1741, d2aa5B_, 0.7117, 2.21, 0.245, 212, 208, MINERALOCORTICOID RECEPTOR WITH BOUND PROGESTERONE
1742, p4ofrA_, 0.7116, 2.91, 0.153, 247, 216, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1743, d5u2bD_, 0.7115, 3.01, 0.180, 229, 217, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1744, d3omoB_, 0.7115, 3.02, 0.147, 249, 218, FRAGMENT-BASED DESIGN OF NOVEL ESTROGEN RECEPTOR LIGANDS
1745, d1mvcA_, 0.7114, 2.80, 0.196, 227, 214, CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1746, d1mznG_, 0.7110, 2.86, 0.148, 244, 216, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1747, p5dxgB_, 0.7109, 2.82, 0.172, 224, 215, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN Y537S MUTANT IN COMPLEX WITH STAPLED PEPTIDE SRC2-P5
1748, d1mznC_, 0.7108, 3.07, 0.192, 234, 219, CRYSTAL STRUCTURE AT 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE
1749, p5ji0A_, 0.7106, 2.29, 0.234, 213, 209, PPARGAMMA-RXRALPHA(S427F) HETERODIMER IN COMPLEX WITH SRC-1 ROSIGLITAZONE AND 9-CIS-RETANOIC ACID
1750, d3e94A_, 0.7106, 2.95, 0.147, 247, 218, CRYSTAL STRUCTURE OF RXRALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIBUTYLTIN AND A COACTIVATOR FRAGMENT
1751, p5tmmB_, 0.7105, 2.21, 0.226, 212, 208, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-6-(4-((1R4S6R)-6-((4- BROMOPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-2- EN-2-YL)PHENYL)HEX-5-ENOIC ACID
1752, p5tm1A_, 0.7105, 2.51, 0.170, 219, 212, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-FLUORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1753, d3kwyA_, 0.7104, 2.89, 0.185, 226, 216, CRYSTAL STRUCTURE OF RXRALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH TRIPHENYLTIN AND A COACTIVATOR FRAGMENT
1754, d3fugA_, 0.7102, 2.96, 0.181, 236, 216, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST 3-[4-HYDROXY-3-(35 588-PENTAMETHYL-5678-TETRAHYDRONAPHTHALEN-2-YL)- PHENYL]ACRYLIC ACID
1755, d2ao6A_, 0.7101, 2.96, 0.147, 247, 218, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TIF2(III) 740-753 PEPTIDE AND R1881
1756, p2q1vA_, 0.7100, 2.82, 0.172, 224, 215, ANCESTRAL CORTICOID RECEPTOR IN COMPLEX WITH CORTISOL
1757, d2p1vA_, 0.7100, 2.99, 0.147, 245, 217, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -PROPOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1758, p4oedA_, 0.7099, 2.82, 0.172, 224, 215, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1759, p5mk4A_, 0.7098, 3.28, 0.159, 255, 220, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 7 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1760, d1xowA_, 0.7098, 2.92, 0.148, 243, 216, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH AN ANDROGEN RECEPTOR NH2- TERMINAL PEPTIDE AR20-30 AND R1881
1761, d4oilA_, 0.7097, 2.80, 0.191, 226, 215, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1762, d3k23A_, 0.7097, 2.83, 0.172, 224, 215, GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11
1763, p3gytA_, 0.7097, 2.23, 0.245, 212, 208, NUCLEAR RECEPTOR DAF-12 FROM PARASITIC NEMATODE STRONGYLOIDES STERCORALIS IN COMPLEX WITH ITS PHYSIOLOGICAL LIGAND DAFACHRONIC ACID DELTA 4
1764, d1r5kB_, 0.7097, 2.24, 0.245, 212, 208, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
1765, d2p1tA_, 0.7096, 2.63, 0.192, 219, 213, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -METHOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1766, d3vhuA_, 0.7095, 2.25, 0.245, 212, 208, MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH SPIRONOLACTONE
1767, d2oz7A_, 0.7095, 2.51, 0.231, 216, 212, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR T877A MUTANT LIGAND- BINDING DOMAIN WITH CYPROTERONE ACETATE
1768, d4oeaA_, 0.7093, 2.18, 0.242, 211, 207, CRYSTAL STRUCTURE OF AR-LBD
1769, d1r5kC_, 0.7093, 2.72, 0.183, 222, 213, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH GW5638
1770, p4ofuA_, 0.7090, 2.69, 0.188, 220, 213, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1771, p4oc7A_, 0.7090, 2.21, 0.246, 210, 207, RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH (E)-3-(3 -ALLYL-6- HYDROXY-[11 -BIPHENYL]-3-YL)ACRYLIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF2
1772, d2amaA_, 0.7090, 2.19, 0.242, 211, 207, CRYSTAL STRUCTURE OF HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH DIHYDROTESTOSTERONE
1773, d4oghA_, 0.7089, 2.87, 0.149, 242, 215, CRYSTAL STRUCTURE OF T877A-AR-LBD
1774, d3pcuA_, 0.7089, 2.88, 0.144, 244, 215, CRYSTAL STRUCTURE OF HUMAN RETINOIC X RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH LX0278 AND SRC1 PEPTIDE
1775, p2q1hA_, 0.7089, 2.20, 0.242, 211, 207, ANCESTRAL CORTICOID RECEPTOR IN COMPLEX WITH ALDOSTERONE
1776, p4oezA_, 0.7088, 2.85, 0.149, 242, 215, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1777, d1xq3A_, 0.7087, 2.32, 0.234, 214, 209, CRYSTAL STRUCTURE OF THE HUMAN ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH R1881
1778, d4oiuA_, 0.7085, 2.86, 0.149, 243, 215, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1779, d5u2bE_, 0.7084, 2.84, 0.149, 242, 215, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1780, p5mkjA_, 0.7084, 2.68, 0.169, 245, 213, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 9 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1781, d4oh5A_, 0.7082, 3.11, 0.174, 242, 219, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1782, p5dkeA_, 0.7081, 3.11, 0.174, 242, 219, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 3-NAPHTHYL-SUBSTITUTED METHYL CIS-DIARYL-ETHYLENE COMPOUND 44 -[2-(NAPHTHALEN-2-YL)PROP-1-ENE-11-DIYL]DIPHENOL
1783, p4oeyA_, 0.7078, 3.14, 0.189, 235, 217, CRYSTAL STRUCTURE OF AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1784, d2q7kA_, 0.7078, 2.21, 0.242, 211, 207, THE ANDROGEN RECEPTOR PROSTATE CANCER MUTANT H874Y LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND AN AR 20-30 PEPTIDE
1785, p5dxpA_, 0.7076, 3.12, 0.165, 249, 218, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 4-[(E)-(1S5S)-BICYCLO[3.3.1]NON-9- YLIDENE(PHENYL)METHYL]PHENOL
1786, p2q3yA_, 0.7076, 3.02, 0.142, 249, 218, ANCESTRAL CORTICIOD RECEPTOR IN COMPLEX WITH DOC
1787, d4olmA_, 0.7074, 2.86, 0.149, 242, 215, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1788, d4k7aA_, 0.7074, 3.10, 0.190, 235, 216, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH MINOXIDIL
1789, p5dvsB_, 0.7072, 2.78, 0.150, 241, 214, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A 2-METHYL-SUBSTITUTED TRIARYL-IMINE 44 -[(2-METHYLPHENYL) CARBONIMIDOYL]DIPHENOL
1790, d4ql8A_, 0.7072, 2.32, 0.244, 213, 209, CRYSTAL STRUCTURE OF ANDROGEN RECEPTOR IN COMPLEX WITH THE LIGAND
1791, d2ax6A_, 0.7072, 2.87, 0.149, 243, 215, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT IN COMPLEX WITH HYDROXYFLUTAMIDE
1792, d2ovmA_, 0.7071, 2.80, 0.150, 242, 214, PROGESTERONE RECEPTOR WITH BOUND ASOPRISNIL AND A PEPTIDE FROM THE CO-REPRESSOR NCOR
1793, d2abiC_, 0.7071, 2.22, 0.242, 211, 207, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
1794, d1rdtA_, 0.7071, 2.91, 0.144, 244, 215, CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHA LIGAND BINDING DOAMIN IN THE RXRALPHA/PPARGAMMA HETERODIMER
1795, p5mj5A_, 0.7069, 2.86, 0.149, 242, 215, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETICHONOKIOL DERIVATIVE 3 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1796, d1xpcA_, 0.7067, 2.87, 0.149, 243, 215, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 19
1797, p5ec9A_, 0.7065, 2.84, 0.149, 242, 215, RETINOIC ACID RECEPTOR ALPHA IN COMPLEX WITH CHIRAL DIHYDROBENZOFURAN BENZOIC ACID 9A AND A FRAGMENT OF THE COACTIVATOR TIF2
1798, d1xp9A_, 0.7065, 2.76, 0.188, 221, 213, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 18
1799, d4xi3C_, 0.7063, 2.23, 0.242, 211, 207, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
1800, d1s9qA_, 0.7063, 2.78, 0.150, 242, 214, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
1801, d2p1uA_, 0.7062, 2.67, 0.189, 221, 212, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH 3-(2 -ETHOXY)- TETRAHYDRONAPHTYL CINNAMIC ACID AND A FRAGMENT OF THE COACTIVATOR TIF-2
1802, d1yimA_, 0.7062, 2.80, 0.150, 241, 214, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 4
1803, d1xp6A_, 0.7062, 2.79, 0.150, 242, 214, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 16
1804, d1uhlA_, 0.7061, 2.63, 0.184, 222, 212, CRYSTAL STRUCTURE OF THE LXRALFA-RXRBETA LBD HETERODIMER
1805, d1xp1A_, 0.7060, 2.90, 0.158, 244, 215, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 15
1806, p5w4vE_, 0.7057, 2.75, 0.150, 240, 213, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1807, p5ufwA_, 0.7056, 2.88, 0.144, 242, 215, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1154
1808, p5dwgB_, 0.7053, 2.74, 0.188, 223, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE TRIARYL-SUBSTITUTED IMINE ANALOG 4-{(E)-(4-HYDROXYPHENYL) [(2-METHYLPHENYL)IMINO]METHYL}BENZENE-13-DIOL
1809, p5ufxA_, 0.7052, 2.79, 0.150, 240, 214, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1074
1810, d2ovhA_, 0.7052, 3.00, 0.148, 242, 216, PROGESTERONE RECEPTOR WITH BOUND ASOPRISNIL AND A PEPTIDE FROM THE CO-REPRESSOR SMRT
1811, d2gpvB_, 0.7050, 3.18, 0.144, 243, 216, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1812, d2gpvA_, 0.7050, 2.59, 0.180, 234, 211, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1813, p5kceA_, 0.7049, 2.22, 0.237, 211, 207, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH AN N-METHYL 2-CHLOROBENZYL OBHS-N DERIVATIVE
1814, d4okwA_, 0.7047, 2.35, 0.244, 213, 209, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1815, d1l2jA_, 0.7046, 3.10, 0.181, 245, 215, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH (R R)-511-CIS-DIETHYL-561112-TETRAHYDROCHRYSENE-28-DIOL
1816, d4rakA_, 0.7042, 2.16, 0.248, 210, 206, CRYSTAL STRUCTURE OF NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2 (LXRB) COMPLEXED WITH PARTIAL AGONIST
1817, d2q7iA_, 0.7042, 3.07, 0.172, 245, 215, THE WILD TYPE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN BOUND WITH TESTOSTERONE AND AN AR 20-30 PEPTIDE
1818, p5mmwA_, 0.7041, 3.05, 0.173, 236, 214, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 6 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1819, d4ohaA_, 0.7041, 2.79, 0.219, 224, 210, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1820, p5w4vC_, 0.7040, 2.27, 0.242, 211, 207, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1821, d4ojbA_, 0.7039, 3.07, 0.172, 245, 215, CRYSTAL STRUCTURE OF W741L-AR-LBD
1822, p4okbA_, 0.7037, 3.10, 0.177, 245, 215, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1823, p4oh6A_, 0.7037, 2.41, 0.229, 214, 210, CRYSTAL STRUCTURE OF T877A-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1824, d2abiB_, 0.7037, 3.12, 0.186, 245, 215, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
1825, p5q0lA_, 0.7036, 2.33, 0.221, 206, 204, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1826, p3up0A_, 0.7036, 2.99, 0.173, 237, 214, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-DELTA7-DAFACHRONIC ACID
1827, d2gpuA_, 0.7034, 2.69, 0.185, 216, 211, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN
1828, d1s9pB_, 0.7033, 3.01, 0.182, 234, 214, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
1829, p4oarA_, 0.7032, 3.15, 0.144, 243, 215, PROGESTERONE RECEPTOR WITH BOUND ULIPRISTAL ACETATE AND A PEPTIDE FROM THE CO-REPRESSOR SMRT
1830, d2qzoA_, 0.7032, 2.59, 0.216, 223, 208, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH WAY-169916
1831, d3d24C1, 0.7031, 2.69, 0.216, 224, 208, CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN OF ESTROGEN- RELATED RECEPTOR ALPHA (ERRALPHA) IN COMPLEX WITH THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR COACTIVATOR- 1ALPHA BOX3 PEPTIDE (PGC-1ALPHA)
1832, d2gpvC_, 0.7030, 2.66, 0.194, 223, 211, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1833, d1xiuA_, 0.7029, 2.77, 0.150, 239, 213, CRYSTAL STRUCTURE OF THE AGONIST-BOUND LIGAND-BINDING DOMAIN OF BIOMPHALARIA GLABRATA RXR
1834, d2iogA_, 0.7028, 2.87, 0.164, 232, 213, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 11F
1835, d1ya3A_, 0.7028, 2.72, 0.240, 236, 208, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1836, d1a52A_, 0.7028, 2.80, 0.150, 241, 213, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO ESTRADIOL
1837, p5q0lC_, 0.7027, 2.34, 0.245, 212, 208, LIGAND BINDING TO FARNESOID-X-RECEPTOR
1838, d4okxA_, 0.7027, 2.85, 0.150, 242, 214, CRYSTAL STRUCTURE OF W741L-AR-LBD BOUND WITH CO-REGULATOR PEPTIDE
1839, d2ewpB_, 0.7027, 2.35, 0.216, 206, 204, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
1840, d3rllA_, 0.7026, 2.78, 0.150, 240, 213, CRYSTAL STRUCTURE OF THE T877A ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH (S)-N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-(4- CYANONAPHTHALEN-1-YLOXY)-2-HYDROXY-2-METHYLPROPANAMIDE
1841, d2axaA_, 0.7026, 2.79, 0.150, 240, 213, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH S-1
1842, d5hcvA_, 0.7025, 2.89, 0.150, 242, 214, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
1843, d5fqpA_, 0.7025, 2.67, 0.175, 234, 211, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 1.
1844, p6c42A_, 0.7024, 3.23, 0.284, 221, 215, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1156
1845, p5tm4B_, 0.7023, 3.34, 0.145, 242, 221, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG 5-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENOXY)PENTANOIC ACID
1846, p3up0B_, 0.7023, 3.34, 0.145, 242, 221, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-DELTA7-DAFACHRONIC ACID
1847, d2ax7A_, 0.7018, 2.78, 0.205, 222, 210, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN T877A MUTANT IN COMPLEX WITH S-1
1848, d1y9rA_, 0.7016, 2.72, 0.214, 217, 210, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1849, p5krkB_, 0.7015, 2.98, 0.150, 241, 213, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 44 -((5-BROMO-23-DIHYDRO-1H-INDEN-1-YLIDENE) METHYLENE)DIPHENOL
1850, d2ax8A_, 0.7014, 3.09, 0.186, 227, 215, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN W741L MUTANT IN COMPLEX WITH S-1
1851, d1qkmA_, 0.7014, 2.48, 0.187, 211, 208, HUMAN OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PARTIAL AGONIST GENISTEIN
1852, p5tm2A_, 0.7013, 2.53, 0.217, 223, 207, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH 25-BIS(2-CHLORO-4-HYDROXYPHENYL)THIOPHENE 1-OXIDE
1853, d1s9pA_, 0.7013, 2.44, 0.237, 221, 207, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
1854, d2oaxF_, 0.7011, 3.05, 0.173, 243, 214, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1855, d3os8B_, 0.7010, 2.52, 0.181, 233, 210, ESTROGEN RECEPTOR
1856, d1sj0A_, 0.7009, 2.92, 0.179, 239, 212, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE ANTAGONIST LIGAND 4-D
1857, d1s9pC_, 0.7009, 3.23, 0.284, 220, 215, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH DIETHYLSTILBESTROL
1858, d1z95A_, 0.7008, 2.80, 0.150, 240, 213, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN W741L MUTANT COMPLEX WITH R-BICALUTAMIDE
1859, d3os8A_, 0.7007, 2.69, 0.210, 224, 210, ESTROGEN RECEPTOR
1860, d3osaB_, 0.7004, 2.76, 0.151, 238, 212, ESTROGEN RECEPTOR
1861, d3osaA_, 0.7003, 2.76, 0.151, 238, 212, ESTROGEN RECEPTOR
1862, d5w9dA_, 0.7002, 2.80, 0.174, 236, 213, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S C417S C530S MUTANT IN COMPLEX WITH ENDOXIFEN
1863, d2oaxA_, 0.7002, 3.03, 0.168, 242, 214, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1864, d2ax9A_, 0.7001, 2.96, 0.184, 234, 212, CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND BINDING DOMAIN IN COMPLEX WITH R-3
1865, d1a52B_, 0.7001, 2.68, 0.186, 218, 210, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO ESTRADIOL
1866, d5jy3A_, 0.6999, 3.33, 0.140, 242, 221, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
1867, d2qxsA_, 0.6999, 2.77, 0.151, 238, 212, CRYSTAL STRUCTURE OF ANTAGONIZING MUTANT 536S OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO RALOXIFENE
1868, p3dzuA2, 0.6998, 2.64, 0.180, 239, 211, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH BVT.13 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1869, d1xnxB_, 0.6995, 2.76, 0.190, 221, 211, CRYSTAL STRUCTURE OF CONSTITUTIVE ANDROSTANE RECEPTOR
1870, d5u2bF_, 0.6993, 2.77, 0.151, 238, 212, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE PHENYLAMINO-SUBSTITUTED ESTROGEN (8R9S13S14S 17S)-13-METHYL-17-(PHENYLAMINO)-78911121314151617-DECAHYDRO- 6H-CYCLOPENTA[A]PHENANTHREN-3-OL WITHOUT A COACTIVATOR PEPTIDE
1871, d4xi3B_, 0.6990, 2.91, 0.160, 230, 213, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
1872, p5ufxB_, 0.6988, 2.67, 0.195, 217, 210, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1074
1873, p3up3A_, 0.6988, 2.67, 0.215, 215, 209, NUCLEAR RECEPTOR DAF-12 FROM HOOKWORM ANCYLOSTOMA CEYLANICUM IN COMPLEX WITH (25S)-CHOLESTENOIC ACID
1874, d2ewpA_, 0.6988, 3.02, 0.178, 238, 214, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
1875, d5fqvA_, 0.6986, 3.10, 0.168, 240, 214, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 5.
1876, d2ewpC_, 0.6985, 3.08, 0.188, 243, 213, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
1877, d3d24A1, 0.6984, 2.70, 0.215, 219, 209, CRYSTAL STRUCTURE OF LIGAND-BINDING DOMAIN OF ESTROGEN- RELATED RECEPTOR ALPHA (ERRALPHA) IN COMPLEX WITH THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR COACTIVATOR- 1ALPHA BOX3 PEPTIDE (PGC-1ALPHA)
1878, p5w4vD_, 0.6983, 2.77, 0.151, 238, 212, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1879, p6chwA_, 0.6980, 3.10, 0.168, 240, 214, ESTROGEN RECEPTOR ALPHA Y537S COVALENTLY BOUND TO ANTAGONIST H3B-5942.
1880, d1ya3C_, 0.6980, 3.22, 0.167, 239, 215, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1881, d3os9A_, 0.6979, 3.22, 0.167, 239, 215, ESTROGEN RECEPTOR
1882, d2abiA_, 0.6979, 3.01, 0.178, 242, 213, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE
1883, d5fqsA_, 0.6978, 2.69, 0.176, 233, 210, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 3.
1884, p3e00A2, 0.6978, 2.79, 0.151, 238, 212, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH GW9662 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1885, d1y9rB_, 0.6978, 2.95, 0.179, 240, 212, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1886, d1pq6C_, 0.6978, 2.47, 0.254, 228, 205, HUMAN LXR BETA HORMONE RECEPTOR / GW3965 COMPLEX
1887, d1vjbB_, 0.6977, 3.19, 0.177, 236, 215, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
1888, p5ufwB_, 0.6973, 2.21, 0.234, 209, 205, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1154
1889, d2jj3B_, 0.6972, 3.06, 0.203, 232, 212, ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
1890, p4iuiB_, 0.6971, 2.74, 0.190, 225, 210, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY DERIVATIVE 4A
1891, p5wzxB_, 0.6970, 3.01, 0.170, 233, 212, STRUCTURAL BASIS FOR A PENTACYCLIC OLEANANE-TYPE TRITERPENOID AS A LIGAND OF FXR
1892, d5fqtA_, 0.6970, 3.28, 0.182, 231, 214, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 4.
1893, d5w9dB_, 0.6969, 3.13, 0.142, 242, 218, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S C417S C530S MUTANT IN COMPLEX WITH ENDOXIFEN
1894, d5hcvC_, 0.6969, 2.75, 0.205, 224, 210, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
1895, d5hjpC1, 0.6968, 3.01, 0.175, 233, 212, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
1896, d2ouzA_, 0.6966, 2.68, 0.206, 223, 209, CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR ALPHA-LASOFOXIFENE COMPLEX
1897, p5w9cA_, 0.6965, 2.44, 0.189, 209, 206, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
1898, d5hcvB_, 0.6962, 2.28, 0.219, 203, 201, IDENTIFICATION OF SPIROOXINDOLE AND DIBENZOXAZEPINE MOTIFS AS POTENT MINERALOCORTICOID RECEPTOR ANTAGONISTS
1899, d1qktA_, 0.6962, 3.21, 0.172, 246, 215, MUTANT ESTROGEN NUCLEAR RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH ESTRADIOL
1900, d5jy3C_, 0.6961, 2.47, 0.184, 232, 207, CRYSTAL STRUCTURE OF LXRBETA (NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 2) COMPLEXED WITH BMS-852927
1901, d3h0aA_, 0.6961, 2.92, 0.171, 233, 210, CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA (PPARG) AND RETINOIC ACID RECEPTOR ALPHA (RXRA) IN COMPLEX WITH 9-CIS RETINOIC ACID CO-ACTIVATOR PEPTIDE AND A PARTIAL AGONIST
1902, d1ya3B_, 0.6961, 2.46, 0.174, 230, 207, CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION
1903, d5kyjB1, 0.6960, 3.02, 0.175, 233, 212, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1904, d5aauB_, 0.6959, 2.22, 0.240, 208, 204, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
1905, d2ayrA1, 0.6954, 2.76, 0.171, 238, 210, A SERM DESIGNED FOR THE TREATMENT OF UTERINE LEIOMYOMA WITH UNIQUE TISSUE SPECIFICITY FOR UTERUS AND OVARIES IN RATS
1906, p6chzA_, 0.6951, 2.35, 0.252, 208, 202, ESTROGEN RECEPTOR ALPHA Y537S BOUND TO ANTAGONIST H3B-9224.
1907, d2ewpD_, 0.6951, 2.51, 0.220, 210, 205, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
1908, d5hjpA1, 0.6947, 3.21, 0.178, 229, 213, IDENTIFICATION OF LXRBETA SELECTIVE AGONISTS FOR THE TREATMENT OF ALZHEIMER S DISEASE
1909, d2oaxD_, 0.6947, 2.90, 0.161, 226, 211, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1910, d1qknA_, 0.6946, 2.71, 0.186, 221, 210, RAT OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH ANTAGONIST RALOXIFENE
1911, d1yinA_, 0.6945, 2.79, 0.276, 212, 210, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 3F
1912, d3dt3B_, 0.6942, 3.03, 0.175, 233, 212, HUMAN ESTROGEN RECEPTOR ALPHA LBD WITH GW368
1913, p5w4vF_, 0.6941, 3.11, 0.188, 237, 213, STRUCTURE OF RORGT BOUND TO A TERTIARY ALCOHOL
1914, d2jj3A_, 0.6937, 2.64, 0.177, 229, 209, ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
1915, d2ertA_, 0.6937, 2.22, 0.235, 208, 204,  
1916, d3os8C_, 0.6936, 3.29, 0.167, 246, 215, ESTROGEN RECEPTOR
1917, d3ertA_, 0.6936, 2.95, 0.171, 233, 211, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
1918, d2oaxC_, 0.6934, 2.63, 0.177, 232, 209, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1919, d5i4vB1, 0.6933, 3.18, 0.173, 248, 214, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
1920, d2i0gB_, 0.6933, 2.72, 0.252, 231, 206, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1921, p5w9cB_, 0.6932, 2.32, 0.238, 210, 206, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
1922, d4xi3A_, 0.6929, 2.45, 0.179, 230, 207, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
1923, d2yatA_, 0.6928, 2.31, 0.234, 208, 205, CRYSTAL STRUCTURE OF ESTRADIOL DERIVED METAL CHELATE AND ESTROGEN RECEPTOR-LIGAND BINDING DOMAIN COMPLEX
1924, d3os8D_, 0.6927, 2.52, 0.180, 222, 206, ESTROGEN RECEPTOR
1925, d2z4bB_, 0.6926, 3.27, 0.172, 242, 215, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
1926, d2i0gA_, 0.6923, 3.29, 0.172, 246, 215, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1927, d1ndeA_, 0.6919, 2.68, 0.212, 221, 208, ESTROGEN RECEPTOR BETA WITH SELECTIVE TRIAZINE MODULATOR
1928, d2z4bA_, 0.6918, 2.18, 0.236, 207, 203, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
1929, p5wzxA_, 0.6917, 2.86, 0.175, 234, 211, STRUCTURAL BASIS FOR A PENTACYCLIC OLEANANE-TYPE TRITERPENOID AS A LIGAND OF FXR
1930, d2oaxE_, 0.6917, 2.83, 0.163, 228, 208, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1931, d5kyjF1, 0.6916, 3.05, 0.175, 241, 211, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1932, d2gpvD_, 0.6916, 3.10, 0.179, 240, 212, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1933, p3dzyA2, 0.6915, 2.29, 0.220, 202, 200, INTACT PPAR GAMMA - RXR ALPHA NUCLEAR RECEPTOR COMPLEX ON DNA BOUND WITH ROSIGLITAZONE 9-CIS RETINOIC ACID AND NCOA2 PEPTIDE
1934, d1vjbA_, 0.6911, 2.86, 0.162, 223, 210, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4- HYDROXYTAMOXIFEN
1935, d2p7zA_, 0.6909, 3.25, 0.182, 246, 214, ESTROGEN RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXY- TAMOXIFEN
1936, d1dkfA_, 0.6908, 2.69, 0.178, 234, 208, CRYSTAL STRUCTURE OF A HETERODIMERIC COMPLEX OF RAR AND RXR LIGAND-BINDING DOMAINS
1937, d5kyaB1, 0.6906, 3.25, 0.182, 246, 214, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1938, d2gpvE_, 0.6905, 2.76, 0.176, 233, 210, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1939, p5e15A_, 0.6903, 2.30, 0.235, 207, 204, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH THE CYCLOFENIL DERIVATIVE 44 -{[4-(2-HYDROXYETHYL) CYCLOHEXYLIDENE]METHANEDIYL}DIPHENOL
1940, d3os9B_, 0.6902, 2.91, 0.162, 222, 210, ESTROGEN RECEPTOR
1941, p2ylyB_, 0.6902, 3.10, 0.179, 234, 212, SULFONAMIDES AS SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS.
1942, d5kyaF1, 0.6897, 2.92, 0.177, 230, 209, BRAIN PENETRANT LIVER X RECEPTOR (LXR) MODULATORS BASED ON A 2456- TETRAHYDROPYRROLO[34-C]PYRAZOLE CORE
1943, d5i4vF_, 0.6897, 2.68, 0.197, 227, 208, DISCOVERY OF NOVEL ORALLY EFFICACIOUS LIVER X RECEPTOR (LXR) BETA AGONISTS
1944, d3dt3A_, 0.6895, 2.74, 0.173, 230, 208, HUMAN ESTROGEN RECEPTOR ALPHA LBD WITH GW368
1945, d2qtuB_, 0.6893, 2.95, 0.171, 224, 210, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
1946, d2giuA_, 0.6890, 2.84, 0.163, 221, 209, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 45
1947, d3r29B_, 0.6887, 3.23, 0.156, 231, 212, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2
1948, d2qtuA_, 0.6885, 2.84, 0.163, 221, 209, ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN COMPLEXED TO A BENZOPYRAN LIGAND
1949, d2gpvF_, 0.6885, 2.79, 0.284, 210, 208, ESTROGEN RELATED RECEPTOR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH 4-HYDROXY-TAMOXIFEN AND A SMRT PEPTIDE
1950, p5uc3A_, 0.6884, 2.56, 0.174, 234, 207, NUCLEAR RECEPTOR
1951, d1g2nA_, 0.6883, 2.35, 0.235, 207, 204, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF THE ULTRASPIRACLE PROTEIN USP THE ORTHOLOG OF RXRS IN INSECTS
1952, d5accA_, 0.6880, 2.51, 0.227, 209, 203, A NOVEL ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATOR AZD9496 DRIVES TUMOUR GROWTH INHIBITION IN ESTROGEN RECEPTOR POSITIVE AND ESR1 MUTANT MODELS
1953, p5mkuA_, 0.6879, 2.13, 0.239, 205, 201, CRYSTAL STRUCTURE OF THE RETINOID X RECEPTOR ALPHA IN COMPLEX WITH SYNTHETIC HONOKIOL DERIVATIVE 4 AND A FRAGMENT OF THE TIF2 CO- ACTIVATOR.
1954, d3a9eA_, 0.6874, 2.63, 0.216, 208, 204, CRYSTAL STRUCTURE OF A MIXED AGONIST-BOUND RAR-ALPHA AND ANTAGONIST- BOUND RXR-ALPHA HETERODIMER LIGAND BINDING DOMAINS
1955, d5fqrA_, 0.6872, 2.37, 0.218, 207, 202, SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR ANTAGONISTS: TETRAHYDROISOQUINOLINE PHENOLS 2.
1956, d2oaxB_, 0.6871, 2.52, 0.224, 217, 205, CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420
1957, d1r1kA_, 0.6868, 2.31, 0.236, 206, 203, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO PONASTERONE A
1958, d1s9qB_, 0.6867, 2.43, 0.223, 208, 202, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
1959, d3ixpA_, 0.6865, 2.62, 0.189, 218, 206, CRYSTAL STRUCTURE OF THE ECDYSONE RECEPTOR BOUND TO BYI08346
1960, p5uc3B_, 0.6863, 2.88, 0.179, 228, 207, NUCLEAR RECEPTOR
1961, p6c42B_, 0.6862, 2.67, 0.155, 221, 206, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH OP1156
1962, d2pogA_, 0.6862, 2.30, 0.236, 206, 203, BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR B AGONISTS (SERBAS). PART 2: STRUCTURE ACTIVITY RELATIONSHIP STUDIES ON THE BENZOPYRAN SCAFFOLD.
1963, d2qxsB_, 0.6860, 2.31, 0.236, 218, 203, CRYSTAL STRUCTURE OF ANTAGONIZING MUTANT 536S OF THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN COMPLEXED TO RALOXIFENE
1964, d1m7wC_, 0.6859, 3.00, 0.181, 236, 210, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1965, d3uucD_, 0.6857, 2.97, 0.172, 222, 209, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
1966, d3uucC_, 0.6856, 2.86, 0.168, 225, 208, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
1967, d1xb7A1, 0.6856, 2.60, 0.241, 212, 203, X-RAY STRUCTURE OF ERRALPHA LBD IN COMPLEX WITH A PGC- 1ALPHA PEPTIDE AT 2.5A RESOLUTION
1968, p5w9cD_, 0.6853, 2.89, 0.173, 219, 208, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
1969, p5w9cC_, 0.6853, 2.51, 0.223, 208, 202, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN C381S; C417S; C530S IN COMPLEX WITH 4-HYDROXYTAMOXIFEN 
1970, d1m7wB_, 0.6853, 2.95, 0.164, 232, 207, HNF4A LIGAND BINDING DOMAIN WITH BOUND FATTY ACID
1971, d1r20A_, 0.6851, 2.63, 0.176, 246, 204, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE HETERODIMER ECR/USP BOUND TO THE SYNTHETIC AGONIST BYI06830
1972, d3r29A_, 0.6850, 2.63, 0.176, 246, 204, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2
1973, d2r40A_, 0.6848, 3.16, 0.186, 228, 210, CRYSTAL STRUCTURE OF 20E BOUND ECR/USP
1974, d3osaC_, 0.6847, 2.35, 0.236, 208, 203, ESTROGEN RECEPTOR
1975, p3gyuA_, 0.6845, 2.18, 0.230, 218, 200, NUCLEAR RECEPTOR DAF-12 FROM PARASITIC NEMATODE STRONGYLOIDES STERCORALIS IN COMPLEX WITH ITS PHYSIOLOGICAL LIGAND DAFACHRONIC ACID DELTA 7
1976, d1hg4E_, 0.6845, 3.18, 0.186, 228, 210, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1977, d2q70A_, 0.6841, 2.58, 0.175, 233, 206, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLXED TO A BENZOPYRAN LIGAND
1978, p5z12C_, 0.6839, 2.62, 0.176, 241, 204, A STRUCTURE OF FXR/RXR 
1979, d4xi3D_, 0.6839, 2.46, 0.219, 216, 201, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH BAZEDOXIFENE
1980, d1hg4D_, 0.6838, 2.59, 0.176, 242, 204, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1981, d3osaD_, 0.6833, 3.07, 0.163, 231, 208, ESTROGEN RECEPTOR
1982, d1hg4A_, 0.6833, 3.02, 0.179, 225, 207, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1983, d2jfaA_, 0.6832, 2.93, 0.183, 233, 208, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH AN AFFINITY- SELECTED COREPRESSOR PEPTIDE
1984, d1hg4B_, 0.6832, 2.85, 0.179, 225, 207, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1985, p4ummF_, 0.6831, 2.57, 0.222, 220, 203, THE CRYO-EM STRUCTURE OF THE PALINDROMIC DNA-BOUND USP-ECR NUCLEAR RECEPTOR REVEALS AN ASYMMETRIC ORGANIZATION WITH ALLOSTERIC DOMAIN POSITIONING
1986, p5dvvB_, 0.6828, 3.33, 0.185, 231, 211, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-IMINE ANALOG 44 -(PHENYLCARBONIMIDOYL)DIPHENOL
1987, d1hg4C_, 0.6826, 3.00, 0.188, 228, 207, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1988, d5aauA1, 0.6824, 2.55, 0.186, 207, 204, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
1989, d2i0jB_, 0.6824, 2.98, 0.178, 227, 208, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1990, p5dvvA_, 0.6819, 2.77, 0.175, 228, 206, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A TRIARYL-IMINE ANALOG 44 -(PHENYLCARBONIMIDOYL)DIPHENOL
1991, d1hg4F_, 0.6819, 2.42, 0.219, 218, 201, ULTRASPIRACLE LIGAND BINDING DOMAIN FROM DROSOPHILA MELANOGASTER
1992, d1uomA_, 0.6818, 2.65, 0.176, 239, 204, THE STRUCTURE OF ESTROGEN RECEPTOR IN COMPLEX WITH A SELECTIVE AND POTENT TETRAHYDROISOCHIOLIN LIGAND.
1993, d2i0jC_, 0.6808, 2.48, 0.243, 212, 202, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
1994, d5aavA1, 0.6807, 2.55, 0.182, 238, 203, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
1995, d2iokA_, 0.6803, 2.66, 0.176, 230, 205, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 1D
1996, d1nhzA_, 0.6803, 3.16, 0.179, 234, 212, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF GLUCOCORTICOID RECEPTOR
1997, p4wvdA_, 0.6802, 2.30, 0.193, 240, 202, IDENTIFICATION OF A NOVEL FXR LIGAND THAT REGULATES METABOLISM
1998, p4wvdB_, 0.6801, 3.17, 0.190, 235, 210, IDENTIFICATION OF A NOVEL FXR LIGAND THAT REGULATES METABOLISM
1999, d2iokB_, 0.6798, 2.13, 0.231, 203, 199, HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND 1D
2000, d4q50F_, 0.6796, 2.71, 0.176, 219, 204, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2001, d1l2jB1, 0.6796, 2.69, 0.184, 238, 206, HUMAN ESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH (R R)-511-CIS-DIETHYL-561112-TETRAHYDROCHRYSENE-28-DIOL
2002, d2i0jA_, 0.6794, 2.72, 0.171, 226, 205, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
2003, p2bj4A_, 0.6790, 2.32, 0.188, 240, 202, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGE-DISPLAY DERIVED PEPTIDE ANTAGONIST
2004, p4iuiA_, 0.6787, 2.32, 0.188, 240, 202, CRYSTAL STRUCTURE OF THE ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH DYNAMIC WAY DERIVATIVE 4A
2005, p2jf9A_, 0.6787, 2.78, 0.185, 221, 205, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
2006, p5tm9A_, 0.6786, 2.32, 0.188, 240, 202, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-3-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)ACRYLIC ACID
2007, d2fszB_, 0.6778, 2.62, 0.172, 241, 203, A SECOND BINDING SITE FOR HYDROXYTAMOXIFEN WITHIN THE COACTIVATOR-BINDING GROOVE OF ESTROGEN RECEPTOR BETA
2008, d2r6yA_, 0.6777, 2.52, 0.192, 210, 203, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SERM
2009, d3uucB_, 0.6776, 2.68, 0.184, 238, 206, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
2010, d2i0jD_, 0.6776, 2.90, 0.175, 225, 206, BENZOPYRANS ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAS) WITH NOVEL ACTIVITY IN MODELS OF BENIGN PROSTATIC HYPERPLASIA
2011, d5tnbC_, 0.6771, 2.89, 0.194, 227, 206, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2012, d3k6pA1, 0.6764, 2.43, 0.194, 209, 201, ESTROGEN RELATED RECEPTOR ALPHA IN COMPLEX WITH AN ETHER BASED LIGAND
2013, d1errA_, 0.6763, 2.34, 0.193, 240, 202, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE
2014, d3tx7B_, 0.6759, 3.07, 0.184, 231, 207, CRYSTAL STRUCTURE OF LRH-1/BETA-CATENIN COMPLEX
2015, d3h52B_, 0.6759, 2.93, 0.176, 223, 205, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2016, d2jfaB_, 0.6758, 3.06, 0.179, 228, 207, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH AN AFFINITY- SELECTED COREPRESSOR PEPTIDE
2017, d2r6wA_, 0.6757, 3.05, 0.197, 227, 208, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO A SERM
2018, d5ak2A1, 0.6754, 3.22, 0.168, 239, 208, OXYPHENYLPROPENOIC ACIDS AS ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS.
2019, p4b7wC_, 0.6754, 2.90, 0.271, 210, 203, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2020, p4b7wA_, 0.6754, 2.89, 0.281, 208, 203, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2021, d2fszA_, 0.6753, 3.15, 0.192, 228, 208, A SECOND BINDING SITE FOR HYDROXYTAMOXIFEN WITHIN THE COACTIVATOR-BINDING GROOVE OF ESTROGEN RECEPTOR BETA
2022, d1lbdA_, 0.6753, 3.09, 0.184, 220, 207, LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA
2023, p5tm9B_, 0.6741, 2.76, 0.172, 222, 203, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-ASC ANALOG (E)-3-(4-((1R4S6R)-6-((3- CHLOROPHENOXY)SULFONYL)-3-(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT- 2-EN-2-YL)PHENYL)ACRYLIC ACID
2024, d5tnbD_, 0.6737, 2.98, 0.180, 221, 205, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2025, d4q50G_, 0.6737, 2.68, 0.187, 218, 203, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2026, d4q50E_, 0.6736, 2.66, 0.192, 211, 203, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2027, d2r6wB_, 0.6731, 2.97, 0.171, 215, 205, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLEXED TO A SERM
2028, d3uucA_, 0.6727, 2.97, 0.176, 215, 205, CRYSTAL STRUCTURE OF HERA-LBD (WT) IN COMPLEX WITH BISPHENOL-C
2029, d1hj1A_, 0.6727, 3.04, 0.157, 227, 204, RAT OESTROGEN RECEPTOR BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH PURE ANTIOESTROGEN ICI164384
2030, d2r6yB_, 0.6726, 2.96, 0.184, 232, 206, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A SERM
2031, p2jf9C_, 0.6725, 3.34, 0.187, 229, 208, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
2032, d1xqcC_, 0.6725, 2.87, 0.191, 225, 204, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
2033, d4q50H_, 0.6720, 3.13, 0.165, 229, 206, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2034, d2ewpE_, 0.6718, 3.14, 0.178, 217, 208, CRYSTAL STRUCTURE OF ESTROGEN RELATED RECEPTOR-3 (ERR-GAMMA) LIGAND BINDING DOMAIND WITH TAMOXIFEN ANALOG GSK5182
2035, d5tnbA_, 0.6714, 3.23, 0.183, 224, 208, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2036, d5tn9C_, 0.6708, 2.52, 0.175, 218, 200, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2037, p3r2aD_, 0.6705, 2.28, 0.177, 249, 198, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
2038, p2bj4B_, 0.6704, 2.91, 0.186, 222, 204, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A PHAGE-DISPLAY DERIVED PEPTIDE ANTAGONIST
2039, d3h52A1, 0.6701, 2.95, 0.185, 229, 205, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2040, d5ak2B_, 0.6700, 2.99, 0.181, 224, 204, OXYPHENYLPROPENOIC ACIDS AS ORAL SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS.
2041, d2aclC_, 0.6699, 2.24, 0.227, 202, 198, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2042, d1xqcA_, 0.6698, 2.24, 0.227, 202, 198, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
2043, d1g1uD_, 0.6691, 2.86, 0.159, 223, 201, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2044, d4q50C_, 0.6688, 3.48, 0.217, 238, 212, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2045, d2qe4A_, 0.6688, 2.81, 0.182, 211, 203, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
2046, p3r2aA_, 0.6684, 2.83, 0.178, 227, 202, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
2047, d1errB_, 0.6684, 3.02, 0.195, 219, 205, HUMAN ESTROGEN RECEPTOR LIGAND-BINDING DOMAIN IN COMPLEX WITH RALOXIFENE
2048, p5tlpB_, 0.6681, 2.94, 0.192, 218, 203, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (Y537S) IN COMPLEX WITH THE OBHS-BSC ANALOG 3-FLUOROPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE AND 3-METHYL-6-PHENYL-3H- IMIDAZO[45-B]PYRIDIN-2-AMINE
2049, d2q70B_, 0.6681, 2.94, 0.191, 223, 204, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN COMPLXED TO A BENZOPYRAN LIGAND
2050, d2pogB_, 0.6680, 3.11, 0.191, 220, 204, BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR B AGONISTS (SERBAS). PART 2: STRUCTURE ACTIVITY RELATIONSHIP STUDIES ON THE BENZOPYRAN SCAFFOLD.
2051, p2jf9B_, 0.6680, 2.39, 0.168, 204, 196, ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH A TAMOXIFEN- SPECIFIC PEPTIDE ANTAGONIST
2052, d1g5yD_, 0.6675, 2.92, 0.197, 221, 203, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2053, d2aclE_, 0.6669, 2.92, 0.183, 214, 202, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2054, d5tn9A_, 0.6668, 2.96, 0.196, 224, 204, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2055, d1xqcD_, 0.6664, 2.90, 0.182, 218, 203, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
2056, p3r2aB_, 0.6662, 2.56, 0.205, 214, 200, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
2057, d2aclA_, 0.6661, 3.11, 0.176, 227, 204, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2058, d1xqcB_, 0.6660, 3.13, 0.172, 224, 204, X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION
2059, d2aclG_, 0.6659, 2.18, 0.237, 197, 194, LIVER X-RECEPTOR ALPHA LIGAND BINDING DOMAIN WITH SB313987
2060, d2qe4B_, 0.6649, 3.11, 0.176, 221, 204, ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST
2061, d4oivB_, 0.6648, 2.53, 0.157, 245, 198, STRUCTURAL BASIS FOR SMALL MOLECULE NDB AS A SELECTIVE ANTAGONIST OF FXR
2062, d3os9C_, 0.6645, 2.54, 0.182, 210, 198, ESTROGEN RECEPTOR
2063, d4q50D_, 0.6632, 2.24, 0.241, 215, 195, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2064, d1g1uA_, 0.6622, 3.01, 0.191, 224, 204, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2065, d1h9uC_, 0.6619, 3.45, 0.220, 229, 209, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
2066, d1h9uD_, 0.6618, 2.97, 0.183, 220, 202, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
2067, d1h9uA_, 0.6618, 2.63, 0.176, 207, 199, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
2068, d1g5yA_, 0.6618, 2.14, 0.237, 197, 194, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2069, p4lsjA_, 0.6617, 3.07, 0.186, 222, 204, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR LIGAND BINDING DOMAIN BOUND TO A DIBENZOXAPINE SULFONAMIDE
2070, p4dorA_, 0.6616, 2.68, 0.186, 207, 199, HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1 LRH-1 IN ITS APO STATE BOUND TO A FRAGMENT OF HUMAN SHP BOX1
2071, d1h9uB_, 0.6615, 2.60, 0.192, 211, 198, THE STRUCTURE OF THE HUMAN RETINOID-X-RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH THE SPECIFIC SYNTHETIC AGONIST LG100268
2072, d3fc6A_, 0.6613, 2.60, 0.187, 211, 198, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
2073, d5tn9D_, 0.6574, 2.82, 0.189, 209, 201, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2074, d1g5yB_, 0.6574, 3.38, 0.216, 229, 208, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2075, d1g5yC_, 0.6564, 2.29, 0.241, 214, 195, THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.
2076, d4q50B_, 0.6562, 2.95, 0.164, 222, 201, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2077, d4q50A_, 0.6559, 3.02, 0.194, 221, 201, THE ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN D538G MUTANT IN COMPLEX WITH 4-HYDROXYTAMOXIFEN
2078, d3kfcC_, 0.6558, 2.05, 0.234, 195, 192, COMPLEX STRUCTURE OF LXR WITH AN AGONIST
2079, d5aavB_, 0.6557, 2.31, 0.231, 214, 195, OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(35- DIFLUORO-4-((1R3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2 349-TETRAHYDRO-1H-PYRIDO(34-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496) A POTENT AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST
2080, d2nxxB_, 0.6552, 2.95, 0.189, 221, 201, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
2081, d5tnbB_, 0.6550, 2.37, 0.231, 214, 195, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-6-(4-(2- (DIMETHYLAMINO)ETHOXY)PHENYL)-5-(4-HYDROXYPHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2082, d2nxxA_, 0.6544, 2.56, 0.188, 204, 197, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
2083, d5tn9B_, 0.6541, 2.96, 0.269, 218, 201, CRYSTAL STRUCTURE OF THE ER-ALPHA LIGAND-BINDING DOMAIN (L372SL536S) IN COMPLEX WITH THE OBHS-BSC 4-BROMOPHENYL (1R2R4S)-5-(4- HYDROXYPHENYL)-6-(4-(2-(PIPERIDIN-1-YL)ETHOXY)PHENYL)-7- OXABICYCLO[2.2.1]HEPT-5-ENE-2-SULFONATE
2084, d1g1uC_, 0.6538, 2.59, 0.178, 221, 197, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2085, d3fc6C_, 0.6529, 2.89, 0.195, 216, 200, HRXRALPHA & MLXRALPHA WITH AN INDOLE PHARMACOPHORE SB786875
2086, d3h52D_, 0.6527, 3.51, 0.221, 228, 208, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2087, d2nxxD_, 0.6525, 2.15, 0.245, 201, 192, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
2088, d2nxxC_, 0.6525, 2.16, 0.245, 201, 192, CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAINS OF THE T.CASTANEUM (COLEOPTERA) HETERODIMER ECRUSP BOUND TO PONASTERONE A
2089, d3os9D_, 0.6515, 2.16, 0.245, 201, 192, ESTROGEN RECEPTOR
2090, p6b0fA_, 0.6513, 3.53, 0.221, 228, 208, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH LSZ102
2091, d1g1uB_, 0.6512, 2.19, 0.187, 225, 193, THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND
2092, d2pjlA1, 0.6502, 2.95, 0.199, 216, 201, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC INVERSE AGONIST REVEALS ITS NOVEL MOLECULAR MECHANISM
2093, d2pjlB1, 0.6493, 2.16, 0.245, 201, 192, CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR ALPHA IN COMPLEX WITH A SYNTHETIC INVERSE AGONIST REVEALS ITS NOVEL MOLECULAR MECHANISM
2094, p3n00A_, 0.6484, 2.34, 0.237, 207, 194, CRYSTAL STRUCTURE OF A DELETION MUTANT OF HUMAN REVERBA LIGAND BINDING DOMAIN BOUND WITH AN NCOR ID1 PEPTIDE DETERMINED TO 2.60A
2095, d2xhsA1, 0.6466, 2.74, 0.179, 219, 196, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF FUSHI TARAZU FACTOR 1 OF DROSOPHILA MELANOGASTER.
2096, d2iz2A1, 0.6464, 3.17, 0.234, 229, 201,  
2097, d3falC_, 0.6449, 3.25, 0.239, 226, 201, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
2098, d4oivA_, 0.6427, 2.93, 0.193, 209, 197, STRUCTURAL BASIS FOR SMALL MOLECULE NDB AS A SELECTIVE ANTAGONIST OF FXR
2099, d3falA_, 0.6420, 2.75, 0.184, 210, 196, HUMANRXR ALPHA & MOUSE LXR ALPHA COMPLEXED WITH RETENOIC ACID AND GSK2186
2100, p4mddA_, 0.6419, 1.94, 0.276, 186, 185, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR BOUND TO A NON- STEROIDAL ANTAGONIST REVEALS REPOSITIONING AND PARTIAL DISORDERING OF ACTIVATION FUNCTION HELIX 12
2101, d2q60D_, 0.6375, 2.79, 0.196, 209, 194, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2102, d2q60A_, 0.6374, 3.53, 0.187, 228, 208, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2103, d2q60C_, 0.6348, 2.88, 0.179, 215, 196, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2104, d5tbpC_, 0.6331, 3.50, 0.187, 224, 208, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2105, d3h52C1, 0.6328, 2.62, 0.175, 211, 194, CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR
2106, p5uc1B_, 0.6319, 3.22, 0.241, 226, 199, STRUCTURAL ANALYSIS OF GLUCOCORTICOID RECEPTOR BETA LIGAND BINDING DOMAIN COMPLEXED WITH GLUCOCORTICOID ANTAGONIST RU-486: IMPLICATION OF HELIX 12 IN ANTAGONISM
2107, d5tbpB_, 0.6318, 2.07, 0.243, 202, 189, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2108, p5uc1A_, 0.6305, 2.58, 0.154, 234, 195, STRUCTURAL ANALYSIS OF GLUCOCORTICOID RECEPTOR BETA LIGAND BINDING DOMAIN COMPLEXED WITH GLUCOCORTICOID ANTAGONIST RU-486: IMPLICATION OF HELIX 12 IN ANTAGONISM
2109, d3eybB_, 0.6296, 3.34, 0.189, 227, 206, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2110, d3eybC_, 0.6294, 3.34, 0.189, 225, 206, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2111, d3eybA_, 0.6293, 2.70, 0.180, 208, 194, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2112, d3eybD_, 0.6291, 2.63, 0.176, 204, 193, STRUCTURAL AND FUNCTIONAL INSIGHTS INTO THE LIGAND BINDING DOMAIN OF A NON-DUPLICATED RXR FROM THE INVERTEBRATE CHORDATE AMPHIOXUS
2113, p3r2aC_, 0.6287, 3.17, 0.237, 229, 198, CRYSTAL STRUCTURE OF RXRALPHA LIGAND-BINDING DOMAIN COMPLEXED WITH COREPRESSOR SMRT2 AND ANTAGONIST RHEIN
2114, d3cjwA1, 0.6275, 3.07, 0.153, 211, 202, CRYSTAL STRUCTURE OF THE HUMAN COUP-TFII LIGAND BINDING DOMAIN
2115, p4mddB_, 0.6239, 3.09, 0.153, 211, 202, CRYSTAL STRUCTURE OF THE GLUCOCORTICOID RECEPTOR BOUND TO A NON- STEROIDAL ANTAGONIST REVEALS REPOSITIONING AND PARTIAL DISORDERING OF ACTIVATION FUNCTION HELIX 12
2116, d2q60B_, 0.6227, 2.16, 0.342, 184, 184, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF POLYANDROCARPA MISAKIENSIS RXR IN TETRAMER IN ABSENCE OF LIGAND
2117, d4n5gB_, 0.6219, 3.80, 0.144, 226, 209, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2118, p4ozrE_, 0.6212, 3.83, 0.129, 226, 209, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (METHYLENE LACTAM CRYSTAL)
2119, d2gl8D_, 0.6211, 3.83, 0.129, 226, 209, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2120, p4b7wD_, 0.6207, 2.03, 0.242, 198, 186, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2121, p4b7wB_, 0.6207, 3.03, 0.278, 210, 194, LIGAND BINDING DOMAIN HUMAN HEPATOCYTE NUCLEAR FACTOR 4ALPHA: APO FORM
2122, p5t97B_, 0.6205, 1.92, 0.250, 196, 184, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- (4-{(1R)-6-HYDROXY-1-METHYL-2-[4-(PROPAN-2 -YL)PHENYL]-1234- TETRAHYDROISOQUINOLIN-1-YL}PHENYL)PROP-2-ENOIC ACID
2123, p2v0vA_, 0.6205, 2.89, 0.155, 232, 193, CRYSTAL STRUCTURE OF REV-ERB BETA
2124, p4zo1B_, 0.6199, 2.74, 0.221, 197, 190, CRYSTAL STRUCTURE OF THE T3-BOUND TR-BETA LIGAND-BINDING DOMAIN IN COMPLEX WITH RXR-ALPHA
2125, d2gl8C_, 0.6194, 2.70, 0.226, 198, 190, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2126, p2v0vD_, 0.6187, 2.42, 0.226, 203, 186, CRYSTAL STRUCTURE OF REV-ERB BETA
2127, d4n5gC_, 0.6183, 3.11, 0.240, 213, 192, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2128, d2gl8A_, 0.6165, 2.82, 0.172, 236, 192, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2129, d2gl8B_, 0.6160, 3.17, 0.170, 205, 194, HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN
2130, p2v0vB_, 0.6154, 3.08, 0.241, 213, 191, CRYSTAL STRUCTURE OF REV-ERB BETA
2131, p5t92A_, 0.6149, 3.10, 0.171, 205, 193, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- {4-[(1R)-2-(4-FLUOROPHENYL)-6-HYDROXY-1-METHY L-1234- TETRAHYDROISOQUINOLIN-1-YL]PHENYL}PROP-2-ENOIC ACID
2132, p6b0fB_, 0.6137, 2.70, 0.246, 199, 187, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH LSZ102
2133, p2v0vC_, 0.6128, 2.71, 0.246, 199, 187, CRYSTAL STRUCTURE OF REV-ERB BETA
2134, p3p0uA_, 0.6091, 2.70, 0.241, 199, 187, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN TESTICULAR RECEPTOR 4
2135, p4n73A_, 0.6063, 2.71, 0.246, 199, 187, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN (LBD) OF REV-ERB BETA BOUND TO COBALT PROTOPORPHYRIN IX
2136, p3p0uB_, 0.6056, 2.09, 0.253, 185, 182, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN TESTICULAR RECEPTOR 4
2137, p5t92B_, 0.6033, 2.92, 0.232, 203, 190, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- {4-[(1R)-2-(4-FLUOROPHENYL)-6-HYDROXY-1-METHY L-1234- TETRAHYDROISOQUINOLIN-1-YL]PHENYL}PROP-2-ENOIC ACID
2138, p5t97A_, 0.5941, 2.92, 0.232, 203, 190, ESTROGEN RECEPTOR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH (2E)-3- (4-{(1R)-6-HYDROXY-1-METHYL-2-[4-(PROPAN-2 -YL)PHENYL]-1234- TETRAHYDROISOQUINOLIN-1-YL}PHENYL)PROP-2-ENOIC ACID
2139, d3nsqB_, 0.5897, 2.26, 0.165, 202, 182, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD COMPLEXED WITH ANTAGONIST DANTHRON
2140, p4n5gA_, 0.5877, 2.65, 0.228, 198, 184, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2141, p2v7cB_, 0.5874, 2.82, 0.249, 209, 185, CRYSTAL STRUCTURE OF REV-ERB BETA
2142, p5gymB_, 0.5870, 2.47, 0.242, 185, 182, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2143, p4n5gD_, 0.5869, 2.62, 0.251, 195, 183, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K8012
2144, p5tbpD_, 0.5868, 2.07, 0.223, 182, 179, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2145, p5tbpA_, 0.5866, 2.07, 0.223, 182, 179, CRYSTAL STRUCTURE OF RXR-ALPHA LIGAND BINDING DOMAIN COMPLEXED WITH SYNTHETIC MODULATOR K8003
2146, p4n8rD_, 0.5861, 2.47, 0.181, 191, 182, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2147, p4n8rA_, 0.5846, 2.19, 0.363, 181, 179, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2148, d4oztU_, 0.5839, 2.89, 0.246, 199, 187, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (PONA CRYSTAL)
2149, p4n8rB_, 0.5835, 2.43, 0.260, 194, 181, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2150, p5gymA_, 0.5808, 2.20, 0.356, 179, 177, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2151, p4n8rC_, 0.5803, 2.95, 0.247, 209, 186, CRYSTAL STRUCTURE OF RXRA LBD COMPLEXED WITH A SYNTHETIC MODULATOR K- 8008
2152, p3cqvA_, 0.5800, 2.48, 0.250, 190, 180, CRYSTAL STRUCTURE OF REVERB BETA IN COMPLEX WITH HEME
2153, p5gymD_, 0.5799, 2.40, 0.256, 192, 180, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2154, p1z5xU_, 0.5775, 2.25, 0.354, 181, 178, HEMIPTERAN ECDYSONE RECEPTOR LIGAND-BINDING DOMAIN COMPLEXED WITH PONASTERONE A
2155, p5gymF_, 0.5773, 2.21, 0.185, 183, 178, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2156, p5gymC_, 0.5770, 2.40, 0.179, 185, 179, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2157, d3nsqA_, 0.5757, 1.98, 0.366, 179, 175, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD COMPLEXED WITH ANTAGONIST DANTHRON
2158, p4logB_, 0.5755, 3.45, 0.173, 222, 191, THE CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR PNR LIGAND BINDING DOMAIN FUSED WITH MBP
2159, p5gymG_, 0.5752, 3.45, 0.173, 222, 191, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2160, d3nspA_, 0.5752, 2.86, 0.352, 198, 182, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD
2161, d4ozrU_, 0.5746, 2.86, 0.352, 198, 182, CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAINS OF THE BOVICOLA OVIS ECDYSONE RECEPTOR ECR/USP HETERODIMER (METHYLENE LACTAM CRYSTAL)
2162, d3nspB_, 0.5743, 3.32, 0.175, 205, 189, CRYSTAL STRUCTURE OF TETRAMERIC RXRALPHA-LBD
2163, p5gymE_, 0.5733, 2.44, 0.198, 183, 177, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2164, p5gymH_, 0.5721, 2.23, 0.186, 177, 172, CRYSTAL STRUCTURE OF RXR-LBD COMPLEXED WITH FLUORESCENT LIGAND AT 2.60 ANGSTROMS RESOLUTION
2165, p4xajB3, 0.5629, 2.67, 0.263, 199, 175, CRYSTAL STRUCTURE OF HUMAN NR2E1/TLX
2166, p4xajA3, 0.5619, 3.02, 0.258, 196, 178, CRYSTAL STRUCTURE OF HUMAN NR2E1/TLX
2167, p4xajD4, 0.5617, 1.85, 0.380, 168, 166, CRYSTAL STRUCTURE OF HUMAN NR2E1/TLX
2168, p4xajC4, 0.5606, 2.85, 0.263, 196, 175, CRYSTAL STRUCTURE OF HUMAN NR2E1/TLX
2169, p4xaiA3, 0.5584, 2.98, 0.267, 196, 176, CRYSTAL STRUCTURE OF RED FLOUR BEETLE NR2E1/TLX
2170, p2v7cA_, 0.5540, 3.02, 0.267, 188, 176, CRYSTAL STRUCTURE OF REV-ERB BETA
2171, p4logA4, 0.5534, 3.01, 0.261, 188, 176, THE CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR PNR LIGAND BINDING DOMAIN FUSED WITH MBP
2172, p4xaiB3, 0.5489, 2.91, 0.254, 197, 177, CRYSTAL STRUCTURE OF RED FLOUR BEETLE NR2E1/TLX
2173, p3f5cB_, 0.5451, 2.92, 0.260, 197, 177, STRUCTURE OF DAX-1:LRH-1 COMPLEX
2174, p3f5cC_, 0.5348, 2.98, 0.219, 195, 178, STRUCTURE OF DAX-1:LRH-1 COMPLEX
2175, p4nufA3, 0.5181, 2.93, 0.263, 198, 175, CRYSTAL STRUCTURE OF SHP/EID1
